1
|
Dickey BL, Gore LR, Slebos R, Sirak B, Isaacs-Soriano KA, Kennedy K, Otto K, Wadsworth JT, Chung CH, Giuliano AR. A cross-sectional study of the association of dental health factors with progression and all-cause mortality in men diagnosed with HPV-associated oropharyngeal cancer. BMC Oral Health 2024; 24:433. [PMID: 38594660 PMCID: PMC11005190 DOI: 10.1186/s12903-024-04047-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Accepted: 02/18/2024] [Indexed: 04/11/2024] Open
Abstract
BACKGROUND Human Papillomavirus-associated oropharyngeal cancer (HPV-OPC) incidence is increasing among men in the United States. Poor dental health has previously been associated with risk of head and neck cancers, oral HPV infection, and persistence but it is not understood whether dental health is associated with outcomes. We sought to determine the association of dental health with progression free survival and overall mortality among men with an HPV-OPC. METHODS A cross sectional study of men diagnosed with HPV-OPC between 2014-2020 at Moffitt Cancer Center in Tampa, FL was conducted. Dental records were abstracted for assessment of dental fitness prior to cancer treatment. Five dental factors including number of teeth lost, pocket depth, gingival score, loss of attachment, and bone loss were individually examined. Risk factor and outcome data were collected from a patient risk questionnaire and medical record. Using item response theory, an overall dental fitness score from five dental factors was developed in which missing data were multiply imputed. Cox proportional hazards model was used to assess whether dental factors were associated with progression-free survival or overall mortality. RESULTS Among 206 HPV-OPC cases, median follow-up was 3.4 years (IQR: 2.4-4.4) during which 40 cases involved progression or mortality and 25 deaths occurred. Overall dentition was significantly associated with progression free survival (p = 0.04) and with overall survival (p = 0.03) though findings were not significant after adjustment for age at diagnosis, stage, and smoking history (p = 0.146 and p = 0.120, respectively). A pocket depth of 7 mm or more was associated with overall survival (HR: 5.21; 95% CI: 1.43-19.11) and this remained significant after adjustment for confounding (aHR: 4.14; 95% CI: 1.72-16.26). CONCLUSIONS Among men diagnosed with an HPV-associated OPC in the US, worse dental health was associated with reduced progression free survival and overall survival, but not after adjustment for confounders. Further studies are needed to examine whether dental health is associated with other prognostic factors and subsequent treatment-related outcomes.
Collapse
Affiliation(s)
- Brittney L Dickey
- Center for Immunization and Infection Research in Cancer, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL, 33612, USA
| | - L Robert Gore
- Biostatistics and Bioinformatics Shared Resource, H. Lee Moffitt Cancer and Research Institute, Tampa, FL, USA
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer and Research Institute, Tampa, FL, USA
| | - Robbert Slebos
- Center for Immunization and Infection Research in Cancer, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - Bradley Sirak
- Center for Immunization and Infection Research in Cancer, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - Kimberly A Isaacs-Soriano
- Center for Immunization and Infection Research in Cancer, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - Kayoko Kennedy
- Center for Immunization and Infection Research in Cancer, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - Kristen Otto
- Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer and Research Institute, Tampa, FL, USA
| | - J Trad Wadsworth
- Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer and Research Institute, Tampa, FL, USA
| | - Christine H Chung
- Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer and Research Institute, Tampa, FL, USA
| | - Anna R Giuliano
- Center for Immunization and Infection Research in Cancer, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL, 33612, USA.
| |
Collapse
|
2
|
Dickey BL, Putney RM, Schell MJ, Berglund AE, Amelio AL, Caudell JJ, Chung CH, Giuliano AR. Identification of a Biomarker Panel from Genome-Wide Methylation to Detect Early HPV-Associated Oropharyngeal Cancer. Cancer Prev Res (Phila) 2024; 17:169-176. [PMID: 38286404 PMCID: PMC10987272 DOI: 10.1158/1940-6207.capr-23-0317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2023] [Revised: 12/05/2023] [Accepted: 01/26/2024] [Indexed: 01/31/2024]
Abstract
As oropharyngeal cancer (OPC) associated with human papillomavirus (HPV) increases in men, the need for a screening test to diagnose OPC early is crucial. This study agnostically identified differentially methylated CpG sites to identify additional biomarkers to improve screening for early OPC.DNA was extracted from oral gargles of 89 early cases and 108 frequency matched healthy controls, and processed for genome-wide methylation using the Illumina Infinium MethylationEPIC BeadChip. Selected sites were combined with our prior methylation data in the EPB41L3 gene (CpG sites 438, 427, and 425) and oral HPV16 and HPV18 status were considered as binary variables (positive/negative). Lasso regression identified CpG sites strongly associated with early OPC. ROC curves with AUC were generated. The panel was validated utilizing bootstrap resampling.Machine learning analyses identified 14 markers that are significantly associated with early OPC, including one EPB41L3 CpG site (438) and oral HPV16 status. A final model was trained on all available samples using the discovered panel and was able to predict early OPC compared with controls with an AUC of 0.970 on the training set. In the bootstrap validation sets, the average AUC was 0.935, indicating adequate internal validity.Our data suggest that this panel can detect OPC early, however external validation of this panel is needed. Further refinement of a panel of biomarkers to diagnose OPC earlier is urgently needed to prevent complex treatment of OPC and associated comorbidities, while reducing risk of recurrence. PREVENTION RELEVANCE This study identified biomarkers using genome-wide methylation to create a panel capable of discerning early oropharyngeal cancer (OPC) from those without OPC. Such a biomarker panel would be an effective tool to detect OPC early and prevent complications of treatment associated with later diagnosis.
Collapse
Affiliation(s)
- Brittney L. Dickey
- Center for Immunization and infection Research in Cancer and the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida USA
| | - Ryan M Putney
- Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida, USA
| | - Michael J. Schell
- Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida, USA
| | - Anders E. Berglund
- Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida, USA
| | - Antonio L. Amelio
- Department of Tumor Biology, Moffitt Cancer Center, Tampa, Florida, USA
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida, USA
| | - Jimmy J. Caudell
- Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida, USA
| | - Christine H. Chung
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida, USA
| | - Anna R. Giuliano
- Center for Immunization and infection Research in Cancer and the Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida USA
| |
Collapse
|
3
|
Geiss C, Hoogland AI, Arredondo B, Rodriguez Y, Bryant C, Chung CH, Patel KB, Gonzalez BD, Jim HSL, Kirtane K, Oswald LB. Psychosocial consequences of head and neck cancer symptom burden after chemoradiation: a mixed-method study. Support Care Cancer 2024; 32:254. [PMID: 38538780 DOI: 10.1007/s00520-024-08424-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2023] [Accepted: 03/05/2024] [Indexed: 04/18/2024]
Abstract
PURPOSE Patients with head and neck cancer (HNC) experience significant symptom burden from combination chemotherapy and radiation (chemoradiation) that affects acute and long-term health-related quality of life (HRQOL). However, psychosocial impacts of HNC symptom burden are not well understood. This study examined psychosocial consequences of treatment-related symptom burden from the perspectives of survivors of HNC and HNC healthcare providers. METHODS This was a cross-sectional, mixed-method study conducted at an NCI-designated comprehensive cancer center. Participants (N = 33) were survivors of HNC who completed a full course of chemoradiation (n = 20) and HNC healthcare providers (n = 13). Participants completed electronic surveys and semi-structured interviews. RESULTS Survivors were M = 61 years old (SD = 9) and predominantly male (75%), White (90%), non-Hispanic (100%), and diagnosed with oropharynx cancer (70%). Providers were mostly female (62%), White (46%) or Asian (31%), and non-Hispanic (85%) and included physicians, registered nurses, an advanced practice nurse practitioner, a registered dietician, and a speech-language pathologist. Three qualitative themes emerged: (1) shock, shame, and self-consciousness, (2) diminished relationship satisfaction, and (3) lack of confidence at work. A subset of survivors (20%) reported clinically low social wellbeing, and more than one-third of survivors (35%) reported clinically significant fatigue, depression, anxiety, and cognitive dysfunction. CONCLUSION Survivors of HNC and HNC providers described how treatment-related symptom burden impacts psychosocial identity processes related to body image, patient-caregiver relationships, and professional work. Results can inform the development of supportive interventions to assist survivors and caregivers with navigating the psychosocial challenges of HNC treatment and survivorship.
Collapse
Affiliation(s)
- Carley Geiss
- Participant Research, Interventions, and Measurement Core, Moffitt Cancer Center, 12902 USF Magnolia Drive, MRC-AS PRISM, Tampa, FL, USA
| | - Aasha I Hoogland
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, 12902 USF Magnolia Drive, MRC-EDU, Tampa, FL, 33612, USA
| | - Brandy Arredondo
- Participant Research, Interventions, and Measurement Core, Moffitt Cancer Center, 12902 USF Magnolia Drive, MRC-AS PRISM, Tampa, FL, USA
| | - Yvelise Rodriguez
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, 12902 USF Magnolia Drive, MRC-EDU, Tampa, FL, 33612, USA
| | - Crystal Bryant
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, 12902 USF Magnolia Drive, MRC-EDU, Tampa, FL, 33612, USA
| | - Christine H Chung
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL, USA
| | - Krupal B Patel
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL, USA
| | - Brian D Gonzalez
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, 12902 USF Magnolia Drive, MRC-EDU, Tampa, FL, 33612, USA
| | - Heather S L Jim
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, 12902 USF Magnolia Drive, MRC-EDU, Tampa, FL, 33612, USA
| | - Kedar Kirtane
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL, USA
| | - Laura B Oswald
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, 12902 USF Magnolia Drive, MRC-EDU, Tampa, FL, 33612, USA.
| |
Collapse
|
4
|
Marzban S, Srivastava S, Kartika S, Bravo R, Safriel R, Zarski A, Anderson A, Chung CH, Amelio AL, West J. Spatial interactions modulate tumor growth and immune infiltration. bioRxiv 2024:2024.01.10.575036. [PMID: 38370722 PMCID: PMC10871273 DOI: 10.1101/2024.01.10.575036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/20/2024]
Abstract
Direct observation of immune cell trafficking patterns and tumor-immune interactions is unlikely in human tumors with currently available technology, but computational simulations based on clinical data can provide insight to test hypotheses. It is hypothesized that patterns of collagen formation evolve as a mechanism of immune escape, but the exact nature of the interaction between immune cells and collagen is poorly understood. Spatial data quantifying the degree of collagen fiber alignment in squamous cell carcinomas indicates that late stage disease is associated with highly aligned fibers. Here, we introduce a computational modeling framework (called Lenia) to discriminate between two hypotheses: immune cell migration that moves 1) parallel or 2) perpendicular to collagen fiber orientation. The modeling recapitulates immune-ECM interactions where collagen patterns provide immune protection, leading to an emergent inverse relationship between disease stage and immune coverage. We also illustrate the capabilities of Lenia to model the evolution of tumor progression and immune predation. Lenia provides a flexible framework for considering a spectrum of local (cell-scale) to global (tumor-scale) dynamics by defining a kernel cell-cell interaction function that governs tumor growth dynamics under immune predation with immune cell migration. Mathematical modeling provides important mechanistic insights into cell interactions. Short-range interaction kernels provide a mechanism for tumor cell survival under conditions with strong Allee effects, while asymmetric tumor-immune interaction kernels lead to poor immune response. Thus, the length scale of tumor-immune interactions drives tumor growth and infiltration.
Collapse
Affiliation(s)
- Sadegh Marzban
- Integrated Mathematical Oncology Dept., H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | - Sonal Srivastava
- Dept. of Tumor Microenvironment and Metastasis, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | - Sharon Kartika
- Dept. of Biological Sciences, Indian Institute of Science Education and Research Kolkata
| | - Rafael Bravo
- Integrated Mathematical Oncology Dept., H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | - Rachel Safriel
- High School Internship Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | - Aidan Zarski
- High School Internship Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | - Alexander Anderson
- Integrated Mathematical Oncology Dept., H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | - Christine H. Chung
- Dept. of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | - Antonio L. Amelio
- Dept. of Tumor Microenvironment and Metastasis, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
- Dept. of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | - Jeffrey West
- Integrated Mathematical Oncology Dept., H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| |
Collapse
|
5
|
Tarasova VD, Tsai J, Masannat J, Hernandez Prera JC, Hallanger Johnson J, Veloski C, Agosto Salgado S, McIver B, Drusbosky LM, Chung CH. Characterization of the Thyroid Cancer Genomic Landscape by Plasma-Based Circulating Tumor DNA Next-Generation Sequencing. Thyroid 2024; 34:197-205. [PMID: 37962267 DOI: 10.1089/thy.2023.0204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2023]
Abstract
Background: The limited availability of targeted therapies in thyroid cancer (TC) has challenged conventional treatment algorithms and has established urgency for the identification of targetable genomic abnormalities. In addition to widely adopted tissue-based next-generation sequencing (NGS), plasma-based circulating tumor DNA (ctDNA) NGS is rapidly emerging as a genomic biomarker detection method and is steadily gaining utility across solid tumors. To date, plasma-based genomic alterations in TC have not been determined. Herein, we profile potential actionable mutations detected through ctDNA in patients with TC subtypes. Methods: A retrospective data analysis of the Guardant Health, Inc. database was performed using the commercially available Guardant360® plasma-NGS test on TC samples from adult patients collected between 2016 and 2021. The landscape of genomic alterations and blood tumor mutation burden (bTMB) were analyzed in patients with different types of TC: anaplastic TC (ATC), papillary TC (PTC), follicular TC (FTC), oncolytic carcinoma of the thyroid (OCA), poorly differentiated TC (PDTC), medullary TC (MTC), and TC not otherwise specified (TC NOS). Results: Of the 1094 patients included most of the patients n = 876 had TC NOS, and 20% had a specific diagnosis (92 ATC, 62 PTC, 14 FTC, 16 OCA, 2 PDTC, and 32 MTC patients). The median age was 65 (range 10-98) and 47.3% were male. 78.3% of patients had one or more genomic alteration detected by ctDNA NGS. TP53 (46.9%) was the most common mutation detected among all TC. BRAFV600E was detected in 27.2% of ATC, 35.7% of PTC, and in none of FTC. RAS was detected in 18.5% of ATC, 11.9% of PTC, and 62.5% of FTC. RET, ALK, and NTRK fusions were seen in 1.1%, 0.5%, and 0.2% of all TC, respectively. RET mutations were detected in 66.7% of MTC. bTMB analysis was performed on 159 patients. The mean bTMB was higher in ATC compared with other types of TC (p = 0.0011, 0.0557, and <0.0001, respectively). Conclusions: Plasma-based comprehensive NGS is a promising NGS method in TC; however, future validation of the clinical utility by analysis of paired tumor and plasma samples is needed.
Collapse
Affiliation(s)
- Valentina D Tarasova
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida, USA
| | - Jill Tsai
- Guardant Health, Inc., Redwood City, California, USA
| | - Jude Masannat
- Guardant Health, Inc., Redwood City, California, USA
| | | | | | - Colleen Veloski
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida, USA
| | - Sarimar Agosto Salgado
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida, USA
| | - Bryan McIver
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida, USA
| | | | - Christine H Chung
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida, USA
| |
Collapse
|
6
|
Xie M, Chaudhary R, Slebos RJ, Lee K, Song F, Poole MI, Hoening DS, Noel LC, Hernandez-Prera JC, Conejo-Garcia JR, Chung CH, Tan AC. Immune landscape in molecular subtypes of human papillomavirus-negative head and neck cancer. Mol Carcinog 2024; 63:120-135. [PMID: 37750589 PMCID: PMC10841270 DOI: 10.1002/mc.23640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Accepted: 09/13/2023] [Indexed: 09/27/2023]
Abstract
Head and neck squamous cell carcinomas (HNSCC) remain a poorly understood disease clinically and immunologically. HPV is a known risk factor of HNSCC associated with better outcome, whereas HPV-negative HNSCC are more heterogeneous in outcome. Gene expression signatures have been developed to classify HNSCC into four molecular subtypes (classical, basal, mesenchymal, and atypical). However, the molecular underpinnings of treatment response and the immune landscape for these molecular subtypes are largely unknown. Herein, we described a comprehensive immune landscape analysis in three independent HNSCC cohorts (>700 patients) using transcriptomics data. We assigned the HPV- HNSCC patients into these four molecular subtypes and characterized the tumor microenvironment using deconvolution method. We determined that atypical and mesenchymal subtypes have greater immune enrichment and exhibit a T-cell exhaustion phenotype, compared to classical and basal subtypes. Further analyses revealed different B cell maturation and antibody isotypes enrichment patterns, and distinct immune microenvironment crosstalk in the atypical and mesenchymal subtypes. Taken together, our study suggests that treatments that enhances B cell activity may benefit patients with HNSCC of the atypical subtypes. The rationale can be utilized in the design of future precision immunotherapy trials based on the molecular subtypes of HPV- HNSCC.
Collapse
Affiliation(s)
- Mengyu Xie
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
| | - Ritu Chaudhary
- Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
| | - Robbert J.C. Slebos
- Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
| | - Kyubum Lee
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
| | - Feifei Song
- Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
| | - Maria I. Poole
- Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
| | - Dirk S. Hoening
- Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
| | - Leenil C. Noel
- Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
| | - Juan C. Hernandez-Prera
- Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
| | - Jose R. Conejo-Garcia
- Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
| | - Christine H. Chung
- Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
| | - Aik Choon Tan
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
- Huntsman Cancer Institute, Department of Oncological Sciences and Biomedical Informatics, University of Utah, Salt Lake City, UT, 84112 USA
| |
Collapse
|
7
|
Wong SJ, Torres-Saavedra PA, Saba NF, Shenouda G, Bumpous JM, Wallace RE, Chung CH, El-Naggar AK, Gwede CK, Burtness B, Tennant PA, Dunlap NE, Redman R, Stokes WA, Rudra S, Mell LK, Sacco AG, Spencer SA, Nabell L, Yao M, Cury FL, Mitchell DL, Jones CU, Firat S, Contessa JN, Galloway T, Currey A, Harris J, Curran WJ, Le QT. Radiotherapy Plus Cisplatin With or Without Lapatinib for Non-Human Papillomavirus Head and Neck Carcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol 2023; 9:1565-1573. [PMID: 37768670 PMCID: PMC10540060 DOI: 10.1001/jamaoncol.2023.3809] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2023] [Accepted: 07/07/2023] [Indexed: 09/29/2023]
Abstract
Importance Patients with locally advanced non-human papillomavirus (HPV) head and neck cancer (HNC) carry an unfavorable prognosis. Chemoradiotherapy (CRT) with cisplatin or anti-epidermal growth factor receptor (EGFR) antibody improves overall survival (OS) of patients with stage III to IV HNC, and preclinical data suggest that a small-molecule tyrosine kinase inhibitor dual EGFR and ERBB2 (formerly HER2 or HER2/neu) inhibitor may be more effective than anti-EGFR antibody therapy in HNC. Objective To examine whether adding lapatinib, a dual EGFR and HER2 inhibitor, to radiation plus cisplatin for frontline therapy of stage III to IV non-HPV HNC improves progression-free survival (PFS). Design, Setting, and Participants This multicenter, phase 2, double-blind, placebo-controlled randomized clinical trial enrolled 142 patients with stage III to IV carcinoma of the oropharynx (p16 negative), larynx, and hypopharynx with a Zubrod performance status of 0 to 1 who met predefined blood chemistry criteria from October 18, 2012, to April 18, 2017 (median follow-up, 4.1 years). Data analysis was performed from December 1, 2020, to December 4, 2020. Intervention Patients were randomized (1:1) to 70 Gy (6 weeks) plus 2 cycles of cisplatin (every 3 weeks) plus either 1500 mg per day of lapatinib (CRT plus lapatinib) or placebo (CRT plus placebo). Main Outcomes and Measures The primary end point was PFS, with 69 events required. Progression-free survival rates between arms for all randomized patients were compared by 1-sided log-rank test. Secondary end points included OS. Results Of the 142 patients enrolled, 127 (median [IQR] age, 58 [53-63] years; 98 [77.2%] male) were randomized; 63 to CRT plus lapatinib and 64 to CRT plus placebo. Final analysis did not suggest improvement in PFS (hazard ratio, 0.91; 95% CI, 0.56-1.46; P = .34) or OS (hazard ratio, 1.06; 95% CI, 0.61-1.86; P = .58) with the addition of lapatinib. There were no significant differences in grade 3 to 4 acute adverse event rates (83.3% [95% CI, 73.9%-92.8%] with CRT plus lapatinib vs 79.7% [95% CI, 69.4%-89.9%] with CRT plus placebo; P = .64) or late adverse event rates (44.4% [95% CI, 30.2%-57.8%] with CRT plus lapatinib vs 40.8% [95% CI, 27.1%-54.6%] with CRT plus placebo; P = .84). Conclusion and Relevance In this randomized clinical trial, dual EGFR-ERBB2 inhibition with lapatinib did not appear to enhance the benefit of CRT. Although the results of this trial indicate that accrual to a non-HPV HNC-specific trial is feasible, new strategies must be investigated to improve the outcome for this population with a poor prognosis. Trial Registration ClinicalTrials.gov Identifier: NCT01711658.
Collapse
Affiliation(s)
| | | | - Nabil F. Saba
- Winship Cancer Institute of Emory University, Atlanta, Georgia
| | - George Shenouda
- The Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
| | | | | | | | | | | | - Barbara Burtness
- Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut
| | - Paul A. Tennant
- Brown Cancer Center, University of Louisville, Louisville, Kentucky
| | - Neal E. Dunlap
- Brown Cancer Center, University of Louisville, Louisville, Kentucky
| | - Rebecca Redman
- Brown Cancer Center, University of Louisville, Louisville, Kentucky
| | | | - Soumon Rudra
- Winship Cancer Institute of Emory University, Atlanta, Georgia
| | - Loren K. Mell
- UC San Diego Moores Cancer Center, La Jolla, California
| | | | | | - Lisle Nabell
- The University of Alabama at Birmingham Cancer Center, Birmingham
| | - Min Yao
- Case Western Reserve University, Cleveland, Ohio
| | - Fabio L. Cury
- Department of Oncology, McGill University, Montreal, Quebec, Canada
| | | | | | | | | | | | - Adam Currey
- Zablocki Veterans Affairs Medical Center, Medical College of Wisconsin, Milwaukee
| | - Jonathan Harris
- Department of Statistics, RTOG Foundation, Philadelphia, Pennsylvania
| | | | | |
Collapse
|
8
|
Aguilar M, Ambrosi G, Anderson H, Arruda L, Attig N, Bagwell C, Barao F, Barbanera M, Barrin L, Bartoloni A, Battiston R, Belyaev N, Berdugo J, Bertucci B, Bindi V, Bollweg K, Bolster J, Borchiellini M, Borgia B, Boschini MJ, Bourquin M, Burger J, Burger WJ, Cai XD, Capell M, Casaus J, Castellini G, Cervelli F, Chang YH, Chen GM, Chen GR, Chen H, Chen HS, Chen Y, Cheng L, Chou HY, Chouridou S, Choutko V, Chung CH, Clark C, Coignet G, Consolandi C, Contin A, Corti C, Cui Z, Dadzie K, D'Angelo F, Dass A, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Felice V, Díaz C, Dimiccoli F, von Doetinchem P, Dong F, Donnini F, Duranti M, Egorov A, Eline A, Faldi F, Feng J, Fiandrini E, Fisher P, Formato V, Gámez C, García-López RJ, Gargiulo C, Gast H, Gervasi M, Giovacchini F, Gómez-Coral DM, Gong J, Goy C, Grandi D, Graziani M, Guracho AN, Haino S, Han KC, Hashmani RK, He ZH, Heber B, Hsieh TH, Hu JY, Huang BW, Ionica M, Incagli M, Jia Y, Jinchi H, Karagöz G, Khan S, Khiali B, Kirn T, Klipfel AP, Kounina O, Kounine A, Koutsenko V, Krasnopevtsev D, Kuhlman A, Kulemzin A, La Vacca G, Laudi E, Laurenti G, LaVecchia G, Lazzizzera I, Lee HT, Lee SC, Li HL, Li JQ, Li M, Li M, Li Q, Li Q, Li QY, Li S, Li SL, Li JH, Li ZH, Liang J, Liang MJ, Lin CH, Lippert T, Liu JH, Lu SQ, Lu YS, Luebelsmeyer K, Luo JZ, Luo SD, Luo X, Mañá C, Marín J, Marquardt J, Martin T, Martínez G, Masi N, Maurin D, Medvedeva T, Menchaca-Rocha A, Meng Q, Molero M, Mott P, Mussolin L, Jozani YN, Negrete J, Nicolaidis R, Nikonov N, Nozzoli F, Ocampo-Peleteiro J, Oliva A, Orcinha M, Ottupara MA, Palermo M, Palmonari F, Paniccia M, Pashnin A, Pauluzzi M, Pensotti S, Plyaskin V, Poluianov S, Qin X, Qu ZY, Quadrani L, Rancoita PG, Rapin D, Conde AR, Robyn E, Rodríguez-García I, Romaneehsen L, Rossi F, Rozhkov A, Rozza D, Sagdeev R, Savin E, Schael S, von Dratzig AS, Schwering G, Seo ES, Shan BS, Siedenburg T, Silvestre G, Song JW, Song XJ, Sonnabend R, Strigari L, Su T, Sun Q, Sun ZT, Tacconi M, Tang XW, Tang ZC, Tian J, Tian Y, Ting SCC, Ting SM, Tomassetti N, Torsti J, Urban T, Usoskin I, Vagelli V, Vainio R, Valencia-Otero M, Valente E, Valtonen E, Vázquez Acosta M, Vecchi M, Velasco M, Vialle JP, Wang CX, Wang L, Wang LQ, Wang NH, Wang QL, Wang S, Wang X, Wang Y, Wang ZM, Wei J, Weng ZL, Wu H, Wu Y, Xiao JN, Xiong RQ, Xiong XZ, Xu W, Yan Q, Yang HT, Yang Y, Yelland A, Yi H, You YH, Yu YM, Yu ZQ, Zhang C, Zhang F, Zhang FZ, Zhang J, Zhang JH, Zhang Z, Zhao F, Zheng C, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zuccon P. Temporal Structures in Positron Spectra and Charge-Sign Effects in Galactic Cosmic Rays. Phys Rev Lett 2023; 131:151002. [PMID: 37897756 DOI: 10.1103/physrevlett.131.151002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/23/2023] [Revised: 08/26/2023] [Accepted: 09/01/2023] [Indexed: 10/30/2023]
Abstract
We present the precision measurements of 11 years of daily cosmic positron fluxes in the rigidity range from 1.00 to 41.9 GV based on 3.4×10^{6} positrons collected with the Alpha Magnetic Spectrometer (AMS) aboard the International Space Station. The positron fluxes show distinctly different time variations from the electron fluxes at short and long timescales. A hysteresis between the electron fluxes and the positron fluxes is observed with a significance greater than 5σ at rigidities below 8.5 GV. On the contrary, the positron fluxes and the proton fluxes show similar time variation. Remarkably, we found that positron fluxes are modulated more than proton fluxes with a significance greater than 5σ for rigidities below 7 GV. These continuous daily positron fluxes, together with AMS daily electron, proton, and helium fluxes over an 11-year solar cycle, provide unique input to the understanding of both the charge-sign and mass dependencies of cosmic rays in the heliosphere.
Collapse
Affiliation(s)
- M Aguilar
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - G Ambrosi
- INFN Sezione di Perugia, 06100 Perugia, Italy
| | - H Anderson
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - L Arruda
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), 1649-003 Lisboa, Portugal
| | - N Attig
- Jülich Supercomputing Centre and JARA-FAME, Research Centre Jülich, 52425 Jülich, Germany
| | - C Bagwell
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - F Barao
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), 1649-003 Lisboa, Portugal
| | - M Barbanera
- INFN Sezione di Perugia, 06100 Perugia, Italy
| | - L Barrin
- European Organization for Nuclear Research (CERN), 1211 Geneva 23, Switzerland
| | | | - R Battiston
- INFN TIFPA, 38123 Trento, Italy
- Università di Trento, 38123 Trento, Italy
| | - N Belyaev
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - J Berdugo
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - B Bertucci
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - V Bindi
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - K Bollweg
- National Aeronautics and Space Administration Johnson Space Center (JSC), Houston, Texas 77058, USA
| | - J Bolster
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - M Borchiellini
- Kapteyn Astronomical Institute, University of Groningen, P.O. Box 800, 9700 AV Groningen, Netherlands
| | - B Borgia
- INFN Sezione di Roma 1, 00185 Roma, Italy
- Università di Roma La Sapienza, 00185 Roma, Italy
| | - M J Boschini
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
| | - M Bourquin
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | - J Burger
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | | | - X D Cai
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - M Capell
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - J Casaus
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | | | | | - Y H Chang
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - G M Chen
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - G R Chen
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - H Chen
- Zhejiang University (ZJU), Hangzhou 310058, China
| | - H S Chen
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - Y Chen
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - L Cheng
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - H Y Chou
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - S Chouridou
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - V Choutko
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - C H Chung
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - C Clark
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
- National Aeronautics and Space Administration Johnson Space Center (JSC), Houston, Texas 77058, USA
| | - G Coignet
- Université Grenoble Alpes, Université Savoie Mont Blanc, CNRS, LAPP-IN2P3, 74000 Annecy, France
| | - C Consolandi
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - A Contin
- INFN Sezione di Bologna, 40126 Bologna, Italy
- Università di Bologna, 40126 Bologna, Italy
| | - C Corti
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - Z Cui
- Shandong University (SDU), Jinan, Shandong 250100, China
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - K Dadzie
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - F D'Angelo
- INFN Sezione di Bologna, 40126 Bologna, Italy
- Università di Bologna, 40126 Bologna, Italy
| | - A Dass
- INFN TIFPA, 38123 Trento, Italy
- Università di Trento, 38123 Trento, Italy
| | - C Delgado
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | | | - M B Demirköz
- Department of Physics, Middle East Technical University (METU), 06800 Ankara, Türkiye
| | - L Derome
- Université Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France
| | | | - V Di Felice
- INFN Sezione di Roma Tor Vergata, 00133 Roma, Italy
| | - C Díaz
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | | | - P von Doetinchem
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - F Dong
- Southeast University (SEU), Nanjing 210096, China
| | - F Donnini
- INFN Sezione di Perugia, 06100 Perugia, Italy
| | - M Duranti
- INFN Sezione di Perugia, 06100 Perugia, Italy
| | - A Egorov
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Eline
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - F Faldi
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - J Feng
- Sun Yat-Sen University (SYSU), Guangzhou 510275, China
| | - E Fiandrini
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - P Fisher
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - V Formato
- INFN Sezione di Roma Tor Vergata, 00133 Roma, Italy
| | - C Gámez
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - R J García-López
- Instituto de Astrofísica de Canarias (IAC), 38205 La Laguna, and Departamento de Astrofísica, Universidad de La Laguna, 38206 La Laguna, Tenerife, Spain
| | - C Gargiulo
- European Organization for Nuclear Research (CERN), 1211 Geneva 23, Switzerland
| | - H Gast
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - M Gervasi
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - F Giovacchini
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - D M Gómez-Coral
- Instituto de Física, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, 01000 Mexico
| | - J Gong
- Southeast University (SEU), Nanjing 210096, China
| | - C Goy
- Université Grenoble Alpes, Université Savoie Mont Blanc, CNRS, LAPP-IN2P3, 74000 Annecy, France
| | - D Grandi
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - M Graziani
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | | | - S Haino
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - K C Han
- National Chung-Shan Institute of Science and Technology (NCSIST), Longtan, Tao Yuan 32546, Taiwan
| | - R K Hashmani
- Department of Physics, Middle East Technical University (METU), 06800 Ankara, Türkiye
| | - Z H He
- Sun Yat-Sen University (SYSU), Guangzhou 510275, China
| | - B Heber
- Institut für Experimentelle und Angewandte Physik, Christian-Alberts-Universität zu Kiel, 24118 Kiel, Germany
| | - T H Hsieh
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - J Y Hu
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - B W Huang
- Zhejiang University (ZJU), Hangzhou 310058, China
| | - M Ionica
- INFN Sezione di Perugia, 06100 Perugia, Italy
| | - M Incagli
- INFN Sezione di Pisa, 56100 Pisa, Italy
| | - Yi Jia
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - H Jinchi
- National Chung-Shan Institute of Science and Technology (NCSIST), Longtan, Tao Yuan 32546, Taiwan
| | - G Karagöz
- Department of Physics, Middle East Technical University (METU), 06800 Ankara, Türkiye
| | - S Khan
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | - B Khiali
- INFN Sezione di Roma Tor Vergata, 00133 Roma, Italy
| | - Th Kirn
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - A P Klipfel
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - O Kounina
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Kounine
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - V Koutsenko
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - D Krasnopevtsev
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Kuhlman
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - A Kulemzin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - G La Vacca
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - E Laudi
- European Organization for Nuclear Research (CERN), 1211 Geneva 23, Switzerland
| | - G Laurenti
- INFN Sezione di Bologna, 40126 Bologna, Italy
| | - G LaVecchia
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - I Lazzizzera
- INFN TIFPA, 38123 Trento, Italy
- Università di Trento, 38123 Trento, Italy
| | - H T Lee
- Academia Sinica Grid Center (ASGC), Nankang, Taipei 11529, Taiwan
| | - S C Lee
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - H L Li
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - J Q Li
- Southeast University (SEU), Nanjing 210096, China
| | - M Li
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | - M Li
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - Q Li
- Southeast University (SEU), Nanjing 210096, China
| | - Q Li
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - Q Y Li
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - S Li
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - S L Li
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - J H Li
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - Z H Li
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - J Liang
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - M J Liang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - C H Lin
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - T Lippert
- Jülich Supercomputing Centre and JARA-FAME, Research Centre Jülich, 52425 Jülich, Germany
| | - J H Liu
- Institute of Electrical Engineering (IEE), Chinese Academy of Sciences, Beijing 100190, China
| | - S Q Lu
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - Y S Lu
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - K Luebelsmeyer
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - J Z Luo
- Southeast University (SEU), Nanjing 210096, China
| | - S D Luo
- Zhejiang University (ZJU), Hangzhou 310058, China
| | - Xi Luo
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - C Mañá
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - J Marín
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - J Marquardt
- Institut für Experimentelle und Angewandte Physik, Christian-Alberts-Universität zu Kiel, 24118 Kiel, Germany
| | - T Martin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
- National Aeronautics and Space Administration Johnson Space Center (JSC), Houston, Texas 77058, USA
| | - G Martínez
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - N Masi
- INFN Sezione di Bologna, 40126 Bologna, Italy
| | - D Maurin
- Université Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France
| | - T Medvedeva
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Menchaca-Rocha
- Instituto de Física, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, 01000 Mexico
| | - Q Meng
- Southeast University (SEU), Nanjing 210096, China
| | - M Molero
- Instituto de Astrofísica de Canarias (IAC), 38205 La Laguna, and Departamento de Astrofísica, Universidad de La Laguna, 38206 La Laguna, Tenerife, Spain
| | - P Mott
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
- National Aeronautics and Space Administration Johnson Space Center (JSC), Houston, Texas 77058, USA
| | - L Mussolin
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - Y Najafi Jozani
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - J Negrete
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - R Nicolaidis
- INFN TIFPA, 38123 Trento, Italy
- Università di Trento, 38123 Trento, Italy
| | - N Nikonov
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | | | - J Ocampo-Peleteiro
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - A Oliva
- INFN Sezione di Bologna, 40126 Bologna, Italy
| | - M Orcinha
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), 1649-003 Lisboa, Portugal
| | - M A Ottupara
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - M Palermo
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - F Palmonari
- INFN Sezione di Bologna, 40126 Bologna, Italy
- Università di Bologna, 40126 Bologna, Italy
| | - M Paniccia
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | - A Pashnin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - M Pauluzzi
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - S Pensotti
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - V Plyaskin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - S Poluianov
- Sodankylä Geophysical Observatory and Space Physics and Astronomy Research Unit, University of Oulu, 90014 Oulu, Finland
| | - X Qin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - Z Y Qu
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - L Quadrani
- INFN Sezione di Bologna, 40126 Bologna, Italy
- Università di Bologna, 40126 Bologna, Italy
| | - P G Rancoita
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
| | - D Rapin
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | | | - E Robyn
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | - I Rodríguez-García
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - L Romaneehsen
- Institut für Experimentelle und Angewandte Physik, Christian-Alberts-Universität zu Kiel, 24118 Kiel, Germany
| | - F Rossi
- INFN TIFPA, 38123 Trento, Italy
- Università di Trento, 38123 Trento, Italy
| | - A Rozhkov
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - D Rozza
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
| | - R Sagdeev
- East-West Center for Space Science, University of Maryland, College Park, Maryland 20742, USA
| | - E Savin
- INFN Sezione di Bologna, 40126 Bologna, Italy
- Università di Bologna, 40126 Bologna, Italy
| | - S Schael
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | | | - G Schwering
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - E S Seo
- IPST, University of Maryland, College Park, Maryland 20742, USA
| | - B S Shan
- Beihang University (BUAA), Beijing 100191, China
| | - T Siedenburg
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - G Silvestre
- INFN Sezione di Perugia, 06100 Perugia, Italy
| | - J W Song
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - X J Song
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - R Sonnabend
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - L Strigari
- INFN Sezione di Roma 1, 00185 Roma, Italy
| | - T Su
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - Q Sun
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - Z T Sun
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - M Tacconi
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - X W Tang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - Z C Tang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - J Tian
- INFN Sezione di Roma Tor Vergata, 00133 Roma, Italy
| | - Y Tian
- Zhejiang University (ZJU), Hangzhou 310058, China
| | - Samuel C C Ting
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
- European Organization for Nuclear Research (CERN), 1211 Geneva 23, Switzerland
| | - S M Ting
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - N Tomassetti
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - J Torsti
- Space Research Laboratory, Department of Physics and Astronomy, University of Turku, 20014 Turku, Finland
| | - T Urban
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
- National Aeronautics and Space Administration Johnson Space Center (JSC), Houston, Texas 77058, USA
| | - I Usoskin
- Sodankylä Geophysical Observatory and Space Physics and Astronomy Research Unit, University of Oulu, 90014 Oulu, Finland
| | - V Vagelli
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Agenzia Spaziale Italiana (ASI), 00133 Roma, Italy
| | - R Vainio
- Space Research Laboratory, Department of Physics and Astronomy, University of Turku, 20014 Turku, Finland
| | - M Valencia-Otero
- Physics Department and Center for High Energy and High Field Physics, National Central University (NCU), Tao Yuan 32054, Taiwan
| | - E Valente
- INFN Sezione di Roma 1, 00185 Roma, Italy
- Università di Roma La Sapienza, 00185 Roma, Italy
| | - E Valtonen
- Space Research Laboratory, Department of Physics and Astronomy, University of Turku, 20014 Turku, Finland
| | - M Vázquez Acosta
- Instituto de Astrofísica de Canarias (IAC), 38205 La Laguna, and Departamento de Astrofísica, Universidad de La Laguna, 38206 La Laguna, Tenerife, Spain
| | - M Vecchi
- Kapteyn Astronomical Institute, University of Groningen, P.O. Box 800, 9700 AV Groningen, Netherlands
| | - M Velasco
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - J P Vialle
- Université Grenoble Alpes, Université Savoie Mont Blanc, CNRS, LAPP-IN2P3, 74000 Annecy, France
| | - C X Wang
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - L Wang
- Institute of Electrical Engineering (IEE), Chinese Academy of Sciences, Beijing 100190, China
| | - L Q Wang
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - N H Wang
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - Q L Wang
- Institute of Electrical Engineering (IEE), Chinese Academy of Sciences, Beijing 100190, China
| | - S Wang
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - X Wang
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - Yu Wang
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - Z M Wang
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - J Wei
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - Z L Weng
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - H Wu
- Southeast University (SEU), Nanjing 210096, China
| | - Y Wu
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - J N Xiao
- Zhejiang University (ZJU), Hangzhou 310058, China
| | - R Q Xiong
- Southeast University (SEU), Nanjing 210096, China
| | - X Z Xiong
- Zhejiang University (ZJU), Hangzhou 310058, China
| | - W Xu
- Shandong University (SDU), Jinan, Shandong 250100, China
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - Q Yan
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - H T Yang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - Y Yang
- National Cheng Kung University, Tainan 70101, Taiwan
| | - A Yelland
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - H Yi
- Southeast University (SEU), Nanjing 210096, China
| | - Y H You
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - Y M Yu
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - Z Q Yu
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - C Zhang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - F Zhang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - F Z Zhang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - J Zhang
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - J H Zhang
- Southeast University (SEU), Nanjing 210096, China
| | - Z Zhang
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - F Zhao
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - C Zheng
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - Z M Zheng
- Beihang University (BUAA), Beijing 100191, China
| | - H L Zhuang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - V Zhukov
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - A Zichichi
- INFN Sezione di Bologna, 40126 Bologna, Italy
- Università di Bologna, 40126 Bologna, Italy
| | - P Zuccon
- INFN TIFPA, 38123 Trento, Italy
- Università di Trento, 38123 Trento, Italy
| |
Collapse
|
9
|
Echevarria MI, Yang GQ, Chen DT, Kirtane K, Russell J, Kish J, Muzaffar J, Otto K, Padhya T, McMullen C, Patel K, Chung CH, Caudell JJ. Phase 1 Dose Escalation of Stereotactic Body Radiation Therapy and Concurrent Cisplatin for Reirradiation of Unresectable, Recurrent Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys 2023; 117:341-347. [PMID: 37105404 DOI: 10.1016/j.ijrobp.2023.04.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2022] [Revised: 03/27/2023] [Accepted: 04/11/2023] [Indexed: 04/29/2023]
Abstract
PURPOSE Patients with locoregional recurrence of squamous cell carcinoma of the head and neck (SCCHN) have relatively poor outcomes; therefore, stereotactic body radiation therapy (SBRT) has been investigated for this patient population. We performed a phase 1 clinical trial to establish a maximum tolerated dose of SBRT with concurrent cisplatin in previously irradiated locoregional SCCHN. METHODS AND MATERIALS Patients with recurrent SCCHN who had previously undergone radiation therapy to doses ≥45 Gy to the area of recurrence ≥6 months before enrollment and who were not surgical candidates or refused surgery were eligible. SBRT was delivered every other day for 5 fractions. Starting dose level was 6 Gy × 5 fractions, followed by 7 Gy × 5 fractions and 8 Gy × 5 fractions. Chemotherapy consisted of cisplatin given before every SBRT fraction at a dose of 15 mg/m2. Patients were monitored for dose-limiting toxicities (DLT) that occurred within 3 months from the start of SBRT. Secondary endpoints included locoregional failure, distant metastasis, and overall survival. RESULTS Twenty patients were enrolled, with 18 patients evaluable for endpoints. One patient at dose level 1 (30 Gy) died of unknown causes 2 weeks following completion of treatment. Therefore, an additional 3 patients were accrued to the 30-Gy dose level, with no further DLTs observed. Three patients were then accrued at dose level 2 (35 Gy) and 9 patients at dose level 3 (40 Gy) without DLTs. At a median follow-up of 9.5 months, cumulative incidence of locoregional failure at 2 years was 61% (95% confidence interval [CI], 12%-66%), cumulative incidence of distant metastasis was 11% (95% CI, 74%-100%) at 2 years, and overall survival was 22% (95% CI, 9%-53%) at 2 years. CONCLUSIONS Concurrent cisplatin and reirradiation with an SBRT dose of ≤40 Gy was safe and feasible in patients with locoregionally recurrent or second primary SCCHN.
Collapse
Affiliation(s)
| | - George Q Yang
- Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida
| | - Dung-Tsa Chen
- Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida
| | - Kedar Kirtane
- Department of Head and Neck Oncology, Moffitt Cancer Center, Tampa, Florida
| | - Jeffery Russell
- Department of Head and Neck Oncology, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah
| | - Julie Kish
- Department of Senior Adult Oncology, Moffitt Cancer Center, Tampa, Florida
| | - Jameel Muzaffar
- Department of Head and Neck Oncology, Moffitt Cancer Center, Tampa, Florida
| | - Kristen Otto
- Department of Head and Neck Oncology, Moffitt Cancer Center, Tampa, Florida
| | - Tapan Padhya
- Department of Head and Neck Oncology, Moffitt Cancer Center, Tampa, Florida
| | - Caitlin McMullen
- Department of Head and Neck Oncology, Moffitt Cancer Center, Tampa, Florida
| | - Krupal Patel
- Department of Head and Neck Oncology, Moffitt Cancer Center, Tampa, Florida
| | - Christine H Chung
- Department of Head and Neck Oncology, Moffitt Cancer Center, Tampa, Florida
| | - Jimmy J Caudell
- Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida
| |
Collapse
|
10
|
Ghahremani P, Marino J, Hernandez-Prera J, de la Iglesia JV, Slebos RJ, Chung CH, Nadeem S. An AI-Ready Multiplex Staining Dataset for Reproducible and Accurate Characterization of Tumor Immune Microenvironment. Med Image Comput Comput Assist Interv 2023; 14225:704-713. [PMID: 37841230 PMCID: PMC10571229 DOI: 10.1007/978-3-031-43987-2_68] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/15/2023]
Abstract
We introduce a new AI-ready computational pathology dataset containing restained and co-registered digitized images from eight head-and-neck squamous cell carcinoma patients. Specifically, the same tumor sections were stained with the expensive multiplex immunofluorescence (mIF) assay first and then restained with cheaper multiplex immunohistochemistry (mIHC). This is a first public dataset that demonstrates the equivalence of these two staining methods which in turn allows several use cases; due to the equivalence, our cheaper mIHC staining protocol can offset the need for expensive mIF staining/scanning which requires highly-skilled lab technicians. As opposed to subjective and error-prone immune cell annotations from individual pathologists (disagreement > 50%) to drive SOTA deep learning approaches, this dataset provides objective immune and tumor cell annotations via mIF/mIHC restaining for more reproducible and accurate characterization of tumor immune microenvironment (e.g. for immunotherapy). We demonstrate the effectiveness of this dataset in three use cases: (1) IHC quantification of CD3/CD8 tumor-infiltrating lymphocytes via style transfer, (2) virtual translation of cheap mIHC stains to more expensive mIF stains, and (3) virtual tumor/immune cellular phenotyping on standard hematoxylin images. The dataset is available at https://github.com/nadeemlab/DeepLIIF.
Collapse
Affiliation(s)
| | - Joseph Marino
- Memorial Sloan Kettering Cancer Center, New York NY 10065, USA
| | | | | | | | | | - Saad Nadeem
- Memorial Sloan Kettering Cancer Center, New York NY 10065, USA
| |
Collapse
|
11
|
Hu M, Coleman S, Fadlullah MZH, Spakowicz D, Chung CH, Tan AC. Deciphering the Tumor-Immune-Microbe Interactions in HPV-Negative Head and Neck Cancer. Genes (Basel) 2023; 14:1599. [PMID: 37628651 PMCID: PMC10454300 DOI: 10.3390/genes14081599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Revised: 08/01/2023] [Accepted: 08/06/2023] [Indexed: 08/27/2023] Open
Abstract
Patients with human papillomavirus-negative head and neck squamous cell carcinoma (HPV-negative HNSCC) have worse outcomes than HPV-positive HNSCC. In our study, we used a published dataset and investigated the microbes enriched in molecularly classified tumor groups. We showed that microbial signatures could distinguish Hypoxia/Immune phenotypes similar to the gene expression signatures. Furthermore, we identified three highly-correlated microbes with immune processes that are crucial for immunotherapy response. The survival of patients in a molecularly heterogenous group shows significant differences based on the co-abundance of the three microbes. Overall, we present evidence that tumor-associated microbiota are critical components of the tumor ecosystem that may impact tumor microenvironment and immunotherapy response. The results of our study warrant future investigation to experimentally validate the conclusions, which have significant impacts on clinical decision-making, such as treatment selection.
Collapse
Affiliation(s)
- Min Hu
- Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA; (M.H.); (S.C.); (M.Z.H.F.)
| | - Samuel Coleman
- Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA; (M.H.); (S.C.); (M.Z.H.F.)
| | | | - Daniel Spakowicz
- Pelotonia Institute for Immuno-Oncology and Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA;
| | - Christine H. Chung
- Department of Head and Neck Endocrine Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA;
| | - Aik Choon Tan
- Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA; (M.H.); (S.C.); (M.Z.H.F.)
- Department of Biomedical Informatics, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA
| |
Collapse
|
12
|
Gatenbee CD, Baker AM, Prabhakaran S, Swinyard O, Slebos RJC, Mandal G, Mulholland E, Andor N, Marusyk A, Leedham S, Conejo-Garcia JR, Chung CH, Robertson-Tessi M, Graham TA, Anderson ARA. Virtual alignment of pathology image series for multi-gigapixel whole slide images. Nat Commun 2023; 14:4502. [PMID: 37495577 PMCID: PMC10372014 DOI: 10.1038/s41467-023-40218-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Accepted: 07/13/2023] [Indexed: 07/28/2023] Open
Abstract
Interest in spatial omics is on the rise, but generation of highly multiplexed images remains challenging, due to cost, expertise, methodical constraints, and access to technology. An alternative approach is to register collections of whole slide images (WSI), generating spatially aligned datasets. WSI registration is a two-part problem, the first being the alignment itself and the second the application of transformations to huge multi-gigapixel images. To address both challenges, we developed Virtual Alignment of pathoLogy Image Series (VALIS), software which enables generation of highly multiplexed images by aligning any number of brightfield and/or immunofluorescent WSI, the results of which can be saved in the ome.tiff format. Benchmarking using publicly available datasets indicates VALIS provides state-of-the-art accuracy in WSI registration and 3D reconstruction. Leveraging existing open-source software tools, VALIS is written in Python, providing a free, fast, scalable, robust, and easy-to-use pipeline for registering multi-gigapixel WSI, facilitating downstream spatial analyses.
Collapse
Affiliation(s)
- Chandler D Gatenbee
- Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, SRB 4, Tampa, FL, 336122, USA.
| | - Ann-Marie Baker
- Evolution and Cancer Laboratory, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, UK
| | - Sandhya Prabhakaran
- Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, SRB 4, Tampa, FL, 336122, USA
| | - Ottilie Swinyard
- Evolution and Cancer Laboratory, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, UK
| | - Robbert J C Slebos
- Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, CSB 6, Tampa, FL, USA
| | - Gunjan Mandal
- Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, MRC, Tampa, FL, 336122, USA
| | - Eoghan Mulholland
- Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX37BN, UK
| | - Noemi Andor
- Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, SRB 4, Tampa, FL, 336122, USA
| | - Andriy Marusyk
- Department of Cancer Physiology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, SRB 4, Tampa, FL, USA
| | - Simon Leedham
- Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX37BN, UK
| | - Jose R Conejo-Garcia
- Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, MRC, Tampa, FL, 336122, USA
| | - Christine H Chung
- Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, CSB 6, Tampa, FL, USA
| | - Mark Robertson-Tessi
- Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, SRB 4, Tampa, FL, 336122, USA
| | - Trevor A Graham
- Evolution and Cancer Laboratory, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, UK
| | - Alexander R A Anderson
- Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, SRB 4, Tampa, FL, 336122, USA.
| |
Collapse
|
13
|
Li T, Patel KB, Yu X, Yao S, Wang L, Chung CH, Wang X. Unveiling targeted cell-free DNA methylation regions through paired methylome analysis of tumor and normal tissues. bioRxiv 2023:2023.06.27.546654. [PMID: 37425680 PMCID: PMC10327111 DOI: 10.1101/2023.06.27.546654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/11/2023]
Abstract
Liquid biopsy analysis of cell-free DNA (cfDNA) has revolutionized cancer research by enabling non-invasive assessment of tumor-derived genetic and epigenetic changes. In this study, we conducted a comprehensive paired-sample differential methylation analysis (psDMR) on reprocessed methylation data from two large datasets, CPTAC and TCGA, to identify and validate differentially methylated regions (DMRs) as potential cfDNA biomarkers for head and neck squamous cell carcinoma (HNSC). Our hypothesis is that the paired sample test provides a more suitable and powerful approach for the analysis of heterogeneous cancers like HNSC. The psDMR analysis revealed a significant number of overlapped hypermethylated DMRs between two datasets, indicating the reliability and relevance of these regions for cfDNA methylation biomarker discovery. We identified several candidate genes, including CALCA, ALX4, and HOXD9, which have been previously established as liquid biopsy methylation biomarkers in various cancer types. Furthermore, we demonstrated the efficacy of targeted region analysis using cfDNA methylation data from oral cavity squamous cell carcinoma and nasopharyngeal carcinoma patients, further validating the utility of psDMR analysis in prioritizing cfDNA methylation biomarkers. Overall, our study contributes to the development of cfDNA-based approaches for early cancer detection and monitoring, expanding our understanding of the epigenetic landscape of HNSC, and providing valuable insights for liquid biopsy biomarker discovery not only in HNSC and other cancer types.
Collapse
Affiliation(s)
- Tingyi Li
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 33612, USA
| | - Krupal B Patel
- Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 33612, USA
| | - Xiaoqing Yu
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 33612, USA
| | - Sijie Yao
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 33612, USA
| | - Liang Wang
- Department of Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 33612, USA
| | - Christine H Chung
- Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 33612, USA
| | - Xuefeng Wang
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 33612, USA
- Moffitt Cancer Center Immuno-Oncology Program, Tampa, Florida, 33612, USA
| |
Collapse
|
14
|
Harrington KJ, Ferris RL, Gillison M, Tahara M, Argiris A, Fayette J, Schenker M, Bratland Å, Walker JWT, Grell P, Even C, Chung CH, Redman R, Coutte A, Salas S, Grant C, de Azevedo S, Soulières D, Hansen AR, Wei L, Khan TA, Miller-Moslin K, Roberts M, Haddad R. Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial. JAMA Oncol 2023; 9:779-789. [PMID: 37022706 PMCID: PMC10080406 DOI: 10.1001/jamaoncol.2023.0147] [Citation(s) in RCA: 11] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2022] [Accepted: 12/10/2022] [Indexed: 04/07/2023]
Abstract
Importance There remains an unmet need to improve clinical outcomes in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Objective To evaluate clinical benefit of first-line nivolumab plus ipilimumab vs nivolumab alone in patients with R/M SCCHN. Design, Setting, and Participants The CheckMate 714, double-blind, phase 2 randomized clinical trial was conducted at 83 sites in 21 countries between October 20, 2016, and January 23, 2019. Eligible participants were aged 18 years or older and had platinum-refractory or platinum-eligible R/M SCCHN and no prior systemic therapy for R/M disease. Data were analyzed from October 20, 2016 (first patient, first visit), to March 8, 2019 (primary database lock), and April 6, 2020 (overall survival database lock). Interventions Patients were randomized 2:1 to receive nivolumab (3 mg/kg intravenously [IV] every 2 weeks) plus ipilimumab (1 mg/kg IV every 6 weeks) or nivolumab (3 mg/kg IV every 2 weeks) plus placebo for up to 2 years or until disease progression, unacceptable toxic effects, or consent withdrawal. Main Outcomes and Measures The primary end points were objective response rate (ORR) and duration of response between treatment arms by blinded independent central review in the population with platinum-refractory R/M SCCHN. Exploratory end points included safety. Results Of 425 included patients, 241 (56.7%; median age, 59 [range, 24-82] years; 194 males [80.5%]) had platinum-refractory disease (nivolumab plus ipilimumab, n = 159; nivolumab, n = 82) and 184 (43.3%; median age, 62 [range, 33-88] years; 152 males [82.6%]) had platinum-eligible disease (nivolumab plus ipilimumab, n = 123; nivolumab, n = 61). At primary database lock, the ORR in the population with platinum-refractory disease was 13.2% (95% CI, 8.4%-19.5%) with nivolumab plus ipilimumab vs 18.3% (95% CI, 10.6%-28.4%) with nivolumab (odds ratio [OR], 0.68; 95.5% CI, 0.33-1.43; P = .29). Median duration of response for nivolumab plus ipilimumab was not reached (NR) (95% CI, 11.0 months to NR) vs 11.1 months (95% CI, 4.1 months to NR) for nivolumab. In the population with platinum-eligible disease, the ORR was 20.3% (95% CI, 13.6%-28.5%) with nivolumab plus ipilimumab vs 29.5% (95% CI, 18.5%-42.6%) with nivolumab. The rates of grade 3 or 4 treatment-related adverse events with nivolumab plus ipilimumab vs nivolumab were 15.8% (25 of 158) vs 14.6% (12 of 82) in the population with platinum-refractory disease and 24.6% (30 of 122) vs 13.1% (8 of 61) in the population with platinum-eligible disease. Conclusions and Relevance The CheckMate 714 randomized clinical trial did not meet its primary end point of ORR benefit with first-line nivolumab plus ipilimumab vs nivolumab alone in platinum-refractory R/M SCCHN. Nivolumab plus ipilimumab was associated with an acceptable safety profile. Research to identify patient subpopulations in R/M SCCHN that would benefit from nivolumab plus ipilimumab over nivolumab monotherapy is warranted. Trial Registration ClinicalTrials.gov Identifier: NCT02823574.
Collapse
Affiliation(s)
- Kevin J. Harrington
- Royal Marsden Hospital/The Institute of Cancer Research National Institute for Health and Care Research Biomedical Research Centre, London, United Kingdom
| | | | - Maura Gillison
- The University of Texas MD Anderson Cancer Center, Houston
| | | | - Athanasios Argiris
- Hygeia Hospital, Marousi, Greece
- Thomas Jefferson University, Philadelphia, Pennsylvania
| | - Jérôme Fayette
- Centre Léon Bérard, Lyon, France
- Hôpital Saint-André, Bordeaux, France
| | | | | | | | - Peter Grell
- Masaryk Memorial Cancer Institute, Brno, Czech Republic
| | | | | | - Rebecca Redman
- University of Louisville, Brown Cancer Center, Louisville, Kentucky
| | | | - Sébastien Salas
- Assistance Publique–Hôpitaux de Marseille, Marseille, France
| | | | | | | | - Aaron R. Hansen
- Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada
| | - Li Wei
- Bristol Myers Squibb, Princeton, New Jersey
| | | | | | | | - Robert Haddad
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
15
|
Aguilar M, Ali Cavasonza L, Alpat B, Ambrosi G, Arruda L, Attig N, Bagwell C, Barao F, Barrin L, Bartoloni A, Başeğmez-du Pree S, Battiston R, Belyaev N, Berdugo J, Bertucci B, Bindi V, Bollweg K, Bolster J, Borchiellini M, Borgia B, Boschini MJ, Bourquin M, Bueno EF, Burger J, Burger WJ, Cai XD, Capell M, Casaus J, Castellini G, Cervelli F, Chang YH, Chen GM, Chen GR, Chen H, Chen HS, Chen Y, Cheng L, Chou HY, Chouridou S, Choutko V, Chung CH, Clark C, Coignet G, Consolandi C, Contin A, Corti C, Cui Z, Dadzie K, Dass A, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Felice V, Díaz C, Dimiccoli F, von Doetinchem P, Dong F, Donnini F, Duranti M, Egorov A, Eline A, Faldi F, Feng J, Fiandrini E, Fisher P, Formato V, Gámez C, García-López RJ, Gargiulo C, Gast H, Gervasi M, Giovacchini F, Gómez-Coral DM, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Guracho AN, Haino S, Han KC, Hashmani RK, He ZH, Heber B, Hsieh TH, Hu JY, Huang BW, Incagli M, Jang WY, Jia Y, Jinchi H, Karagöz G, Khiali B, Kim GN, Kirn T, Kounina O, Kounine A, Koutsenko V, Krasnopevtsev D, Kuhlman A, Kulemzin A, La Vacca G, Laudi E, Laurenti G, LaVecchia G, Lazzizzera I, Lee HT, Lee SC, Li HL, Li JQ, Li M, Li M, Li Q, Li Q, Li QY, Li S, Li SL, Li JH, Li ZH, Liang J, Liang MJ, Lin CH, Lippert T, Liu JH, Lu SQ, Lu YS, Luebelsmeyer K, Luo JZ, Luo SD, Luo X, Machate F, Mañá C, Marín J, Marquardt J, Martin T, Martínez G, Masi N, Maurin D, Medvedeva T, Menchaca-Rocha A, Meng Q, Mikhailov VV, Molero M, Mott P, Mussolin L, Negrete J, Nikonov N, Nozzoli F, Ocampo-Peleteiro J, Oliva A, Orcinha M, Ottupara MA, Palermo M, Palmonari F, Paniccia M, Pashnin A, Pauluzzi M, Pensotti S, Plyaskin V, Poluianov S, Qin X, Qu ZY, Quadrani L, Rancoita PG, Rapin D, Reina Conde A, Robyn E, Romaneehsen L, Rozhkov A, Rozza D, Sagdeev R, Schael S, Schultz von Dratzig A, Schwering G, Seo ES, Shan BS, Siedenburg T, Song JW, Song XJ, Sonnabend R, Strigari L, Su T, Sun Q, Sun ZT, Tacconi M, Tang XW, Tang ZC, Tian J, Tian Y, Ting SCC, Ting SM, Tomassetti N, Torsti J, Urban T, Usoskin I, Vagelli V, Vainio R, Valencia-Otero M, Valente E, Valtonen E, Vázquez Acosta M, Vecchi M, Velasco M, Vialle JP, Wang CX, Wang L, Wang LQ, Wang NH, Wang QL, Wang S, Wang X, Wang Y, Wang ZM, Wei J, Weng ZL, Wu H, Wu Y, Xiao JN, Xiong RQ, Xiong XZ, Xu W, Yan Q, Yang HT, Yang Y, Yashin II, Yelland A, Yi H, You YH, Yu YM, Yu ZQ, Zannoni M, Zhang C, Zhang F, Zhang FZ, Zhang J, Zhang JH, Zhang Z, Zhao F, Zheng C, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zuccon P. Properties of Cosmic-Ray Sulfur and Determination of the Composition of Primary Cosmic-Ray Carbon, Neon, Magnesium, and Sulfur: Ten-Year Results from the Alpha Magnetic Spectrometer. Phys Rev Lett 2023; 130:211002. [PMID: 37295095 DOI: 10.1103/physrevlett.130.211002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/09/2023] [Revised: 03/28/2023] [Accepted: 04/27/2023] [Indexed: 06/12/2023]
Abstract
We report the properties of primary cosmic-ray sulfur (S) in the rigidity range 2.15 GV to 3.0 TV based on 0.38×10^{6} sulfur nuclei collected by the Alpha Magnetic Spectrometer experiment (AMS). We observed that above 90 GV the rigidity dependence of the S flux is identical to the rigidity dependence of Ne-Mg-Si fluxes, which is different from the rigidity dependence of the He-C-O-Fe fluxes. We found that, similar to N, Na, and Al cosmic rays, over the entire rigidity range, the traditional primary cosmic rays S, Ne, Mg, and C all have sizeable secondary components, and the S, Ne, and Mg fluxes are well described by the weighted sum of the primary silicon flux and the secondary fluorine flux, and the C flux is well described by the weighted sum of the primary oxygen flux and the secondary boron flux. The primary and secondary contributions of the traditional primary cosmic-ray fluxes of C, Ne, Mg, and S (even Z elements) are distinctly different from the primary and secondary contributions of the N, Na, and Al (odd Z elements) fluxes. The abundance ratio at the source for S/Si is 0.167±0.006, for Ne/Si is 0.833±0.025, for Mg/Si is 0.994±0.029, and for C/O is 0.836±0.025. These values are determined independent of cosmic-ray propagation.
Collapse
Affiliation(s)
- M Aguilar
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - L Ali Cavasonza
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - B Alpat
- INFN Sezione di Perugia, 06100 Perugia, Italy
| | - G Ambrosi
- INFN Sezione di Perugia, 06100 Perugia, Italy
| | - L Arruda
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), 1649-003 Lisboa, Portugal
| | - N Attig
- Jülich Supercomputing Centre and JARA-FAME, Research Centre Jülich, 52425 Jülich, Germany
| | - C Bagwell
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - F Barao
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), 1649-003 Lisboa, Portugal
| | - L Barrin
- European Organization for Nuclear Research (CERN), 1211 Geneva 23, Switzerland
| | | | - S Başeğmez-du Pree
- Kapteyn Astronomical Institute, University of Groningen, P.O. Box 800, 9700 AV Groningen, Netherlands
| | - R Battiston
- INFN TIFPA, 38123 Trento, Italy
- Università di Trento, 38123 Trento, Italy
| | - N Belyaev
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - J Berdugo
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - B Bertucci
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - V Bindi
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - K Bollweg
- National Aeronautics and Space Administration Johnson Space Center (JSC), Houston, Texas 77058, USA
| | - J Bolster
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - M Borchiellini
- Kapteyn Astronomical Institute, University of Groningen, P.O. Box 800, 9700 AV Groningen, Netherlands
| | - B Borgia
- INFN Sezione di Roma 1, 00185 Roma, Italy
- Università di Roma La Sapienza, 00185 Roma, Italy
| | - M J Boschini
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
| | - M Bourquin
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | - E F Bueno
- Kapteyn Astronomical Institute, University of Groningen, P.O. Box 800, 9700 AV Groningen, Netherlands
| | - J Burger
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | | | - X D Cai
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - M Capell
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - J Casaus
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | | | | | - Y H Chang
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - G M Chen
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - G R Chen
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - H Chen
- Zhejiang University (ZJU), Hangzhou 310058, China
| | - H S Chen
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - Y Chen
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - L Cheng
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - H Y Chou
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - S Chouridou
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - V Choutko
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - C H Chung
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - C Clark
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
- National Aeronautics and Space Administration Johnson Space Center (JSC), Houston, Texas 77058, USA
| | - G Coignet
- Université Grenoble Alpes, Université Savoie Mont Blanc, CNRS, LAPP-IN2P3, 74000 Annecy, France
| | - C Consolandi
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - A Contin
- INFN Sezione di Bologna, 40126 Bologna, Italy
- Università di Bologna, 40126 Bologna, Italy
| | - C Corti
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - Z Cui
- Shandong University (SDU), Jinan, Shandong 250100, China
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - K Dadzie
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Dass
- INFN TIFPA, 38123 Trento, Italy
- Università di Trento, 38123 Trento, Italy
| | - C Delgado
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | | | - M B Demirköz
- Department of Physics, Middle East Technical University (METU), 06800 Ankara, Türkiye
| | - L Derome
- Université Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France
| | | | - V Di Felice
- INFN Sezione di Roma Tor Vergata, 00133 Roma, Italy
| | - C Díaz
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | | | - P von Doetinchem
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - F Dong
- Southeast University (SEU), Nanjing 210096, China
| | - F Donnini
- INFN Sezione di Perugia, 06100 Perugia, Italy
| | - M Duranti
- INFN Sezione di Perugia, 06100 Perugia, Italy
| | - A Egorov
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Eline
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - F Faldi
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - J Feng
- Sun Yat-Sen University (SYSU), Guangzhou 510275, China
| | - E Fiandrini
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - P Fisher
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - V Formato
- INFN Sezione di Roma Tor Vergata, 00133 Roma, Italy
| | - C Gámez
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - R J García-López
- Instituto de Astrofísica de Canarias (IAC), 38205 La Laguna, and Departamento de Astrofísica, Universidad de La Laguna, 38206 La Laguna, Tenerife, Spain
| | - C Gargiulo
- European Organization for Nuclear Research (CERN), 1211 Geneva 23, Switzerland
| | - H Gast
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - M Gervasi
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - F Giovacchini
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - D M Gómez-Coral
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - J Gong
- Southeast University (SEU), Nanjing 210096, China
| | - C Goy
- Université Grenoble Alpes, Université Savoie Mont Blanc, CNRS, LAPP-IN2P3, 74000 Annecy, France
| | - V Grabski
- Instituto de Física, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, 01000 Mexico
| | - D Grandi
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - M Graziani
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | | | - S Haino
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - K C Han
- National Chung-Shan Institute of Science and Technology (NCSIST), Longtan, Tao Yuan 32546, Taiwan
| | - R K Hashmani
- Department of Physics, Middle East Technical University (METU), 06800 Ankara, Türkiye
| | - Z H He
- Sun Yat-Sen University (SYSU), Guangzhou 510275, China
| | - B Heber
- Institut für Experimentelle und Angewandte Physik, Christian-Alberts-Universität zu Kiel, 24118 Kiel, Germany
| | - T H Hsieh
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - J Y Hu
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - B W Huang
- Zhejiang University (ZJU), Hangzhou 310058, China
| | - M Incagli
- INFN Sezione di Pisa, 56100 Pisa, Italy
| | - W Y Jang
- CHEP, Kyungpook National University, 41566 Daegu, Korea
| | - Yi Jia
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - H Jinchi
- National Chung-Shan Institute of Science and Technology (NCSIST), Longtan, Tao Yuan 32546, Taiwan
| | - G Karagöz
- Department of Physics, Middle East Technical University (METU), 06800 Ankara, Türkiye
| | - B Khiali
- INFN Sezione di Roma Tor Vergata, 00133 Roma, Italy
| | - G N Kim
- CHEP, Kyungpook National University, 41566 Daegu, Korea
| | - Th Kirn
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - O Kounina
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Kounine
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - V Koutsenko
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - D Krasnopevtsev
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Kuhlman
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - A Kulemzin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - G La Vacca
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - E Laudi
- European Organization for Nuclear Research (CERN), 1211 Geneva 23, Switzerland
| | - G Laurenti
- INFN Sezione di Bologna, 40126 Bologna, Italy
| | - G LaVecchia
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - I Lazzizzera
- INFN TIFPA, 38123 Trento, Italy
- Università di Trento, 38123 Trento, Italy
| | - H T Lee
- Academia Sinica Grid Center (ASGC), Nankang, Taipei 11529, Taiwan
| | - S C Lee
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - H L Li
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - J Q Li
- Southeast University (SEU), Nanjing 210096, China
| | - M Li
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | - M Li
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - Q Li
- Southeast University (SEU), Nanjing 210096, China
| | - Q Li
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - Q Y Li
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - S Li
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - S L Li
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - J H Li
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - Z H Li
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - J Liang
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - M J Liang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - C H Lin
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - T Lippert
- Jülich Supercomputing Centre and JARA-FAME, Research Centre Jülich, 52425 Jülich, Germany
| | - J H Liu
- Institute of Electrical Engineering (IEE), Chinese Academy of Sciences, Beijing 100190, China
| | - S Q Lu
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - Y S Lu
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - K Luebelsmeyer
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - J Z Luo
- Southeast University (SEU), Nanjing 210096, China
| | - S D Luo
- Zhejiang University (ZJU), Hangzhou 310058, China
| | - Xi Luo
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - F Machate
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - C Mañá
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - J Marín
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - J Marquardt
- Institut für Experimentelle und Angewandte Physik, Christian-Alberts-Universität zu Kiel, 24118 Kiel, Germany
| | - T Martin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
- National Aeronautics and Space Administration Johnson Space Center (JSC), Houston, Texas 77058, USA
| | - G Martínez
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - N Masi
- INFN Sezione di Bologna, 40126 Bologna, Italy
| | - D Maurin
- Université Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France
| | - T Medvedeva
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Menchaca-Rocha
- Instituto de Física, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, 01000 Mexico
| | - Q Meng
- Southeast University (SEU), Nanjing 210096, China
| | - V V Mikhailov
- NRNU MEPhI (Moscow Engineering Physics Institute), Moscow, 115409 Russia
| | - M Molero
- Instituto de Astrofísica de Canarias (IAC), 38205 La Laguna, and Departamento de Astrofísica, Universidad de La Laguna, 38206 La Laguna, Tenerife, Spain
| | - P Mott
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
- National Aeronautics and Space Administration Johnson Space Center (JSC), Houston, Texas 77058, USA
| | - L Mussolin
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - J Negrete
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - N Nikonov
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | | | - J Ocampo-Peleteiro
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - A Oliva
- INFN Sezione di Bologna, 40126 Bologna, Italy
| | - M Orcinha
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), 1649-003 Lisboa, Portugal
| | - M A Ottupara
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - M Palermo
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - F Palmonari
- INFN Sezione di Bologna, 40126 Bologna, Italy
- Università di Bologna, 40126 Bologna, Italy
| | - M Paniccia
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | - A Pashnin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - M Pauluzzi
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - S Pensotti
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - V Plyaskin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - S Poluianov
- Sodankylä Geophysical Observatory and Space Physics and Astronomy Research Unit, University of Oulu, 90014 Oulu, Finland
| | - X Qin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - Z Y Qu
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - L Quadrani
- INFN Sezione di Bologna, 40126 Bologna, Italy
- Università di Bologna, 40126 Bologna, Italy
| | - P G Rancoita
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
| | - D Rapin
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | | | - E Robyn
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | - L Romaneehsen
- Institut für Experimentelle und Angewandte Physik, Christian-Alberts-Universität zu Kiel, 24118 Kiel, Germany
| | - A Rozhkov
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - D Rozza
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
| | - R Sagdeev
- East-West Center for Space Science, University of Maryland, College Park, Maryland 20742, USA
| | - S Schael
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | | | - G Schwering
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - E S Seo
- IPST, University of Maryland, College Park, Maryland 20742, USA
| | - B S Shan
- Beihang University (BUAA), Beijing 100191, China
| | - T Siedenburg
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - J W Song
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - X J Song
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - R Sonnabend
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - L Strigari
- INFN Sezione di Roma 1, 00185 Roma, Italy
| | - T Su
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - Q Sun
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - Z T Sun
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - M Tacconi
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - X W Tang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - Z C Tang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - J Tian
- INFN Sezione di Roma Tor Vergata, 00133 Roma, Italy
| | - Y Tian
- Zhejiang University (ZJU), Hangzhou 310058, China
| | - Samuel C C Ting
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
- European Organization for Nuclear Research (CERN), 1211 Geneva 23, Switzerland
| | - S M Ting
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - N Tomassetti
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - J Torsti
- Space Research Laboratory, Department of Physics and Astronomy, University of Turku, 20014 Turku, Finland
| | - T Urban
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
- National Aeronautics and Space Administration Johnson Space Center (JSC), Houston, Texas 77058, USA
| | - I Usoskin
- Sodankylä Geophysical Observatory and Space Physics and Astronomy Research Unit, University of Oulu, 90014 Oulu, Finland
| | - V Vagelli
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Agenzia Spaziale Italiana (ASI), 00133 Roma, Italy
| | - R Vainio
- Space Research Laboratory, Department of Physics and Astronomy, University of Turku, 20014 Turku, Finland
| | - M Valencia-Otero
- Physics Department and Center for High Energy and High Field Physics, National Central University (NCU), Tao Yuan 32054, Taiwan
| | - E Valente
- INFN Sezione di Roma 1, 00185 Roma, Italy
- Università di Roma La Sapienza, 00185 Roma, Italy
| | - E Valtonen
- Space Research Laboratory, Department of Physics and Astronomy, University of Turku, 20014 Turku, Finland
| | - M Vázquez Acosta
- Instituto de Astrofísica de Canarias (IAC), 38205 La Laguna, and Departamento de Astrofísica, Universidad de La Laguna, 38206 La Laguna, Tenerife, Spain
| | - M Vecchi
- Kapteyn Astronomical Institute, University of Groningen, P.O. Box 800, 9700 AV Groningen, Netherlands
| | - M Velasco
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - J P Vialle
- Université Grenoble Alpes, Université Savoie Mont Blanc, CNRS, LAPP-IN2P3, 74000 Annecy, France
| | - C X Wang
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - L Wang
- Institute of Electrical Engineering (IEE), Chinese Academy of Sciences, Beijing 100190, China
| | - L Q Wang
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - N H Wang
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - Q L Wang
- Institute of Electrical Engineering (IEE), Chinese Academy of Sciences, Beijing 100190, China
| | - S Wang
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - X Wang
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - Yu Wang
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - Z M Wang
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - J Wei
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - Z L Weng
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - H Wu
- Southeast University (SEU), Nanjing 210096, China
| | - Y Wu
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - J N Xiao
- Zhejiang University (ZJU), Hangzhou 310058, China
| | - R Q Xiong
- Southeast University (SEU), Nanjing 210096, China
| | - X Z Xiong
- Zhejiang University (ZJU), Hangzhou 310058, China
| | - W Xu
- Shandong University (SDU), Jinan, Shandong 250100, China
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - Q Yan
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - H T Yang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - Y Yang
- National Cheng Kung University, Tainan 70101, Taiwan
| | - I I Yashin
- NRNU MEPhI (Moscow Engineering Physics Institute), Moscow, 115409 Russia
| | - A Yelland
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - H Yi
- Southeast University (SEU), Nanjing 210096, China
| | - Y H You
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - Y M Yu
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - Z Q Yu
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - M Zannoni
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - C Zhang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - F Zhang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - F Z Zhang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - J Zhang
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - J H Zhang
- Southeast University (SEU), Nanjing 210096, China
| | - Z Zhang
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - F Zhao
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - C Zheng
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - Z M Zheng
- Beihang University (BUAA), Beijing 100191, China
| | - H L Zhuang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - V Zhukov
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - A Zichichi
- INFN Sezione di Bologna, 40126 Bologna, Italy
- Università di Bologna, 40126 Bologna, Italy
| | - P Zuccon
- INFN TIFPA, 38123 Trento, Italy
- Università di Trento, 38123 Trento, Italy
| |
Collapse
|
16
|
Ghahremani P, Marino J, Hernandez-Prera J, de la Iglesia JV, Slebos RJ, Chung CH, Nadeem S. An AI-Ready Multiplex Staining Dataset for Reproducible and Accurate Characterization of Tumor Immune Microenvironment. ArXiv 2023:arXiv:2305.16465v1. [PMID: 37292462 PMCID: PMC10246071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
We introduce a new AI-ready computational pathology dataset containing restained and co-registered digitized images from eight head-and-neck squamous cell carcinoma patients. Specifically, the same tumor sections were stained with the expensive multiplex immunofluorescence (mIF) assay first and then restained with cheaper multiplex immunohistochemistry (mIHC). This is a first public dataset that demonstrates the equivalence of these two staining methods which in turn allows several use cases; due to the equivalence, our cheaper mIHC staining protocol can offset the need for expensive mIF staining/scanning which requires highly-skilled lab technicians. As opposed to subjective and error-prone immune cell annotations from individual pathologists (disagreement > 50%) to drive SOTA deep learning approaches, this dataset provides objective immune and tumor cell annotations via mIF/mIHC restaining for more reproducible and accurate characterization of tumor immune microenvironment (e.g. for immunotherapy). We demonstrate the effectiveness of this dataset in three use cases: (1) IHC quantification of CD3/CD8 tumor-infiltrating lymphocytes via style transfer, (2) virtual translation of cheap mIHC stains to more expensive mIF stains, and (3) virtual tumor/immune cellular phenotyping on standard hematoxylin images. The dataset is available at \url{https://github.com/nadeemlab/DeepLIIF}.
Collapse
|
17
|
Kirtane K, Hoogland AI, Li X, Rodriguez Y, Scheel K, Small BJ, Oswald LB, Muzaffar J, Kish JA, Bonomi M, Bhateja P, Saba NF, Steuer CE, Chung CH, Jim HSL. Patient-reported outcomes in immunotherapy for head and neck cancer. Head Neck 2023. [PMID: 37141438 DOI: 10.1002/hed.27388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2022] [Revised: 04/21/2023] [Accepted: 04/25/2023] [Indexed: 05/06/2023] Open
Abstract
BACKGROUND Data about patient-reported outcomes (PROs) among patients with head and neck squamous cell carcinoma (HNSCC) treated with immune checkpoint inhibitors are sparse. Our exploratory study evaluated PROs in patients with HNSCC starting treatment with immune checkpoint inhibitor monotherapy or combination therapy with cetuximab. METHODS Patients were recruited prior to receipt of their first checkpoint inhibitor therapy infusion. Participants completed measures of checkpoint inhibitor toxicities and quality of life (QOL) at on-treatment clinic visits. RESULTS Among patients treated with checkpoint inhibitor monotherapy (n = 48) or combination therapy (n = 38) toxicity increased over time (p < 0.05), while overall QOL improved from baseline to 12 weeks, with stable or declining QOL thereafter (p < 0.05). There were no group differences in change in toxicity index or QOL. Toxicity index scores were significantly higher in the combination group at 18-20 weeks and 6 months post-initiation of immune checkpoint inhibitor (p < 0.05). There were no significant group differences at baseline, the 6-8 week (p = 0.13) or 3-month (p = 0.09) evaluations. The combination group reported better emotional well-being at baseline than the monotherapy group (p = 0.04), There were no other group differences QOL at baseline or later timepoints. CONCLUSIONS Despite increasing patient-reported toxicity, checkpoint inhibitor monotherapy and combination therapy were associated with similar transient improvements, then worsening, of QOL in patients with HNSCC.
Collapse
Affiliation(s)
- Kedar Kirtane
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida, USA
| | - Aasha I Hoogland
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida, USA
| | - Xiaoyin Li
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida, USA
| | - Yvelise Rodriguez
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida, USA
| | - Kelsey Scheel
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida, USA
| | - Brent J Small
- School of Aging Studies, University of South Florida, Tampa, Florida, USA
| | - Laura B Oswald
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida, USA
| | - Jameel Muzaffar
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida, USA
| | - Julie A Kish
- Department of Personalized Medicine, Moffitt Cancer Center, Tampa, Florida, USA
| | - Marcelo Bonomi
- Department of Internal Medicine and The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA
| | - Priyanka Bhateja
- Department of Internal Medicine and The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA
| | - Nabil F Saba
- Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA
| | - Conor E Steuer
- Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA
| | - Christine H Chung
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida, USA
| | - Heather S L Jim
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida, USA
| |
Collapse
|
18
|
Chaudhary R, Slebos RJ, Noel LC, Song F, Poole MI, Hoening DS, Hernandez-Prera JC, Conejo-Garcia JR, Guevara-Patino JA, Wang X, Xie M, Tan AC, Chung CH. EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma. Cancer Res Commun 2023; 3:896-907. [PMID: 37377902 PMCID: PMC10202124 DOI: 10.1158/2767-9764.crc-22-0443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Revised: 02/01/2023] [Accepted: 05/02/2023] [Indexed: 06/29/2023]
Abstract
Head and neck squamous cell carcinoma (HNSCC) has one of the most hypoxic and immunosuppressive tumor microenvironments (TME) among solid tumors. However, there is no proven therapeutic strategy to remodel the TME to be less hypoxic and proinflammatory. In this study, we classified tumors according to a Hypoxia-Immune signature, characterized the immune cells in each subgroup, and analyzed the signaling pathways to identify a potential therapeutic target that can remodel the TME. We confirmed that hypoxic tumors had significantly higher numbers of immunosuppressive cells, as evidenced by a lower ratio of CD8+ T cells to FOXP3+ regulatory T cells, compared with nonhypoxic tumors. Patients with hypoxic tumors had worse outcomes after treatment with pembrolizumab or nivolumab, anti-programmed cell death-1 inhibitors. Our expression analysis also indicated that hypoxic tumors predominantly increased the expression of the EGFR and TGFβ pathway genes. Cetuximab, an anti-EGFR inhibitor, decreased the expression of hypoxia signature genes, suggesting that it may alleviate the effects of hypoxia and remodel the TME to become more proinflammatory. Our study provides a rationale for treatment strategies combining EGFR-targeted agents and immunotherapy in the management of hypoxic HNSCC. Significance While the hypoxic and immunosuppressive TME of HNSCC has been well described, comprehensive evaluation of the immune cell components and signaling pathways contributing to immunotherapy resistance has been poorly characterized. We further identified additional molecular determinants and potential therapeutic targets of the hypoxic TME to fully leverage currently available targeted therapies that can be administered with immunotherapy.
Collapse
Affiliation(s)
- Ritu Chaudhary
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida
| | - Robbert J.C. Slebos
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida
| | - Leenil C. Noel
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida
| | - Feifei Song
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida
| | - Maria I. Poole
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida
| | - Dirk S. Hoening
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida
| | | | | | | | - Xuefeng Wang
- Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida
| | - Mengyu Xie
- Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida
| | - Aik Choon Tan
- Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
| | - Christine H. Chung
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida
| |
Collapse
|
19
|
Agosto Salgado S, Kaye ER, Sargi Z, Chung CH, Papaleontiou M. Management of Advanced Thyroid Cancer: Overview, Advances, and Opportunities. Am Soc Clin Oncol Educ Book 2023; 43:e389708. [PMID: 37186883 DOI: 10.1200/edbk_389708] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/17/2023]
Abstract
Thyroid cancer is the most common endocrine malignancy with almost one million people living with thyroid cancer in the United States. Although early-stage well-differentiated thyroid cancers account for the majority of thyroid cancers on diagnosis and have excellent survival rates, the incidence of advanced-stage disease has increased over the past few years and confers poorer prognosis. Until recently, patients with advanced thyroid cancer had limited therapeutic options. However, the landscape of thyroid cancer treatment has dramatically changed in the past decade with the current availability of several novel effective therapeutic options, leading to significant advances and improved patient outcomes in the management of advanced disease. In this review, we summarize the current status of advanced thyroid cancer treatment options and discuss recent advances made in targeted therapies that have proven promising to clinically benefit patients with advanced thyroid cancer.
Collapse
Affiliation(s)
- Sarimar Agosto Salgado
- Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
| | - Erin Rachel Kaye
- Department of Otolaryngology-Head and Neck Surgery, University of Miami Miller School of Medicine, Miami, FL
| | - Zoukaa Sargi
- Department of Otolaryngology and Neurosurgery, University of Miami Miller School of Medicine, Miami, FL
| | - Christine H Chung
- Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
| | - Maria Papaleontiou
- Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI
| |
Collapse
|
20
|
Aguilar M, Cavasonza LA, Ambrosi G, Arruda L, Attig N, Bagwell C, Barao F, Barrin L, Bartoloni A, Başeğmez-du Pree S, Battiston R, Behlmann M, Belyaev N, Berdugo J, Bertucci B, Bindi V, Bollweg K, Bolster J, Borgia B, Boschini MJ, Bourquin M, Bueno EF, Burger J, Burger WJ, Burmeister S, Cai XD, Capell M, Casaus J, Castellini G, Cervelli F, Chang YH, Chen GM, Chen GR, Chen HS, Chen Y, Cheng L, Chou HY, Chouridou S, Choutko V, Chung CH, Clark C, Coignet G, Consolandi C, Contin A, Corti C, Cui Z, Dadzie K, Dass A, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Felice V, Díaz C, Dimiccoli F, von Doetinchem P, Dong F, Donnini F, Duranti M, Egorov A, Eline A, Faldi F, Feng J, Fiandrini E, Fisher P, Formato V, Freeman C, Gámez C, García-López RJ, Gargiulo C, Gast H, Gervasi M, Giovacchini F, Gómez-Coral DM, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Guracho AN, Haino S, Han KC, Hashmani RK, He ZH, Heber B, Hsieh TH, Hu JY, Incagli M, Jang WY, Jia Y, Jinchi H, Karagöz G, Khiali B, Kim GN, Kirn T, Kounina O, Kounine A, Koutsenko V, Krasnopevtsev D, Kuhlman A, Kulemzin A, La Vacca G, Laudi E, Laurenti G, LaVecchia G, Lazzizzera I, Lee HT, Lee SC, Li HL, Li JQ, Li M, Li Q, Li QY, Li S, Li SL, Li JH, Li ZH, Liang J, Liang MJ, Light C, Lin CH, Lippert T, Liu JH, Lu SQ, Lu YS, Luebelsmeyer K, Luo JZ, Luo X, Machate F, Mañá C, Marín J, Marquardt J, Martin T, Martínez G, Masi N, Maurin D, Medvedeva T, Menchaca-Rocha A, Meng Q, Mikhailov VV, Molero M, Mott P, Mussolin L, Negrete J, Nikonov N, Nozzoli F, Ocampo-Peleteiro J, Oliva A, Orcinha M, Palermo M, Palmonari F, Paniccia M, Pashnin A, Pauluzzi M, Pensotti S, Plyaskin V, Pohl M, Poluianov S, Qin X, Qu ZY, Quadrani L, Rancoita PG, Rapin D, Conde AR, Robyn E, Rosier-Lees S, Rozhkov A, Rozza D, Sagdeev R, Schael S, von Dratzig AS, Schwering G, Seo ES, Shan BS, Siedenburg T, Song JW, Song XJ, Sonnabend R, Strigari L, Su T, Sun Q, Sun ZT, Tacconi M, Tang XW, Tang ZC, Tian J, Ting SCC, Ting SM, Tomassetti N, Torsti J, Urban T, Usoskin I, Vagelli V, Vainio R, Valencia-Otero M, Valente E, Valtonen E, Vázquez Acosta M, Vecchi M, Velasco M, Vialle JP, Wang CX, Wang L, Wang LQ, Wang NH, Wang QL, Wang S, Wang X, Wang Y, Wang ZM, Wei J, Weng ZL, Wu H, Xiong RQ, Xu W, Yan Q, Yang Y, Yashin II, Yelland A, Yi H, Yu YM, Yu ZQ, Zannoni M, Zhang C, Zhang F, Zhang FZ, Zhang JH, Zhang Z, Zhao F, Zheng C, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zuccon P. Temporal Structures in Electron Spectra and Charge Sign Effects in Galactic Cosmic Rays. Phys Rev Lett 2023; 130:161001. [PMID: 37154630 DOI: 10.1103/physrevlett.130.161001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/22/2022] [Revised: 11/21/2022] [Accepted: 02/09/2023] [Indexed: 05/10/2023]
Abstract
We present the precision measurements of 11 years of daily cosmic electron fluxes in the rigidity interval from 1.00 to 41.9 GV based on 2.0×10^{8} electrons collected with the Alpha Magnetic Spectrometer (AMS) aboard the International Space Station. The electron fluxes exhibit variations on multiple timescales. Recurrent electron flux variations with periods of 27 days, 13.5 days, and 9 days are observed. We find that the electron fluxes show distinctly different time variations from the proton fluxes. Remarkably, a hysteresis between the electron flux and the proton flux is observed with a significance of greater than 6σ at rigidities below 8.5 GV. Furthermore, significant structures in the electron-proton hysteresis are observed corresponding to sharp structures in both fluxes. This continuous daily electron data provide unique input to the understanding of the charge sign dependence of cosmic rays over an 11-year solar cycle.
Collapse
Affiliation(s)
- M Aguilar
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - L Ali Cavasonza
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - G Ambrosi
- INFN Sezione di Perugia, 06100 Perugia, Italy
| | - L Arruda
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), 1649-003 Lisboa, Portugal
| | - N Attig
- Jülich Supercomputing Centre and JARA-FAME, Research Centre Jülich, 52425 Jülich, Germany
| | - C Bagwell
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - F Barao
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), 1649-003 Lisboa, Portugal
| | - L Barrin
- European Organization for Nuclear Research (CERN), 1211 Geneva 23, Switzerland
| | | | - S Başeğmez-du Pree
- Kapteyn Astronomical Institute, University of Groningen, P.O. Box 800, 9700 AV Groningen, Netherlands
| | - R Battiston
- INFN TIFPA, 38123 Trento, Italy
- Università di Trento, 38123 Trento, Italy
| | - M Behlmann
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - N Belyaev
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - J Berdugo
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - B Bertucci
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - V Bindi
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - K Bollweg
- National Aeronautics and Space Administration Johnson Space Center (JSC), Houston, Texas 77058, USA
| | - J Bolster
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - B Borgia
- INFN Sezione di Roma 1, 00185 Roma, Italy
- Università di Roma La Sapienza, 00185 Roma, Italy
| | - M J Boschini
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
| | - M Bourquin
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | - E F Bueno
- Kapteyn Astronomical Institute, University of Groningen, P.O. Box 800, 9700 AV Groningen, Netherlands
| | - J Burger
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | | | - S Burmeister
- Institut für Experimentelle und Angewandte Physik, Christian-Alberts-Universität zu Kiel, 24118 Kiel, Germany
| | - X D Cai
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - M Capell
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - J Casaus
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | | | | | - Y H Chang
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - G M Chen
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - G R Chen
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - H S Chen
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - Y Chen
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - L Cheng
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - H Y Chou
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - S Chouridou
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - V Choutko
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - C H Chung
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - C Clark
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
- National Aeronautics and Space Administration Johnson Space Center (JSC), Houston, Texas 77058, USA
| | - G Coignet
- Université Grenoble Alpes, Université Savoie Mont Blanc, CNRS, LAPP-IN2P3, 74000 Annecy, France
| | - C Consolandi
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - A Contin
- INFN Sezione di Bologna, 40126 Bologna, Italy
- Università di Bologna, 40126 Bologna, Italy
| | - C Corti
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - Z Cui
- Shandong University (SDU), Jinan, Shandong 250100, China
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - K Dadzie
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Dass
- INFN TIFPA, 38123 Trento, Italy
- Università di Trento, 38123 Trento, Italy
| | - C Delgado
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | | | - M B Demirköz
- Department of Physics, Middle East Technical University (METU), 06800 Ankara, Turkey
| | - L Derome
- Université Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France
| | | | - V Di Felice
- INFN Sezione di Roma Tor Vergata, 00133 Roma, Italy
| | - C Díaz
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | | | - P von Doetinchem
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - F Dong
- Southeast University (SEU), Nanjing 210096, China
| | - F Donnini
- INFN Sezione di Perugia, 06100 Perugia, Italy
| | - M Duranti
- INFN Sezione di Perugia, 06100 Perugia, Italy
| | - A Egorov
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Eline
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - F Faldi
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - J Feng
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - E Fiandrini
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - P Fisher
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - V Formato
- INFN Sezione di Roma Tor Vergata, 00133 Roma, Italy
| | - C Freeman
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - C Gámez
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - R J García-López
- Instituto de Astrofísica de Canarias (IAC), 38205 La Laguna, Tenerife, Spain and Departamento de Astrofísica, Universidad de La Laguna, 38206 La Laguna, Tenerife, Spain
| | - C Gargiulo
- European Organization for Nuclear Research (CERN), 1211 Geneva 23, Switzerland
| | - H Gast
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - M Gervasi
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - F Giovacchini
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - D M Gómez-Coral
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - J Gong
- Southeast University (SEU), Nanjing 210096, China
| | - C Goy
- Université Grenoble Alpes, Université Savoie Mont Blanc, CNRS, LAPP-IN2P3, 74000 Annecy, France
| | - V Grabski
- Instituto de Física, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, 01000 Mexico
| | - D Grandi
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - M Graziani
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | | | - S Haino
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - K C Han
- National Chung-Shan Institute of Science and Technology (NCSIST), Longtan, Tao Yuan 32546, Taiwan
| | - R K Hashmani
- Department of Physics, Middle East Technical University (METU), 06800 Ankara, Turkey
| | - Z H He
- Sun Yat-Sen University (SYSU), Guangzhou, 510275, China
| | - B Heber
- Institut für Experimentelle und Angewandte Physik, Christian-Alberts-Universität zu Kiel, 24118 Kiel, Germany
| | - T H Hsieh
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - J Y Hu
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - M Incagli
- INFN Sezione di Pisa, 56100 Pisa, Italy
| | - W Y Jang
- CHEP, Kyungpook National University, 41566 Daegu, Korea
| | - Yi Jia
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - H Jinchi
- National Chung-Shan Institute of Science and Technology (NCSIST), Longtan, Tao Yuan 32546, Taiwan
| | - G Karagöz
- Department of Physics, Middle East Technical University (METU), 06800 Ankara, Turkey
| | - B Khiali
- INFN Sezione di Roma Tor Vergata, 00133 Roma, Italy
| | - G N Kim
- CHEP, Kyungpook National University, 41566 Daegu, Korea
| | - Th Kirn
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - O Kounina
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Kounine
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - V Koutsenko
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - D Krasnopevtsev
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Kuhlman
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - A Kulemzin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - G La Vacca
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - E Laudi
- European Organization for Nuclear Research (CERN), 1211 Geneva 23, Switzerland
| | - G Laurenti
- INFN Sezione di Bologna, 40126 Bologna, Italy
| | - G LaVecchia
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - I Lazzizzera
- INFN TIFPA, 38123 Trento, Italy
- Università di Trento, 38123 Trento, Italy
| | - H T Lee
- Academia Sinica Grid Center (ASGC), Nankang, Taipei 11529, Taiwan
| | - S C Lee
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - H L Li
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - J Q Li
- Southeast University (SEU), Nanjing 210096, China
| | - M Li
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - Q Li
- Southeast University (SEU), Nanjing 210096, China
| | - Q Y Li
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - S Li
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - S L Li
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - J H Li
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - Z H Li
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - J Liang
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - M J Liang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - C Light
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - C H Lin
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - T Lippert
- Jülich Supercomputing Centre and JARA-FAME, Research Centre Jülich, 52425 Jülich, Germany
| | - J H Liu
- Institute of Electrical Engineering (IEE), Chinese Academy of Sciences, Beijing 100190, China
| | - S Q Lu
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - Y S Lu
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - K Luebelsmeyer
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - J Z Luo
- Southeast University (SEU), Nanjing 210096, China
| | - Xi Luo
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - F Machate
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - C Mañá
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - J Marín
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - J Marquardt
- Institut für Experimentelle und Angewandte Physik, Christian-Alberts-Universität zu Kiel, 24118 Kiel, Germany
| | - T Martin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
- National Aeronautics and Space Administration Johnson Space Center (JSC), Houston, Texas 77058, USA
| | - G Martínez
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - N Masi
- INFN Sezione di Bologna, 40126 Bologna, Italy
| | - D Maurin
- Université Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France
| | - T Medvedeva
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Menchaca-Rocha
- Instituto de Física, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, 01000 Mexico
| | - Q Meng
- Southeast University (SEU), Nanjing 210096, China
| | - V V Mikhailov
- NRNU MEPhI (Moscow Engineering Physics Institute), Moscow, 115409 Russia
| | - M Molero
- Instituto de Astrofísica de Canarias (IAC), 38205 La Laguna, Tenerife, Spain and Departamento de Astrofísica, Universidad de La Laguna, 38206 La Laguna, Tenerife, Spain
| | - P Mott
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
- National Aeronautics and Space Administration Johnson Space Center (JSC), Houston, Texas 77058, USA
| | - L Mussolin
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - J Negrete
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - N Nikonov
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | | | - J Ocampo-Peleteiro
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - A Oliva
- INFN Sezione di Bologna, 40126 Bologna, Italy
| | - M Orcinha
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), 1649-003 Lisboa, Portugal
| | - M Palermo
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - F Palmonari
- INFN Sezione di Bologna, 40126 Bologna, Italy
- Università di Bologna, 40126 Bologna, Italy
| | - M Paniccia
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | - A Pashnin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - M Pauluzzi
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - S Pensotti
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - V Plyaskin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - M Pohl
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | - S Poluianov
- Sodankylä Geophysical Observatory and Space Physics and Astronomy Research Unit, University of Oulu, 90014 Oulu, Finland
| | - X Qin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - Z Y Qu
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - L Quadrani
- INFN Sezione di Bologna, 40126 Bologna, Italy
- Università di Bologna, 40126 Bologna, Italy
| | - P G Rancoita
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
| | - D Rapin
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | | | - E Robyn
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | - S Rosier-Lees
- Université Grenoble Alpes, Université Savoie Mont Blanc, CNRS, LAPP-IN2P3, 74000 Annecy, France
| | - A Rozhkov
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - D Rozza
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
| | - R Sagdeev
- East-West Center for Space Science, University of Maryland, College Park, Maryland 20742, USA
| | - S Schael
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | | | - G Schwering
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - E S Seo
- IPST, University of Maryland, College Park, Maryland 20742, USA
| | - B S Shan
- Beihang University (BUAA), Beijing 100191, China
| | - T Siedenburg
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - J W Song
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - X J Song
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - R Sonnabend
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - L Strigari
- INFN Sezione di Roma 1, 00185 Roma, Italy
| | - T Su
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - Q Sun
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - Z T Sun
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - M Tacconi
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - X W Tang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - Z C Tang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - J Tian
- INFN Sezione di Roma Tor Vergata, 00133 Roma, Italy
| | - Samuel C C Ting
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
- European Organization for Nuclear Research (CERN), 1211 Geneva 23, Switzerland
| | - S M Ting
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - N Tomassetti
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - J Torsti
- Space Research Laboratory, Department of Physics and Astronomy, University of Turku, 20014 Turku, Finland
| | - T Urban
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
- National Aeronautics and Space Administration Johnson Space Center (JSC), Houston, Texas 77058, USA
| | - I Usoskin
- Sodankylä Geophysical Observatory and Space Physics and Astronomy Research Unit, University of Oulu, 90014 Oulu, Finland
| | - V Vagelli
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Agenzia Spaziale Italiana (ASI), 00133 Roma, Italy
| | - R Vainio
- Space Research Laboratory, Department of Physics and Astronomy, University of Turku, 20014 Turku, Finland
| | - M Valencia-Otero
- Physics Department and Center for High Energy and High Field Physics, National Central University (NCU), Tao Yuan 32054, Taiwan
| | - E Valente
- INFN Sezione di Roma 1, 00185 Roma, Italy
- Università di Roma La Sapienza, 00185 Roma, Italy
| | - E Valtonen
- Space Research Laboratory, Department of Physics and Astronomy, University of Turku, 20014 Turku, Finland
| | - M Vázquez Acosta
- Instituto de Astrofísica de Canarias (IAC), 38205 La Laguna, Tenerife, Spain and Departamento de Astrofísica, Universidad de La Laguna, 38206 La Laguna, Tenerife, Spain
| | - M Vecchi
- Kapteyn Astronomical Institute, University of Groningen, P.O. Box 800, 9700 AV Groningen, Netherlands
| | - M Velasco
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - J P Vialle
- Université Grenoble Alpes, Université Savoie Mont Blanc, CNRS, LAPP-IN2P3, 74000 Annecy, France
| | - C X Wang
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - L Wang
- Institute of Electrical Engineering (IEE), Chinese Academy of Sciences, Beijing 100190, China
| | - L Q Wang
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - N H Wang
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - Q L Wang
- Institute of Electrical Engineering (IEE), Chinese Academy of Sciences, Beijing 100190, China
| | - S Wang
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - X Wang
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - Yu Wang
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - Z M Wang
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - J Wei
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - Z L Weng
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - H Wu
- Southeast University (SEU), Nanjing 210096, China
| | - R Q Xiong
- Southeast University (SEU), Nanjing 210096, China
| | - W Xu
- Shandong University (SDU), Jinan, Shandong 250100, China
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - Q Yan
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - Y Yang
- National Cheng Kung University, Tainan 70101, Taiwan
| | - I I Yashin
- NRNU MEPhI (Moscow Engineering Physics Institute), Moscow, 115409 Russia
| | - A Yelland
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - H Yi
- Southeast University (SEU), Nanjing 210096, China
| | - Y M Yu
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - Z Q Yu
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - M Zannoni
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - C Zhang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - F Zhang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - F Z Zhang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - J H Zhang
- Southeast University (SEU), Nanjing 210096, China
| | - Z Zhang
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - F Zhao
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - C Zheng
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - Z M Zheng
- Beihang University (BUAA), Beijing 100191, China
| | - H L Zhuang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - V Zhukov
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - A Zichichi
- INFN Sezione di Bologna, 40126 Bologna, Italy
- Università di Bologna, 40126 Bologna, Italy
| | - P Zuccon
- INFN TIFPA, 38123 Trento, Italy
- Università di Trento, 38123 Trento, Italy
| |
Collapse
|
21
|
Lin CN, Chung CH, Tan AC. Abstract 5409: NuKit: a deep learning platform for histopathological Images. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-5409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Hematoxylin and eosin (H&E) staining is the most common type of histopathological images used for quantitative data analysis. For histopathological image analysis, nucleus segmentation represents one of the initial steps in quantitative data analysis pipelines. Recently, deep learning methods for nucleus segmentation on histopathological images become the mainstream in digital pathology. However, adopting these pre-trained models in digital pathology or clinical research remains limited. Two main factors limit the usage of deep learning methods in routine research: 1) many models required some technical background to execute the programs, and 2) the speed of returning the results to the users. To overcome these limitations, we have developed and implemented NuKit, a deep learning platform which accelerates nucleus segmentation and provides prompt results to the users. NuKit platform consists of two deep learning models coupled with an interactive graphical user interface (GUI) to provide fast and automatic nucleus segmentation “on the fly”. The two deep learning models are: 1) the whole image segmentation model and 2) the click segmentation model. Both deep learning models provide complementary tasks in nucleus segmentation in the NuKit platform. The whole image segmentation model performs whole image nucleus whereas the click segmentation model supplements the nucleus segmentation with user-driven input to edits the segmented nuclei. We used PanNuke as the training data set which contains 160,368 nuclei extracted from 7,901 image tiles. The sources of this data set were curated from The Cancer Genome Atlas (TCGA) and included a very few in-house data. For test sets, we used several popular data sets such as TCGA (not used in the training set). We used DICE coefficient as the metric for comparisons of NuKit with other deep learning methods. For the results, we observed that NuKit achieved comparable results with the state-of-the-art deep learning methods and outperforms those non-deep learning methods. For TNBC and CoNSeP data sets, NuKit achieved DICE 0.793 and 0.854 comparing to HoVer-Net 0.749 and 0.664. For CoNSeP test data set, NuKit achieved DICE 0.860 comparing to Cell Profiler 0.434 and QuPath 0.588. In addition, both pre-trained models were embedded in the NuKit GUI, which provides interactive and prompt response to users in analyzing their histopathological images. The outputs of NuKit are interoperable with other quantitative image analysis tools to facilitate the ecosystem of computational pathology to many formats to combine with other software to construct pipelines.
In summary, we have introduced NuKit, an innovation platform which combines two deep learning models coupled with interactive GUI to accelerate nucleus segmentation task in histopathological images. We believe that NuKit provides a new platform to bridge the pre-trained deep learning models into digital pathology and clinical usage.
Citation Format: Ching-Nung Lin, Christine H. Chung, Aik Choon Tan. NuKit: a deep learning platform for histopathological Images. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5409.
Collapse
Affiliation(s)
- Ching-Nung Lin
- 1University of Utah Huntsman Cancer Institute, Salt Lake City, UT
| | | | - Aik Choon Tan
- 1University of Utah Huntsman Cancer Institute, Salt Lake City, UT
| |
Collapse
|
22
|
Saba NF, Steuer CE, Ekpenyong A, McCook-Veal A, Magliocca K, Patel M, Schmitt NC, Stokes W, Bates JE, Rudra S, Remick J, McDonald M, Abousaud M, Tan AC, Fadlullah MZH, Chaudhary R, Muzaffar J, Kirtane K, Liu Y, Chen GZ, Shin DM, Teng Y, Chung CH. Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial. Nat Med 2023; 29:880-887. [PMID: 37012550 PMCID: PMC10205145 DOI: 10.1038/s41591-023-02275-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2022] [Accepted: 02/24/2023] [Indexed: 04/05/2023]
Abstract
Anti-programmed cell death protein 1 (PD-1) therapy is a standard of care in recurrent metastatic head and neck squamous cell carcinoma (RMHNSCC). Vascular endothelial growth factor inhibitors, including tyrosine kinase inhibitors, have immunomodulatory properties and have offered promising results when combined with anti-PD-1 agents. We conducted a phase 2, multicenter, single-arm trial of pembrolizumab and cabozantinib in patients with RMHNSCC who had Response Evaluation Criteria in Solid Tumors v.1.1 measurable disease and no contraindications to either agent. We assessed the primary end points of tolerability and overall response rate to the combination with secondary end points of progression-free survival and overall survival and performed correlative studies with PDL-1 and combined positive score, CD8+ T cell infiltration and tumor mutational burden. A total of 50 patients were screened and 36 were enrolled with 33 evaluable for response. The primary end point was met, with 17 out of 33 patients having a partial response (52%) and 13 (39%) stable disease with an overall clinical benefit rate of 91%. Median and 1-year overall survival were 22.3 months (95% confidence interval (CI) = 11.7-32.9) and 68.4% (95% CI = 45.1%-83.5%), respectively. Median and 1-year progression-free survival were 14.6 months (95% CI = 8.2-19.6) and 54% (95% CI = 31.5%-72%), respectively. Grade 3 or higher treatment-related adverse events included increased aspartate aminotransferase (n = 2, 5.6%). In 16 patients (44.4%), the dose of cabozantinib was reduced to 20 mg daily. The overall response rate correlated positively with baseline CD8+ T cell infiltration. There was no observed correlation between tumor mutational burden and clinical outcome. Pembrolizumab and cabozantinib were well tolerated and showed promising clinical activity in patients with RMHNSCC. Further investigation of similar combinations are needed in RMHNSCC. The trial is registered at ClinicalTrials.gov under registration no. NCT03468218 .
Collapse
Affiliation(s)
- Nabil F Saba
- Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA.
- Winship Cancer Institute of Emory University, Atlanta, GA, USA.
| | - Conor E Steuer
- Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA
- Winship Cancer Institute of Emory University, Atlanta, GA, USA
| | - Asari Ekpenyong
- Winship Cancer Institute of Emory University, Atlanta, GA, USA
| | - Ashley McCook-Veal
- Winship Cancer Institute of Emory University, Atlanta, GA, USA
- Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, USA
| | - Kelly Magliocca
- Winship Cancer Institute of Emory University, Atlanta, GA, USA
- Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA
| | - Mihir Patel
- Winship Cancer Institute of Emory University, Atlanta, GA, USA
- Department of Otolaryngology, Emory University, Atlanta, GA, USA
| | - Nicole C Schmitt
- Winship Cancer Institute of Emory University, Atlanta, GA, USA
- Department of Otolaryngology, Emory University, Atlanta, GA, USA
| | - William Stokes
- Winship Cancer Institute of Emory University, Atlanta, GA, USA
- Department of Radiation Oncology, Emory University, Atlanta, GA, USA
| | - James E Bates
- Winship Cancer Institute of Emory University, Atlanta, GA, USA
- Department of Radiation Oncology, Emory University, Atlanta, GA, USA
| | - Soumon Rudra
- Winship Cancer Institute of Emory University, Atlanta, GA, USA
- Department of Radiation Oncology, Emory University, Atlanta, GA, USA
| | - Jill Remick
- Winship Cancer Institute of Emory University, Atlanta, GA, USA
- Department of Radiation Oncology, Emory University, Atlanta, GA, USA
| | - Mark McDonald
- Winship Cancer Institute of Emory University, Atlanta, GA, USA
- Department of Radiation Oncology, Emory University, Atlanta, GA, USA
| | - Marin Abousaud
- Astellas Pharma Global Development Inc., Astellas Pharma, Northbrook, USA
| | - Aik Choon Tan
- Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
| | | | - Ritu Chaudhary
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | - Jameel Muzaffar
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | - Kedar Kirtane
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | - Yuan Liu
- Winship Cancer Institute of Emory University, Atlanta, GA, USA
- Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, USA
| | - Georgia Z Chen
- Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA
| | - Dong M Shin
- Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA
- Winship Cancer Institute of Emory University, Atlanta, GA, USA
| | - Yong Teng
- Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA
- Winship Cancer Institute of Emory University, Atlanta, GA, USA
| | - Christine H Chung
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, USA
| |
Collapse
|
23
|
Patel KB, Padhya TA, Huang J, Hernandez-Prera JC, Li T, Chung CH, Wang L, Wang X. Plasma cell-free DNA methylome profiling in pre- and post-surgery oral cavity squamous cell carcinoma. Mol Carcinog 2023; 62:493-502. [PMID: 36636912 PMCID: PMC10023468 DOI: 10.1002/mc.23501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2022] [Revised: 11/29/2022] [Accepted: 12/30/2022] [Indexed: 01/14/2023]
Abstract
Head and neck squamous cell carcinoma (HNSCC), a highly heterogeneous disease that involves multiple anatomic sites, is a leading cause of cancer-related mortality worldwide. Although the utility of noninvasive biomarkers based on circulating cell-free DNA (cfDNA) methylation profiling has been widely recognized, limited studies have been reported so far regarding the dynamics of cfDNA methylome in oral cavity squamous cell carcinoma (OCSCC). It is hypothesized in this study that comparison of methylation profiles in pre- and postsurgery plasma samples will reveal OCSCC-specific prognostic and diagnostic biomarkers. As a strategy to further prioritize tumor-specific targets, top differential methylated regions (DMRs) were called by reanalyzing methylation data from paired tumor and normal tissue collected in the the cancer genome atlas head-neck squamous cell carcinoma (TCGA) head and neck cancer cohort. Matched plasma samples from eight patients with OCSCC were collected at Moffitt Cancer Center before and after surgical resection. Plasma-derived cfDNA was analyzed by cfMBD-seq, which is a high-sensitive methylation profiling assay. Differential methylation analysis was then performed based on the matched samples profiled. In the top 200 HNSCC-specific DMRs detected based on the TCGA data set, a total of 23 regions reached significance in the plasma-based DMR test. The top five validated DMR regions (ranked by the significance in the plasma study) are located in the promoter regions of genes PENK, NXPH1, ZIK1, TBXT, and CDO1, respectively. The genome-wide cfDNA DMR analysis further highlighted candidate biomarkers located in genes SFRP4, SOX1, IRF4, and PCDH17. The prognostic relevance of candidate genes was confirmed by survival analysis using the TCGA data. This study supports the utility of cfDNA-based methylome profiling as a promising noninvasive biomarker source for OCSCC and HNSCC.
Collapse
Affiliation(s)
- Krupal B Patel
- Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA
| | - Tapan A Padhya
- Otolaryngology - Head and Neck Surgery, University of South Florida Morsani College of Medicine, Tampa, USA
| | - Jinyong Huang
- Department of Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA
| | - Juan C Hernandez-Prera
- Department of Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA
| | - Tingyi Li
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA
| | - Christine H Chung
- Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA
| | - Liang Wang
- Department of Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA
| | - Xuefeng Wang
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA
- Moffitt Cancer Center Immuno-Oncology Program, Tampa, FL 33612, USA
| |
Collapse
|
24
|
Patel KB, Padhya TA, Huang J, Hernandez‐Prera JC, Li T, Chung CH, Wang L, Wang X. Cover Image, Volume 62, Issue 4. Mol Carcinog 2023. [DOI: 10.1002/mc.23530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]
Affiliation(s)
- Krupal B. Patel
- Department of Head and Neck‐Endocrine Oncology H. Lee Moffitt Cancer Center & Research Institute Tampa Florida USA
| | - Tapan A. Padhya
- Otolaryngology–Head and Neck Surgery University of South Florida Morsani College of Medicine Tampa USA
| | - Jinyong Huang
- Department of Tumor Biology H. Lee Moffitt Cancer Center & Research Institute Tampa Florida USA
| | | | - Tingyi Li
- Department of Biostatistics and Bioinformatics H. Lee Moffitt Cancer Center & Research Institute Tampa Florida USA
| | - Christine H. Chung
- Department of Head and Neck‐Endocrine Oncology H. Lee Moffitt Cancer Center & Research Institute Tampa Florida USA
| | - Liang Wang
- Department of Tumor Biology H. Lee Moffitt Cancer Center & Research Institute Tampa Florida USA
| | - Xuefeng Wang
- Department of Biostatistics and Bioinformatics H. Lee Moffitt Cancer Center & Research Institute Tampa Florida USA
- Moffitt Cancer Center Immuno‐Oncology Program Tampa Florida USA
| |
Collapse
|
25
|
Bauman JE, Saba NF, Roe D, Bauman JR, Kaczmar J, Bhatia A, Muzaffar J, Julian R, Wang S, Bearelly S, Baker A, Steuer C, Giri A, Burtness B, Centuori S, Caulin C, Klein R, Saboda K, Obara S, Chung CH. Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer. J Clin Oncol 2023:JCO2201994. [PMID: 36977289 DOI: 10.1200/jco.22.01994] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/30/2023] Open
Abstract
PURPOSE Primary or acquired resistance to cetuximab, an antiepidermal growth factor receptor monoclonal antibody (mAb), minimizes its utility in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Aberrant hepatocyte growth factor/cMet pathway activation is an established resistance mechanism. Dual pathway targeting may overcome resistance. PATIENTS AND METHODS This multicenter, randomized, noncomparative phase II study evaluated ficlatuzumab, an antihepatocyte growth factor mAb, with or without cetuximab in recurrent/metastatic HNSCC. The primary end point was median progression-free survival (PFS); an arm met significance criteria if the lower bound of the 90% CI excluded the historical control of 2 months. Key eligibility criteria were HNSCC with known human papillomavirus (HPV) status, cetuximab resistance (progression within 6 months of exposure in the definitive or recurrent/metastatic setting), and resistance to platinum and anti-PD-1 mAb. Secondary end points included objective response rate (ORR), toxicity, and the association of HPV status and cMet overexpression with efficacy. Continuous Bayesian futility monitoring was used. RESULTS From 2018 to 2020, 60 patients were randomly assigned and 58 were treated. Twenty-seven versus 33 patients were allocated to monotherapy versus combination. Arms were balanced for major prognostic factors. The monotherapy arm closed early for futility. The combination arm met prespecified significance criteria with a median PFS of 3.7 months (lower bound 90% CI, 2.3 months; P = .04); the ORR was 6 of 32 (19%), including two complete and four partial responses. Exploratory analyses were limited to the combination arm: the median PFS was 2.3 versus 4.1 months (P = .03) and the ORR was 0 of 16 (0%) versus 6 of 16 (38%; P = .02) in the HPV-positive versus HPV-negative subgroups, respectively. cMet overexpression was associated with reduced hazard of progression in HPV-negative but not HPV-positive disease (P interaction = .02). CONCLUSION The ficlatuzumab-cetuximab arm met significance criteria for PFS and warrants phase III development. HPV-negative HNSCC merits consideration as a selection criterion.
Collapse
Affiliation(s)
- Julie E Bauman
- Division of Hematology/Oncology, Department of Medicine, George Washington (GW) University and GW Cancer Center, Washington, DC
- Division of Hematology/Oncology, Department of Medicine, University of Arizona (UA) College of Medicine-Tucson and UA Comprehensive Cancer Center, Tucson, AZ
| | - Nabil F Saba
- Department of Hematology and Medical Oncology, Emory University and Winship Cancer Institute, Atlanta, GA
| | - Denise Roe
- Department of Epidemiology and Biostatistics, UA Mel and Enid Zuckerman College of Public Health, Tucson, AZ
- Biostatistics and Bioinformatics Shared Resource, UA Comprehensive Cancer Center, Tucson, AZ
| | - Jessica R Bauman
- Department of Hematology/Oncology, Temple-Fox Chase Cancer Center, Philadelphia, PA
| | - John Kaczmar
- Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina (MUSC) College of Medicine and MUSC Hollings Cancer Center, Charleston, SC
| | - Aarti Bhatia
- Division of Oncology, Department of Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, CT
| | - Jameel Muzaffar
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL
| | - Ricklie Julian
- Division of Hematology/Oncology, Department of Medicine, University of Arizona (UA) College of Medicine-Tucson and UA Comprehensive Cancer Center, Tucson, AZ
| | - Steven Wang
- Department of Otolaryngology-Head and Neck Surgery, UA College of Medicine-Tucson and UA Comprehensive Cancer Center, Tucson, AZ
| | - Shethal Bearelly
- Department of Otolaryngology-Head and Neck Surgery, UA College of Medicine-Tucson and UA Comprehensive Cancer Center, Tucson, AZ
| | - Audrey Baker
- Department of Otolaryngology-Head and Neck Surgery, UA College of Medicine-Tucson and UA Comprehensive Cancer Center, Tucson, AZ
| | - Conor Steuer
- Department of Hematology and Medical Oncology, Emory University and Winship Cancer Institute, Atlanta, GA
| | - Anshu Giri
- Department of Hematology/Oncology, Temple-Fox Chase Cancer Center, Philadelphia, PA
| | - Barbara Burtness
- Division of Oncology, Department of Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, CT
| | - Sara Centuori
- Division of Hematology/Oncology, Department of Medicine, University of Arizona (UA) College of Medicine-Tucson and UA Comprehensive Cancer Center, Tucson, AZ
| | - Carlos Caulin
- Department of Otolaryngology-Head and Neck Surgery, UA College of Medicine-Tucson and UA Comprehensive Cancer Center, Tucson, AZ
| | - Robert Klein
- Department of Pathology, UA College of Medicine-Tucson and UA Comprehensive Cancer Center, Tucson, AZ
| | - Kathylynn Saboda
- Biostatistics and Bioinformatics Shared Resource, UA Comprehensive Cancer Center, Tucson, AZ
| | - Stefanie Obara
- Division of Hematology/Oncology, Department of Medicine, University of Arizona (UA) College of Medicine-Tucson and UA Comprehensive Cancer Center, Tucson, AZ
| | - Christine H Chung
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL
| |
Collapse
|
26
|
Lin CN, Chung CH, Tan AC. NuKit: A deep learning platform for fast nucleus segmentation of histopathological images. J Bioinform Comput Biol 2023; 21:2350002. [PMID: 36958934 PMCID: PMC10362904 DOI: 10.1142/s0219720023500026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Nucleus segmentation represents the initial step for histopathological image analysis pipelines, and it remains a challenge in many quantitative analysis methods in terms of accuracy and speed. Recently, deep learning nucleus segmentation methods have demonstrated to outperform previous intensity- or pattern-based methods. However, the heavy computation of deep learning provides impression of lagging response in real time and hampered the adoptability of these models in routine research. We developed and implemented NuKit a deep learning platform, which accelerates nucleus segmentation and provides prompt results to the users. NuKit platform consists of two deep learning models coupled with an interactive graphical user interface (GUI) to provide fast and automatic nucleus segmentation "on the fly". Both deep learning models provide complementary tasks in nucleus segmentation. The whole image segmentation model performs whole image nucleus whereas the click segmentation model supplements the nucleus segmentation with user-driven input to edits the segmented nuclei. We trained the NuKit whole image segmentation model on a large public training data set and tested its performance in seven independent public image data sets. The whole image segmentation model achieves average [Formula: see text] and [Formula: see text]. The outputs could be exported into different file formats, as well as provides seamless integration with other image analysis tools such as QuPath. NuKit can be executed on Windows, Mac, and Linux using personal computers.
Collapse
Affiliation(s)
- Ching-Nung Lin
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112, USA
| | - Christine H Chung
- Department of Head and Neck Endocrine Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
| | - Aik Choon Tan
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112, USA
| |
Collapse
|
27
|
Subramaniam RM, DeMora L, Yao M, Yom SS, Gillison M, Caudell JJ, Waldron J, Xia P, Chung CH, Truong MT, Echevarria M, Chan JW, Geiger JL, Mell L, Seaward S, Thorstad WL, Beitler JJ, Sultanem K, Blakaj D, Le QT. 18F-FDG PET/CT Prediction of Treatment Outcomes in Human Papillomavirus-Positive, Locally Advanced Oropharyngeal Cancer Patients Receiving Deintensified Therapy: Results from NRG-HN002. J Nucl Med 2023; 64:362-367. [PMID: 36215572 PMCID: PMC10071810 DOI: 10.2967/jnumed.122.264424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2022] [Revised: 08/24/2022] [Accepted: 08/24/2022] [Indexed: 11/16/2022] Open
Abstract
The purpose of this study was to determine the negative predictive value (NPV) of a 12- to 14-wk posttreatment PET/CT for 2-y progression-free survival (PFS) and locoregional control (LRC) in patients with p16-positive locoregionally advanced oropharyngeal cancer (LA-OPC). Study was a secondary endpoint in NRG-HN002, a noncomparative phase II trial in p16-positive LA-OPC, stage T1-T2, N1-N2b or T3, N0-N2b, and ≤10 pack-year smoking. Patients were randomized in a 1:1 ratio to reduced-dose intensity-modulated radiotherapy (IMRT) with or without cisplatin. Methods: PET/CT scans were reviewed centrally. Tumor response evaluations for the primary site, right neck, and left neck were performed using a 5-point ordinal scale (Hopkins criteria). Overall scores were then assigned as negative, positive, or indeterminate. Patients with a negative score for all 3 evaluation sites were given an overall score of negative. The hypotheses were NPV for PFS and LRC at 2-y posttreatment ≤ 90% versus >90% (1-sided P value, 0.10). Results: A total of 316 patients were enrolled, of whom 306 were randomized and eligible. Of these, 131 (42.8%) patients consented to a posttherapy PET/CT, and 117 (89.3%) patients were eligible for PET/CT analysis. The median time from the end of treatment to PET/CT scan was 94 d (range, 52-139 d). Estimated 2-y PFS and LRC rates in the analysis subgroup were 91.3% (95% CI, 84.6, 95.8%) and 93.8% (95% CI, 87.6, 97.5%), respectively. Posttreatment scans were negative for residual tumor for 115 patients (98.3%) and positive for 2 patients (1.7%). NPV for 2-y PFS was 92.0% (90% lower confidence bound [LCB] 87.7%; P = 0.30) and for LRC was 94.5% (90% LCB 90.6%; P = 0.07). Conclusion: In the context of deintensification with reduced-dose radiation, the NPV of a 12- to 14-wk posttherapy PET/CT for 2-y LRC is estimated to be >90%, similar to that reported for patients receiving standard chemoradiation. However, there is insufficient evidence to conclude that the NPV is >90% for PFS.
Collapse
Affiliation(s)
- Rathan M Subramaniam
- Otago Medical School, University of Otago, Otago, New Zealand;
- Duke University, Durham, North Carolina
| | - Lyudmila DeMora
- NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania
| | - Min Yao
- University Hospitals Cleveland, Cleveland, Ohio
| | - Sue S Yom
- University of California, San Francisco, California
| | - Maura Gillison
- University of Texas MD Anderson Cancer Center, Houston, Texas
| | | | - John Waldron
- Princess Margaret Hospital, Toronto, Oneida, Canada
| | - Ping Xia
- Cleveland Clinic, Cleveland, Ohio
| | | | | | | | - Jason W Chan
- University of California, San Francisco, California
| | | | - Loren Mell
- UC San Diego Moores Cancer Center, San Diego, California
| | - Samantha Seaward
- Kaiser Permanente NCI Community Oncology Research Program, Vallejo, California
| | - Wade L Thorstad
- Washington University School of Medicine, St. Louis, Missouri
| | | | | | - Diagjin Blakaj
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio; and
| | | |
Collapse
|
28
|
Sherman EJ, Harris J, Bible KC, Xia P, Ghossein RA, Chung CH, Riaz N, Gunn GB, Foote RL, Yom SS, Wong SJ, Koyfman SA, Dzeda MF, Clump DA, Khan SA, Shah MH, Redmond K, Torres-Saavedra PA, Le QT, Lee NY. Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial. Lancet Oncol 2023; 24:175-186. [PMID: 36681089 PMCID: PMC9969528 DOI: 10.1016/s1470-2045(22)00763-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2022] [Revised: 12/08/2022] [Accepted: 12/15/2022] [Indexed: 01/20/2023]
Abstract
BACKGROUND Anaplastic thyroid cancer is a rare and aggressive cancer with no standard radiotherapy-based local treatment. Based on data suggesting synergy between pazopanib and paclitaxel in anaplastic thyroid cancer, NRG Oncology did a double-blind, placebo-controlled, randomised phase 2 clinical trial comparing concurrent paclitaxel and intensity-modulated radiotherapy (IMRT) with the addition of pazopanib or placebo with the aim of improving overall survival in this patient population. METHODS Eligible patients were aged 18 years or older with a pathological diagnosis of anaplastic thyroid cancer, any TNM stage, Zubrod performance status of 0-2, no recent haemoptysis or bleeding, and no brain metastases. Patients were enrolled from 34 centres in the USA. Initially, a run-in was done to establish safety. In the randomised phase 2 trial, patients in the experimental group (pazopanib) received 2-3 weeks of weekly paclitaxel (80 mg/m2) intravenously and daily pazopanib suspension 400 mg orally followed by concurrent weekly paclitaxel (50 mg/m2), daily pazopanib (300 mg), and IMRT 66 Gy given in 33 daily fractions (2 Gy fractions). In the control group (placebo), pazopanib was replaced by matching placebo. Patients were randomly assigned (1:1) to the two treatment groups by permuted block randomisation by NRG Oncology with stratification by metastatic disease. All investigators, patients, and funders of the study were masked to group allocation. The primary endpoint was overall survival in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study treatment. This trial is registered with Clinicaltrials.gov, NCT01236547, and is complete. FINDINGS The safety run-showed the final dosing regimen to be safe based on two out of nine participants having adverse events of predefined concern. Between June 23, 2014, and Dec 30, 2016, 89 patients were enrolled to the phase 2 trial, of whom 71 were eligible (36 in the pazopanib group and 35 in the placebo group; 34 [48%] males and 37 [52%] females). At the final analysis (data cutoff March 9, 2020), with a median follow-up of 2·9 years (IQR 0·002-4·0), 61 patients had died. Overall survival was not significantly improved with pazopanib versus placebo, with a median overall survival of 5·7 months (95% CI 4·0-12·8) in the pazopanib group versus 7·3 months (4·3-10·6) in the placebo group (hazard ratio 0·86, 95% CI 0·52-1·43; one-sided log-rank p=0·28). 1-year overall survival was 37·1% (95% CI 21·1-53·2) in the pazopanib group and 29·0% (13·2-44·8) in the placebo group. The incidence of grade 3-5 adverse events did not differ significantly between the treatment groups (pazopanib 88·9% [32 of 36 patients] and placebo 85·3% [29 of 34 patients]; p=0·73). The most common clinically significant grade 3-4 adverse events in the 70 eligible treated patients (36 in the pazopanib group and 34 in the placebo group) were dysphagia (13 [36%] vs 10 [29%]), radiation dermatitis (8 [22%] vs 13 [38%]), increased alanine aminotransferase (12 [33%] vs none), increased aspartate aminotransferase (eight [22%] vs none), and oral mucositis (five [14%] vs eight [24%]). Treatment-related serious adverse events were reported for 16 (44%) patients on pazopanib and 12 (35%) patients on placebo. The most common serious adverse events were dehydration and thromboembolic event (three [8%] each) in patients on pazopanib and oral mucositis (three [8%]) in those on placebo. There was one treatment-related death in each group (sepsis in the pazopanib group and pneumonitis in the placebo group). INTERPRETATION To our knowledge, this study is the largest randomised anaplastic thyroid cancer study that has completed accrual showing feasibility in a multicenter NCI National Clinical Trials Network setting. Although no significant improvement in overall survival was recorded in the pazopanib group, the treatment combination was shown to be feasible and safe, and hypothesis-generating data that might warrant further investigation were generated. FUNDING National Cancer Institute and Novartis.
Collapse
Affiliation(s)
- Eric J Sherman
- Department of Medicine, Division of Head and Neck Oncology, Solid Tumor Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY, USA.
| | - Jonathan Harris
- NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, USA
| | | | - Ping Xia
- Cleveland Clinic Foundation, Cleveland, OH, USA
| | - Ronald A Ghossein
- Department of Medicine, Division of Head and Neck Oncology, Solid Tumor Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | | | - Nadeem Riaz
- Department of Medicine, Division of Head and Neck Oncology, Solid Tumor Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - G Brandon Gunn
- The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | | | - Sue S Yom
- Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA
| | | | | | - Michael F Dzeda
- Christiana Care Health System-Helen F Graham Cancer Center & Research Institute, Newark, DE, USA
| | | | - Saad A Khan
- UT Southwestern Harold C Simmons Comprehensive Cancer Center, Dallas, TX, USA
| | - Manisha H Shah
- Ohio State University Comprehensive Cancer Center, OSU Wexner Medical Center, Columbus, OH, USA
| | - Kevin Redmond
- Radiation Oncology, University of Cincinnati-Barrett Cancer Center, Cincinnati, OH, USA
| | - Pedro A Torres-Saavedra
- NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, USA
| | - Quynh-Thu Le
- Stanford Cancer Institute Palo Alto, Stanford, CA, USA
| | - Nancy Y Lee
- Department of Medicine, Division of Head and Neck Oncology, Solid Tumor Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| |
Collapse
|
29
|
Rodriguez CP, Kang H, Geiger JL, Burtness B, Chung CH, Pickering CR, Fakhry C, Le QT, Yom SS, Galloway TJ, Golemis E, Li A, Shoop J, Wong S, Mehra R, Skinner H, Saba NF, Flores ER, Myers JN, Ford JM, Karchin R, Ferris RL, Kunos C, Lynn JM, Malik S. Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. J Natl Cancer Inst 2022; 114:1619-1627. [PMID: 36053203 PMCID: PMC9745425 DOI: 10.1093/jnci/djac163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2022] [Revised: 05/03/2022] [Accepted: 06/15/2022] [Indexed: 01/11/2023] Open
Abstract
TP53 mutation is the most frequent genetic event in head and neck squamous cell carcinoma (HNSCC), found in more than 80% of patients with human papillomavirus-negative disease. As mutations in the TP53 gene are associated with worse outcomes in HNSCC, novel therapeutic approaches are needed for patients with TP53-mutated tumors. The National Cancer Institute sponsored a Clinical Trials Planning Meeting to address the issues of identifying and developing clinical trials for patients with TP53 mutations. Subcommittees, or breakout groups, were tasked with developing clinical studies in both the locally advanced and recurrent and/or metastatic (R/M) disease settings as well as considering signal-seeking trial designs. A fourth breakout group was focused on identifying and standardizing biomarker integration into trial design; this information was provided to the other breakout groups prior to the meeting to aid in study development. A total of 4 concepts were prioritized to move forward for further development and implementation. This article summarizes the proceedings of the Clinical Trials Planning Meeting with the goal of developing clinical trials for patients with TP53-mutant HNSCC that can be conducted within the National Clinical Trials Network.
Collapse
Affiliation(s)
| | - Hyunseok Kang
- Department of Medicine, University of California San Francisco, San Francisco, CA, USA
| | - Jessica L Geiger
- Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH, USA
| | | | - Christine H Chung
- Department of Head and Neck-Endocrine Oncology, Moffit Cancer Center, Tampa, FL, USA
| | - Curtis R Pickering
- Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Carole Fakhry
- Division of Head and Neck Surgery, Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University, Baltimore, MD, USA
| | - Quynh Thu Le
- Department of Radiation Oncology-Radiation Therapy, Stanford University, Palo Alto, CA, USA
| | - Sue S Yom
- Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA
| | - Thomas J Galloway
- Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
| | - Erica Golemis
- Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA
| | - Alice Li
- Kaiser Permanente Oakland, Oakland, CA, USA
| | | | - Stuart Wong
- Division of Neoplastic Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Ranee Mehra
- Division of Hematology/Oncology, Department of Medicine, University of Maryland, Baltimore, MD, USA
| | - Heath Skinner
- Department of Radiation Oncology, University of Pittsburgh, Pittsburgh, PA, USA
| | - Nabil F Saba
- Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA
| | - Elsa R Flores
- Department of Molecular Oncology, Moffit Cancer Center, Tampa, FL, USA
| | - Jeffrey N Myers
- Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - James M Ford
- Department of Medicine, Stanford University, Palo Alto, CA, USA
| | - Rachel Karchin
- Department of Oncology, Johns Hopkins University, Baltimore, MD, USA
| | - Robert L Ferris
- Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA
| | | | - Jean M Lynn
- National Institutes of Health, Bethesda, MD, USA
| | - Shakun Malik
- National Institutes of Health, Bethesda, MD, USA
| |
Collapse
|
30
|
Dickey BL, Nedjai B, Preece MD, Schell MJ, Boulware D, Whiting J, Sirak B, Abrahamsen M, Isaacs‐Soriano KA, Kennedy K, Chung CH, Giuliano AR. Methylation of HPV16 and EPB41L3 in oral gargles and the detection of early and late oropharyngeal cancer. Cancer Med 2022; 11:3735-3742. [PMID: 35619332 PMCID: PMC9582688 DOI: 10.1002/cam4.4757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2021] [Revised: 01/13/2022] [Accepted: 04/03/2022] [Indexed: 11/25/2022] Open
Abstract
As oropharyngeal cancer (OPC) associated with human papillomavirus (HPV) increases in men, the need for a screening test to diagnose OPC early is crucial. While HPV-associated OPC has a favorable prognosis, recurrence is likely, and metastatic OPC is often incurable regardless of HPV status. Our previous study of pretreatment, male OPC cases (n = 101) and age- and smoking-matched controls (n = 101) found methylation of the host EPB41L3 tumor suppressor gene and HPV16 in the oral gargle was correlated with these biomarkers in the tumor. Methylation of these genes in the oral gargle was significantly (p < 0.0001) higher among cases compared to controls. To further study the utility of HPV16/EPB41L3 methylation, we expanded the sample size and specifically increased the number of early OPC cases (T1-T2, N0-N1; small tumors with a single ipsilateral node <3 cm) to evaluate these biomarkers in early and late OPC. This study included 228 OPC cases, 92 of which were early cases and frequency matched to 142 healthy controls. In logistic regression, the AUC for HPV16/EPB41L3 methylation for all OPC cases was 0.82. Among early and late OPC cases, the AUC was 0.78 and 0.85, respectively. For early cases, 76% sensitivity was achieved, replicating results from our prior study, with a specificity of 65%, indicating room for improvement. The ability of HPV16/EPB41L3 methylation to distinguish OPC from healthy controls highlights its utility as a potential biomarker for OPC. However, the inability to predict early OPC better than late stage OPC indicates the need for additional biomarkers to improve screening performance.
Collapse
Affiliation(s)
- Brittney L. Dickey
- Center for Immunization and Infection Research in CancerH. Lee Moffitt Cancer Center and Research InstituteTampaFloridaUSA
- Department of Cancer EpidemiologyH. Lee Moffitt Cancer Center and Research InstituteTampaFloridaUSA
| | - Belinda Nedjai
- Centre for Cancer PreventionWolfson Institute of Preventive Medicine, Queen Mary UniversityLondonUK
| | - Matthew D. Preece
- Centre for Cancer PreventionWolfson Institute of Preventive Medicine, Queen Mary UniversityLondonUK
| | - Michael J. Schell
- Department of Biostatistics and BioinformaticsH. Lee Moffitt Cancer and Research InstituteTampaFloridaUSA
| | - David Boulware
- Department of Biostatistics and BioinformaticsH. Lee Moffitt Cancer and Research InstituteTampaFloridaUSA
| | - Junmin Whiting
- Department of Biostatistics and BioinformaticsH. Lee Moffitt Cancer and Research InstituteTampaFloridaUSA
| | - Bradley Sirak
- Center for Immunization and Infection Research in CancerH. Lee Moffitt Cancer Center and Research InstituteTampaFloridaUSA
| | - Martha Abrahamsen
- Center for Immunization and Infection Research in CancerH. Lee Moffitt Cancer Center and Research InstituteTampaFloridaUSA
| | - Kimberly A. Isaacs‐Soriano
- Center for Immunization and Infection Research in CancerH. Lee Moffitt Cancer Center and Research InstituteTampaFloridaUSA
| | - Kayoko Kennedy
- Center for Immunization and Infection Research in CancerH. Lee Moffitt Cancer Center and Research InstituteTampaFloridaUSA
| | - Christine H. Chung
- Department of Head and Neck‐Endocrine OncologyH. Lee Moffitt Cancer and Research InstituteTampaFloridaUSA
| | - Anna R. Giuliano
- Center for Immunization and Infection Research in CancerH. Lee Moffitt Cancer Center and Research InstituteTampaFloridaUSA
- Department of Cancer EpidemiologyH. Lee Moffitt Cancer Center and Research InstituteTampaFloridaUSA
| |
Collapse
|
31
|
Kim S, Wuthrick E, Blakaj D, Eroglu Z, Verschraegen C, Thapa R, Mills M, Dibs K, Liveringhouse C, Russell J, Caudell JJ, Tarhini A, Markowitz J, Kendra K, Wu R, Chen DT, Berglund A, Michael L, Aoki M, Wang MH, Hamaidi I, Cheng P, de la Iglesia J, Slebos RJ, Chung CH, Knepper TC, Moran-Segura CM, Nguyen JV, Perez BA, Rose T, Harrison L, Messina JL, Sondak VK, Tsai KY, Khushalani NI, Brohl AS. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. Lancet 2022; 400:1008-1019. [PMID: 36108657 PMCID: PMC9533323 DOI: 10.1016/s0140-6736(22)01659-2] [Citation(s) in RCA: 35] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/10/2022] [Revised: 08/24/2022] [Accepted: 08/24/2022] [Indexed: 10/14/2022]
Abstract
BACKGROUND Merkel cell carcinoma is among the most aggressive and lethal of primary skin cancers, with a high rate of distant metastasis. Anti-programmed death receptor 1 (anti-PD-1) and programmed death ligand 1 (PD-L1) monotherapy is currently standard of care for unresectable, recurrent, or metastatic Merkel cell carcinoma. We assessed treatment with combined nivolumab plus ipilimumab, with or without stereotactic body radiotherapy (SBRT) in patients with advanced Merkel cell carcinoma as a first-line therapy or following previous treatment with anti-PD-1 and PD-L1 monotherapy. METHODS In this randomised, open label, phase 2 trial, we randomly assigned adults from two cancer sites in the USA (one in Florida and one in Ohio) to group A (combined nivolumab and ipilimumab) or group B (combined nivolumab and ipilimumab plus SBRT) in a 1:1 ratio. Eligible patients were aged at least 18 years with histologically proven advanced stage (unresectable, recurrent, or stage IV) Merkel cell carcinoma, a minimum of two tumour lesions measureable by CT, MRI or clinical exam, and tumour tissue available for exploratory biomarker analysis. Patients were stratified by previous immune-checkpoint inhibitor (ICI) status to receive nivolumab 240 mg intravenously every 2 weeks plus ipilimumab 1 mg/kg intravenously every 6 weeks (group A) or the same schedule of combined nivolumab and ipilimumab with the addition of SBRT to at least one tumour site (24 Gy in three fractions at week 2; group B). Patients had to have at least two measurable sites of disease so one non-irradiated site could be followed for response. The primary endpoint was objective response rate (ORR) in all randomly assigned patients who received at least one dose of combined nivolumab and ipilimumab. ORR was defined as the proportion of patients with a complete response or partial response per immune-related Response Evaluation Criteria in Solid Tumours. Response was assessed every 12 weeks. Safety was assessed in all patients. This trial is registered with ClinicalTrials.gov, NCT03071406. FINDINGS 50 patients (25 in both group A and group B) were enrolled between March 14, 2017, and Dec 21, 2021, including 24 ICI-naive patients (13 [52%] of 25 group A patients and 11 [44%] of 25 group B patients]) and 26 patients with previous ICI (12 [48%] of 25 group A patients and 14 [56%] of 25 group B patients]). One patient in group B did not receive SBRT due to concerns about excess toxicity. Median follow-up was 14·6 months (IQR 9·1-26·5). Two patients in group B were excluded from the analysis of the primary endpoint because the target lesions were irradiated and so the patients were deemed non-evaluable. Of the ICI-naive patients, 22 (100%) of 22 (95% CI 82-100) had an objective response, including nine (41% [95% CI 21-63]) with complete response. Of the patients who had previously had ICI exposure, eight (31%) of 26 patients (95% CI 15-52) had an objective response and four (15% [5-36]) had a complete response. No significant differences in ORR were observed between groups A (18 [72%] of 25 patients) and B (12 [52%] of 23 patients; p=0·26). Grade 3 or 4 treatment-related adverse events were observed in 10 (40%) of 25 patients in group A and 8 (32%) of 25 patients in group B. INTERPRETATION First-line combined nivolumab and ipilimumab in patients with advanced Merkel cell carcinoma showed a high ORR with durable responses and an expected safety profile. Combined nivolumab and ipilimumab also showed clinical benefit in patients with previous anti-PD-1 and PD-L1 treatment. Addition of SBRT did not improve efficacy of combined nivolumab and ipilimumab. The combination of nivolumab and ipilimumab represents a new first-line and salvage therapeutic option for advanced Merkel cell carcinoma. FUNDING Bristol Myers Squibb Rare Population Malignancy Program.
Collapse
Affiliation(s)
- Sungjune Kim
- Department of Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA; Department of Immunology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
| | - Evan Wuthrick
- Department of Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Dukagjin Blakaj
- Department of Radiation Oncology, Ohio State University James Cancer Hospital Solove Research Institute, Columbus, OH, USA
| | - Zeynep Eroglu
- Department of Cutaneous Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Claire Verschraegen
- Department of Medical Oncology, Ohio State University James Cancer Hospital Solove Research Institute, Columbus, OH, USA
| | - Ram Thapa
- Department of Biostatistics and Bioinformatics, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Matthew Mills
- Department of Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Khaled Dibs
- Department of Radiation Oncology, Ohio State University James Cancer Hospital Solove Research Institute, Columbus, OH, USA
| | - Casey Liveringhouse
- Department of Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Jeffery Russell
- Department of Head and Neck and Cutaneous Oncology, University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA
| | - Jimmy J Caudell
- Department of Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Ahmad Tarhini
- Department of Cutaneous Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Joseph Markowitz
- Department of Cutaneous Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Kari Kendra
- Department of Medical Oncology, Ohio State University James Cancer Hospital Solove Research Institute, Columbus, OH, USA
| | - Richard Wu
- Department of Medical Oncology, Ohio State University James Cancer Hospital Solove Research Institute, Columbus, OH, USA
| | - Dung-Tsa Chen
- Department of Biostatistics and Bioinformatics, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Anders Berglund
- Department of Biostatistics and Bioinformatics, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Lauren Michael
- Department of Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Mia Aoki
- Department of Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Min-Hsuan Wang
- Department of Immunology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Imene Hamaidi
- Department of Immunology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Pingyan Cheng
- Department of Immunology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Janis de la Iglesia
- Department of Pathology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Robbert J Slebos
- Department of Head and Neck Endocrine Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Christine H Chung
- Department of Head and Neck Endocrine Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Todd C Knepper
- Department of Precision Medicine, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Carlos M Moran-Segura
- Department of Pathology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Jonathan V Nguyen
- Department of Pathology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Bradford A Perez
- Department of Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Trevor Rose
- Department of Radiology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Louis Harrison
- Department of Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Jane L Messina
- Department of Pathology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Vernon K Sondak
- Department of Cutaneous Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Kenneth Y Tsai
- Department of Pathology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Nikhil I Khushalani
- Department of Cutaneous Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Andrew S Brohl
- Department of Cutaneous Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| |
Collapse
|
32
|
Cárdenas SD, Reznik CJ, Ranaweera R, Song F, Chung CH, Fertig EJ, Gevertz JL. Model-informed experimental design recommendations for distinguishing intrinsic and acquired targeted therapeutic resistance in head and neck cancer. NPJ Syst Biol Appl 2022; 8:32. [PMID: 36075912 PMCID: PMC9458753 DOI: 10.1038/s41540-022-00244-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Accepted: 08/05/2022] [Indexed: 11/09/2022] Open
Abstract
The promise of precision medicine has been limited by the pervasive resistance to many targeted therapies for cancer. Inferring the timing (i.e., pre-existing or acquired) and mechanism (i.e., drug-induced) of such resistance is crucial for designing effective new therapeutics. This paper studies cetuximab resistance in head and neck squamous cell carcinoma (HNSCC) using tumor volume data obtained from patient-derived tumor xenografts. We ask if resistance mechanisms can be determined from this data alone, and if not, what data would be needed to deduce the underlying mode(s) of resistance. To answer these questions, we propose a family of mathematical models, with each member of the family assuming a different timing and mechanism of resistance. We present a method for fitting these models to individual volumetric data, and utilize model selection and parameter sensitivity analyses to ask: which member(s) of the family of models best describes HNSCC response to cetuximab, and what does that tell us about the timing and mechanisms driving resistance? We find that along with time-course volumetric data to a single dose of cetuximab, the initial resistance fraction and, in some instances, dose escalation volumetric data are required to distinguish among the family of models and thereby infer the mechanisms of resistance. These findings can inform future experimental design so that we can best leverage the synergy of wet laboratory experimentation and mathematical modeling in the study of novel targeted cancer therapeutics.
Collapse
Affiliation(s)
- Santiago D Cárdenas
- Department of Mathematics and Statistics, The College of New Jersey, Ewing, NJ, USA
| | - Constance J Reznik
- Department of Mathematics and Statistics, The College of New Jersey, Ewing, NJ, USA.,Datacor, Inc., Florham Park, NJ, USA
| | - Ruchira Ranaweera
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | - Feifei Song
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | - Christine H Chung
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | - Elana J Fertig
- Convergence Institute, Department of Oncology, Department of Biomedical Engineering, Department of Applied Mathematics and Statistics, Johns Hopkins University, Baltimore, MD, USA.
| | - Jana L Gevertz
- Department of Mathematics and Statistics, The College of New Jersey, Ewing, NJ, USA.
| |
Collapse
|
33
|
Oswald LB, Arredondo B, Geiss C, Vigoureux TF, Hoogland AI, Chung CH, Muzaffar J, Patel KB, Gonzalez BD, Jim HS, Kirtane K. Considerations for developing supportive care interventions for survivors of head and neck cancer: A qualitative study. Psychooncology 2022; 31:1519-1526. [PMID: 35726386 PMCID: PMC9452460 DOI: 10.1002/pon.5985] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2022] [Revised: 05/16/2022] [Accepted: 06/04/2022] [Indexed: 11/10/2022]
Abstract
OBJECTIVE This study aimed to describe considerations for developing supportive care interventions targeted to head and neck cancer (HNC) survivors. METHODS One-time semi-structured interviews (N = 33) were conducted with HNC survivors who had recently finished treatment (n = 20) and HNC providers (e.g., physicians, nurses; n = 13). Interviews were transcribed verbatim and coded using inductive applied thematic analysis techniques to identify themes. RESULTS HNC survivors (75% male; M = 61 years old) and providers (54% physicians; 62% female) were unanimously supportive of developing HNC-specific supportive care interventions. Participants described potential benefits of offering interventions at various points throughout the HNC treatment and survivorship trajectory rather than at a single critical time. Many participants preferred group-based interventions because of the high value of peer-support. Others described how group interventions may not be appropriate for all HNC survivors due to risks for negative social comparisons and exacerbated anxiety. Participants suggested topics that should be addressed in HNC-specific interventions including education about acute and long-term side effects, symptom management, nutritional support, relationship/social role changes, grief/loss, and fear of recurrence. CONCLUSIONS HNC-specific supportive care interventions are critically needed, as survivors experience persistent symptoms and distinct psychosocial concerns that impact quality of life. Findings from this study can inform the development of supportive care interventions targeted to the unique psychosocial concerns of HNC survivors.
Collapse
Affiliation(s)
- Laura B. Oswald
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA
| | - Brandy Arredondo
- Participant Research, Interventions, and Measurement Core, Moffitt Cancer Center, Tampa, FL, USA
| | - Carley Geiss
- Participant Research, Interventions, and Measurement Core, Moffitt Cancer Center, Tampa, FL, USA
| | | | - Aasha I. Hoogland
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA
| | - Christine H. Chung
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | - Jameel Muzaffar
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | - Krupal B. Patel
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | - Brian D. Gonzalez
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA
| | - Heather S.L. Jim
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA
| | - Kedar Kirtane
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, USA
| |
Collapse
|
34
|
Aguilar M, Cavasonza LA, Ambrosi G, Arruda L, Attig N, Barao F, Barrin L, Bartoloni A, Başeğmez-du Pree S, Battiston R, Behlmann M, Berdugo J, Bertucci B, Bindi V, Bollweg K, Borgia B, Boschini MJ, Bourquin M, Bueno EF, Burger J, Burger WJ, Burmeister S, Cai XD, Capell M, Casaus J, Castellini G, Cervelli F, Chang YH, Chen GM, Chen GR, Chen HS, Chen Y, Cheng L, Chou HY, Chouridou S, Choutko V, Chung CH, Clark C, Coignet G, Consolandi C, Contin A, Corti C, Cui Z, Dadzie K, Dass A, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Felice V, Díaz C, Dimiccoli F, von Doetinchem P, Dong F, Donnini F, Duranti M, Egorov A, Eline A, Feng J, Fiandrini E, Fisher P, Formato V, Freeman C, Gámez C, García-López RJ, Gargiulo C, Gast H, Gervasi M, Giovacchini F, Gómez-Coral DM, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Haino S, Han KC, Hashmani RK, He ZH, Heber B, Hsieh TH, Hu JY, Incagli M, Jang WY, Jia Y, Jinchi H, Karagöz G, Khiali B, Kim GN, Kirn T, Konyushikhin M, Kounina O, Kounine A, Koutsenko V, Krasnopevtsev D, Kuhlman A, Kulemzin A, La Vacca G, Laudi E, Laurenti G, Lazzizzera I, Lee HT, Lee SC, Li HL, Li JQ, Li M, Li Q, Li QY, Li S, Li SL, Li JH, Li ZH, Liang J, Liang MJ, Light C, Lin CH, Lippert T, Liu JH, Lu SQ, Lu YS, Luebelsmeyer K, Luo JZ, Luo X, Machate F, Mañá C, Marín J, Marquardt J, Martin T, Martínez G, Masi N, Maurin D, Medvedeva T, Menchaca-Rocha A, Meng Q, Mikhailov VV, Molero M, Mott P, Mussolin L, Negrete J, Nikonov N, Nozzoli F, Ocampo-Peleteiro J, Oliva A, Orcinha M, Palermo M, Palmonari F, Paniccia M, Pashnin A, Pauluzzi M, Pensotti S, Plyaskin V, Pohl M, Poluianov S, Qin X, Qu ZY, Quadrani L, Rancoita PG, Rapin D, Conde AR, Robyn E, Rosier-Lees S, Rozhkov A, Rozza D, Sagdeev R, Schael S, von Dratzig AS, Schwering G, Seo ES, Shan BS, Siedenburg T, Song JW, Song XJ, Sonnabend R, Strigari L, Su T, Sun Q, Sun ZT, Tacconi M, Tang XW, Tang ZC, Tian J, Ting SCC, Ting SM, Tomassetti N, Torsti J, Urban T, Usoskin I, Vagelli V, Vainio R, Valencia-Otero M, Valente E, Valtonen E, Vázquez Acosta M, Vecchi M, Velasco M, Vialle JP, Wang CX, Wang L, Wang LQ, Wang NH, Wang QL, Wang S, Wang X, Wang Y, Wang ZM, Wei J, Weng ZL, Wu H, Xiong RQ, Xu W, Yan Q, Yang Y, Yashin II, Yi H, Yu YM, Yu ZQ, Zannoni M, Zhang C, Zhang F, Zhang FZ, Zhang JH, Zhang Z, Zhao F, Zheng C, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zuccon P. Properties of Daily Helium Fluxes. Phys Rev Lett 2022; 128:231102. [PMID: 35749176 DOI: 10.1103/physrevlett.128.231102] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/01/2022] [Accepted: 05/06/2022] [Indexed: 06/15/2023]
Abstract
We present the precision measurement of 2824 daily helium fluxes in cosmic rays from May 20, 2011 to October 29, 2019 in the rigidity interval from 1.71 to 100 GV based on 7.6×10^{8} helium nuclei collected with the Alpha Magnetic Spectrometer (AMS) aboard the International Space Station. The helium flux and the helium to proton flux ratio exhibit variations on multiple timescales. In nearly all the time intervals from 2014 to 2018, we observed recurrent helium flux variations with a period of 27 days. Shorter periods of 9 days and 13.5 days are observed in 2016. The strength of all three periodicities changes with time and rigidity. In the entire time period, we found that below ∼7 GV the helium flux exhibits larger time variations than the proton flux, and above ∼7 GV the helium to proton flux ratio is time independent. Remarkably, below 2.4 GV a hysteresis between the helium to proton flux ratio and the helium flux was observed at greater than the 7σ level. This shows that at low rigidity the modulation of the helium to proton flux ratio is different before and after the solar maximum in 2014.
Collapse
Affiliation(s)
- M Aguilar
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - L Ali Cavasonza
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - G Ambrosi
- INFN Sezione di Perugia, 06100 Perugia, Italy
| | - L Arruda
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), 1649-003 Lisboa, Portugal
| | - N Attig
- Jülich Supercomputing Centre and JARA-FAME, Research Centre Jülich, 52425 Jülich, Germany
| | - F Barao
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), 1649-003 Lisboa, Portugal
| | - L Barrin
- European Organization for Nuclear Research (CERN), 1211 Geneva 23, Switzerland
| | | | - S Başeğmez-du Pree
- Kapteyn Astronomical Institute, University of Groningen, P.O. Box 800, 9700 AV Groningen, Netherlands
| | - R Battiston
- INFN TIFPA, 38123 Povo, Trento, Italy
- Università di Trento, 38123 Povo, Trento, Italy
| | - M Behlmann
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - J Berdugo
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - B Bertucci
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - V Bindi
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - K Bollweg
- National Aeronautics and Space Administration Johnson Space Center (JSC), Houston, Texas 77058, USA
| | - B Borgia
- INFN Sezione di Roma 1, 00185 Roma, Italy
- Università di Roma La Sapienza, 00185 Roma, Italy
| | - M J Boschini
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
| | - M Bourquin
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | - E F Bueno
- Kapteyn Astronomical Institute, University of Groningen, P.O. Box 800, 9700 AV Groningen, Netherlands
| | - J Burger
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | | | - S Burmeister
- Institut für Experimentelle und Angewandte Physik, Christian-Alberts-Universität zu Kiel, 24118 Kiel, Germany
| | - X D Cai
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - M Capell
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - J Casaus
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | | | | | - Y H Chang
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - G M Chen
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - G R Chen
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - H S Chen
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - Y Chen
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - L Cheng
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - H Y Chou
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - S Chouridou
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - V Choutko
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - C H Chung
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - C Clark
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
- National Aeronautics and Space Administration Johnson Space Center (JSC), Houston, Texas 77058, USA
| | - G Coignet
- Université Grenoble Alpes, Université Savoie Mont Blanc, CNRS, LAPP-IN2P3, 74000 Annecy, France
| | - C Consolandi
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - A Contin
- INFN Sezione di Bologna, 40126 Bologna, Italy
- Università di Bologna, 40126 Bologna, Italy
| | - C Corti
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - Z Cui
- Shandong University (SDU), Jinan, Shandong 250100, China
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - K Dadzie
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Dass
- INFN TIFPA, 38123 Povo, Trento, Italy
- Università di Trento, 38123 Povo, Trento, Italy
| | - C Delgado
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | | | - M B Demirköz
- Department of Physics, Middle East Technical University (METU), 06800 Ankara, Turkey
| | - L Derome
- Université Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France
| | | | - V Di Felice
- INFN Sezione di Roma Tor Vergata, 00133 Roma, Italy
| | - C Díaz
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | | | - P von Doetinchem
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - F Dong
- Southeast University (SEU), Nanjing 210096, China
| | - F Donnini
- INFN Sezione di Roma Tor Vergata, 00133 Roma, Italy
| | - M Duranti
- INFN Sezione di Perugia, 06100 Perugia, Italy
| | - A Egorov
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Eline
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - J Feng
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - E Fiandrini
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - P Fisher
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - V Formato
- INFN Sezione di Roma Tor Vergata, 00133 Roma, Italy
| | - C Freeman
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - C Gámez
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - R J García-López
- Instituto de Astrofísica de Canarias (IAC), 38205 La Laguna, and Departamento de Astrofísica, Universidad de La Laguna, 38206 La Laguna, Tenerife, Spain
| | - C Gargiulo
- European Organization for Nuclear Research (CERN), 1211 Geneva 23, Switzerland
| | - H Gast
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - M Gervasi
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - F Giovacchini
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - D M Gómez-Coral
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - J Gong
- Southeast University (SEU), Nanjing 210096, China
| | - C Goy
- Université Grenoble Alpes, Université Savoie Mont Blanc, CNRS, LAPP-IN2P3, 74000 Annecy, France
| | - V Grabski
- Instituto de Física, Universidad Nacional Autónoma de México (UNAM), Ciudad de México 01000, Mexico
| | - D Grandi
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - M Graziani
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - S Haino
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - K C Han
- National Chung-Shan Institute of Science and Technology (NCSIST), Longtan, Tao Yuan 32546, Taiwan
| | - R K Hashmani
- Department of Physics, Middle East Technical University (METU), 06800 Ankara, Turkey
| | - Z H He
- Sun Yat-Sen University (SYSU), Guangzhou 510275, China
| | - B Heber
- Institut für Experimentelle und Angewandte Physik, Christian-Alberts-Universität zu Kiel, 24118 Kiel, Germany
| | - T H Hsieh
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - J Y Hu
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - M Incagli
- INFN Sezione di Pisa, 56100 Pisa, Italy
| | - W Y Jang
- CHEP, Kyungpook National University, 41566 Daegu, Korea
| | - Yi Jia
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - H Jinchi
- National Chung-Shan Institute of Science and Technology (NCSIST), Longtan, Tao Yuan 32546, Taiwan
| | - G Karagöz
- Department of Physics, Middle East Technical University (METU), 06800 Ankara, Turkey
| | - B Khiali
- INFN Sezione di Roma Tor Vergata, 00133 Roma, Italy
| | - G N Kim
- CHEP, Kyungpook National University, 41566 Daegu, Korea
| | - Th Kirn
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - M Konyushikhin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - O Kounina
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Kounine
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - V Koutsenko
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - D Krasnopevtsev
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Kuhlman
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - A Kulemzin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - G La Vacca
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - E Laudi
- European Organization for Nuclear Research (CERN), 1211 Geneva 23, Switzerland
| | - G Laurenti
- INFN Sezione di Bologna, 40126 Bologna, Italy
| | - I Lazzizzera
- INFN TIFPA, 38123 Povo, Trento, Italy
- Università di Trento, 38123 Povo, Trento, Italy
| | - H T Lee
- Academia Sinica Grid Center (ASGC), Nankang, Taipei 11529, Taiwan
| | - S C Lee
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - H L Li
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - J Q Li
- Southeast University (SEU), Nanjing 210096, China
| | - M Li
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - Q Li
- Southeast University (SEU), Nanjing 210096, China
| | - Q Y Li
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - S Li
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - S L Li
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - J H Li
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - Z H Li
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - J Liang
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - M J Liang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - C Light
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - C H Lin
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - T Lippert
- Jülich Supercomputing Centre and JARA-FAME, Research Centre Jülich, 52425 Jülich, Germany
| | - J H Liu
- Institute of Electrical Engineering (IEE), Chinese Academy of Sciences, Beijing 100190, China
| | - S Q Lu
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - Y S Lu
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - K Luebelsmeyer
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - J Z Luo
- Southeast University (SEU), Nanjing 210096, China
| | - Xi Luo
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - F Machate
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - C Mañá
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - J Marín
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - J Marquardt
- Institut für Experimentelle und Angewandte Physik, Christian-Alberts-Universität zu Kiel, 24118 Kiel, Germany
| | - T Martin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
- National Aeronautics and Space Administration Johnson Space Center (JSC), Houston, Texas 77058, USA
| | - G Martínez
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - N Masi
- INFN Sezione di Bologna, 40126 Bologna, Italy
- Università di Bologna, 40126 Bologna, Italy
| | - D Maurin
- Université Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France
| | - T Medvedeva
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Menchaca-Rocha
- Instituto de Física, Universidad Nacional Autónoma de México (UNAM), Ciudad de México 01000, Mexico
| | - Q Meng
- Southeast University (SEU), Nanjing 210096, China
| | - V V Mikhailov
- NRNU MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russia
| | - M Molero
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - P Mott
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
- National Aeronautics and Space Administration Johnson Space Center (JSC), Houston, Texas 77058, USA
| | - L Mussolin
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - J Negrete
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - N Nikonov
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - F Nozzoli
- INFN TIFPA, 38123 Povo, Trento, Italy
| | - J Ocampo-Peleteiro
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - A Oliva
- INFN Sezione di Bologna, 40126 Bologna, Italy
| | - M Orcinha
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), 1649-003 Lisboa, Portugal
| | - M Palermo
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - F Palmonari
- INFN Sezione di Bologna, 40126 Bologna, Italy
- Università di Bologna, 40126 Bologna, Italy
| | - M Paniccia
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | - A Pashnin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - M Pauluzzi
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - S Pensotti
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - V Plyaskin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - M Pohl
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | - S Poluianov
- Sodankylä Geophysical Observatory and Space Physics and Astronomy Research Unit, University of Oulu, 90014 Oulu, Finland
| | - X Qin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - Z Y Qu
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - L Quadrani
- INFN Sezione di Bologna, 40126 Bologna, Italy
- Università di Bologna, 40126 Bologna, Italy
| | - P G Rancoita
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
| | - D Rapin
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | - A Reina Conde
- INFN Sezione di Bologna, 40126 Bologna, Italy
- Instituto de Astrofísica de Canarias (IAC), 38205 La Laguna, and Departamento de Astrofísica, Universidad de La Laguna, 38206 La Laguna, Tenerife, Spain
| | - E Robyn
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | - S Rosier-Lees
- Université Grenoble Alpes, Université Savoie Mont Blanc, CNRS, LAPP-IN2P3, 74000 Annecy, France
| | - A Rozhkov
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - D Rozza
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - R Sagdeev
- East-West Center for Space Science, University of Maryland, College Park, Maryland 20742, USA
| | - S Schael
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | | | - G Schwering
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - E S Seo
- IPST, University of Maryland, College Park, Maryland 20742, USA
| | - B S Shan
- Beihang University (BUAA), Beijing 100191, China
| | - T Siedenburg
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - J W Song
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - X J Song
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - R Sonnabend
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - L Strigari
- INFN Sezione di Roma 1, 00185 Roma, Italy
| | - T Su
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - Q Sun
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - Z T Sun
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - M Tacconi
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - X W Tang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - Z C Tang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - J Tian
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - Samuel C C Ting
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
- European Organization for Nuclear Research (CERN), 1211 Geneva 23, Switzerland
| | - S M Ting
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - N Tomassetti
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - J Torsti
- Space Research Laboratory, Department of Physics and Astronomy, University of Turku, 20014 Turku, Finland
| | - T Urban
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
- National Aeronautics and Space Administration Johnson Space Center (JSC), Houston, Texas 77058, USA
| | - I Usoskin
- Sodankylä Geophysical Observatory and Space Physics and Astronomy Research Unit, University of Oulu, 90014 Oulu, Finland
| | - V Vagelli
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Agenzia Spaziale Italiana (ASI), 00133 Roma, Italy
| | - R Vainio
- Space Research Laboratory, Department of Physics and Astronomy, University of Turku, 20014 Turku, Finland
| | - M Valencia-Otero
- Physics Department and Center for High Energy and High Field Physics, National Central University (NCU), Tao Yuan 32054, Taiwan
| | - E Valente
- INFN Sezione di Roma 1, 00185 Roma, Italy
- Università di Roma La Sapienza, 00185 Roma, Italy
| | - E Valtonen
- Space Research Laboratory, Department of Physics and Astronomy, University of Turku, 20014 Turku, Finland
| | - M Vázquez Acosta
- Instituto de Astrofísica de Canarias (IAC), 38205 La Laguna, and Departamento de Astrofísica, Universidad de La Laguna, 38206 La Laguna, Tenerife, Spain
| | - M Vecchi
- Kapteyn Astronomical Institute, University of Groningen, P.O. Box 800, 9700 AV Groningen, Netherlands
| | - M Velasco
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - J P Vialle
- Université Grenoble Alpes, Université Savoie Mont Blanc, CNRS, LAPP-IN2P3, 74000 Annecy, France
| | - C X Wang
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - L Wang
- Institute of Electrical Engineering (IEE), Chinese Academy of Sciences, Beijing 100190, China
| | - L Q Wang
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - N H Wang
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - Q L Wang
- Institute of Electrical Engineering (IEE), Chinese Academy of Sciences, Beijing 100190, China
| | - S Wang
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - X Wang
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - Yu Wang
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - Z M Wang
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - J Wei
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - Z L Weng
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - H Wu
- Southeast University (SEU), Nanjing 210096, China
| | - R Q Xiong
- Southeast University (SEU), Nanjing 210096, China
| | - W Xu
- Shandong University (SDU), Jinan, Shandong 250100, China
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - Q Yan
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - Y Yang
- National Cheng Kung University, Tainan 70101, Taiwan
| | - I I Yashin
- NRNU MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russia
| | - H Yi
- Southeast University (SEU), Nanjing 210096, China
| | - Y M Yu
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - Z Q Yu
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - M Zannoni
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - C Zhang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - F Zhang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - F Z Zhang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - J H Zhang
- Southeast University (SEU), Nanjing 210096, China
| | - Z Zhang
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - F Zhao
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing 100049, China
| | - C Zheng
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong 250100, China
| | - Z M Zheng
- Beihang University (BUAA), Beijing 100191, China
| | - H L Zhuang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100049, China
| | - V Zhukov
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - A Zichichi
- INFN Sezione di Bologna, 40126 Bologna, Italy
- Università di Bologna, 40126 Bologna, Italy
| | - P Zuccon
- INFN TIFPA, 38123 Povo, Trento, Italy
- Università di Trento, 38123 Povo, Trento, Italy
| |
Collapse
|
35
|
Wang X, Muzaffar J, Kirtane K, Song F, Johnson M, Schell MJ, Li J, Yoder SJ, Conejo-Garcia JR, Guevara-Patino JA, Bonomi M, Bhateja P, Rocco JW, Steuer CE, Saba NF, Chung CH. T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma. J Immunother Cancer 2022; 10:jitc-2022-004512. [PMID: 35676062 PMCID: PMC9185557 DOI: 10.1136/jitc-2022-004512] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/13/2022] [Indexed: 01/02/2023] Open
Abstract
BACKGROUND T cell receptor (TCR) signaling profile is a fundamental property that underpins both adaptive and innate immunity in the host. Despite its potential clinical relevance, the TCR repertoire in peripheral blood has not been thoroughly explored for its value as an immunotherapy efficacy biomarker in head and neck squamous cell carcinoma (HNSCC). The purpose of the present study is to characterize and compare the TCR repertoire in peripheral blood mononuclear cells (PBMC) from patients with HNSCC treated with the combination of cetuximab and nivolumab. METHODS We used the immunoSEQ assay to sequence the TCR beta (TCR-B) chain repertoire from serially obtained PBMC at baseline and during the treatments from a total of 41 patients who received the combination (NCT03370276). Key TCR repertoire metrics, including diversity and clonality, were calculated and compared between patients with different therapy responses and clinical characteristics (eg, human papillomavirus (HPV) status and smoking history). Patient survival outcomes were compared according to patient groups stratified by the TCR-B clonotyping. To confirm the observed patterns in TCR spectrum, samples from patients who achieved complete response (CR) and partial response (PR) were further profiled with the immunoSEQ deep resolution assay. RESULTS Our data indicated that the patients who achieved CR and PR had an increased TCR sequence diversity in their baseline samples, this tendency being more pronounced in HPV-negative patients or those with a smoking history. Notably, the CR/PR group had the lowest proportion of patients with oligoclonal TCR clones (2 out of 8 patients), followed by the stable disease group (9 out of 20 patients) and lastly the progressive disease group (7 out of 10 patients). An overall trend toward favorable patient survival was also observed in the polyclonal group. Finally, we reported the shared TCR clones across patients within the same response group, as well as the shared clones by aligning immunoSEQ reads with TCR data retrieved from The Cancer Genome Atlas- head and neck squamous cell carcinoma (TCGA-HNSC) cohort. CONCLUSIONS Our data suggest that, despite the great clinical heterogeneity of HNSCC and the limited responders in the present cohort, the peripheral TCR repertoires from pretreatment PBMC may be developed as biomarkers for the benefit of immunotherapy in HNSCC.
Collapse
Affiliation(s)
- Xuefeng Wang
- Department of Biostatistics and Bioinformatics, H Lee Moffitt Cancer Center and Research Center Inc, Tampa, Florida, USA
| | - Jameel Muzaffar
- Department of Head and Neck-Endocrine Oncology, H Lee Moffitt Cancer Center and Research Center Inc, Tampa, Florida, USA
| | - Kedar Kirtane
- Department of Head and Neck-Endocrine Oncology, H Lee Moffitt Cancer Center and Research Center Inc, Tampa, Florida, USA
| | - Feifei Song
- Department of Head and Neck-Endocrine Oncology, H Lee Moffitt Cancer Center and Research Center Inc, Tampa, Florida, USA
| | - Matthew Johnson
- Department of Head and Neck-Endocrine Oncology, H Lee Moffitt Cancer Center and Research Center Inc, Tampa, Florida, USA
| | - Michael J Schell
- Department of Biostatistics and Bioinformatics, H Lee Moffitt Cancer Center and Research Center Inc, Tampa, Florida, USA
| | - Jiannong Li
- Department of Biostatistics and Bioinformatics, H Lee Moffitt Cancer Center and Research Center Inc, Tampa, Florida, USA
| | - Sean J Yoder
- Department of Molecular Genomics Core, H Lee Moffitt Cancer Center and Research Center Inc, Tampa, Florida, USA
| | - Jose R Conejo-Garcia
- Department of Immunology, H Lee Moffitt Cancer Center and Research Center Inc, Tampa, Florida, USA
| | - Jose A Guevara-Patino
- Department of Immunology, H Lee Moffitt Cancer Center and Research Center Inc, Tampa, Florida, USA
| | - Marcelo Bonomi
- Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Priyanka Bhateja
- Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - James W Rocco
- Department of Otolaryngology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
| | - Conor E Steuer
- Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA
| | - Nabil F Saba
- Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA
| | - Christine H Chung
- Department of Head and Neck-Endocrine Oncology, H Lee Moffitt Cancer Center and Research Center Inc, Tampa, Florida, USA
| |
Collapse
|
36
|
Saba NF, Ekpenyong A, McCook-Veal A, Patel M, Schmitt NC, Stokes WA, Bates JE, Rudra S, Abousaud MI, Muzaffar J, Kirtane K, Teng Y, Steuer CE, Shin DM, Liu Y, Chung CH. A phase II trial of pembrolizumab and cabozantinib in patients (pts) with recurrent metastatic head and neck squamous cell carcinoma (RMHNSCC). J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.6008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6008 Background: Pembrolizumab (pembro) is an immune checkpoint inhibitor (ICI) approved for treating pts with recurrent/metastatic (RM) HNSCC. Cabozantinib (cabo) is a multiple receptor tyrosine kinase inhibitor (TKI) targeting MET and VEGFR2 shown to reduce tumor growth, metastasis, and angiogenesis and has immuno-modulatory properties. Methods: This is a phase II, open label multi-center, single arm trial evaluating the tolerability and clinical benefit of pembro administered at 200 mg every 3 weeks and cabo 40 mg daily for pts with RM HNSCC who have not received prior ICI. It had a lead-in safety cohort allowing reduction of cabo dose to 20mg daily. Eligible pts had RM HNSCC, deemed incurable, with a tumor PD-L1 CPS > 1, RECIST 1.1 measurable disease, a life expectancy of > 3 months, an Eastern Cooperative Group (ECOG) Performance Status (PS) of 0-1. Enrollment was initiated in March of 2019. We estimated that the ORR will improve to 35% with pembro+ cabo (from a historic of 18%) with a significance level of 0.05 and 80% power. Results: A total of 47 pts were screened, 13 screen failures [cavitation on scan (4), inability to swallow pills (2), other exclusions (7)]; 34 pts were enrolled, 32 were dosed and 31 evaluable (at least one follow-up scan). Pts had cancers of the oropharynx (21, 65%), nasopharynx (6, 19%), larynx/hypopharynx (4, 13%) and oral cavity (1,3%). 32 patients received cabo at 40 mg daily; 13 patients (41%) were dose reduced to 20mg daily [mucositis, increased liver function (LFT) tests, diarrhea]; males (n=29, 90%), median age 63 years (range 53-67); presence of distant metastases (34, 100%); prior radiation (29, 90%), chemotherapy (14, 43%); ECOG PS =0 (16, 50%), 1 (16,50%); HPV/p16 positive (17, 53%), negative (5, 16%), not applicable (10, 29%); the most frequent adverse event (AE) (all grades) was fatigue (16,50.0%), grade 3 or 4 treatment-related AE were increased LFTs, hyponatremia (3, 9.3% each). With a median follow up of 12.7 months (mos) (range 6.9- 20.5 mos), a RECIST 1.1 overall response rate ORR= 45.2% (CR=0; PR=14, 45.2%; SD =14, 45.2%; PD=3.0, 10%) with an overall clinical benefit of 90.4% were observed; The 1-yr OS was 67.7% (95% CI, 42.9%-83.6%; median 22.3 mos) and 1-yr PFS was 51.8% (95% CI, 28.8%-70.7%; median 14.6 mos). Conclusions: This phase II trial of pembro + cabo met its primary endpoint of ORR. The regimen is well-tolerated with very encouraging clinical activity in RM HNSCC and warrants further exploration in this disease. The study was supported by a grant from Exelixis to NFS. Clinical trial information: NCT03468218.
Collapse
Affiliation(s)
- Nabil F. Saba
- Winship Cancer Institute Emory University School of Medicine, Atlanta, GA
| | | | | | - Mihir Patel
- Department of Otolaryngology Head and Neck Surgery, Winship Cancer Institute, Emory University, Atlanta, GA
| | | | | | | | | | | | - Jameel Muzaffar
- Head and Neck and Endocrine Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | | | | | | | - Dong Moon Shin
- Winship Cancer Institute of Emory University, Atlanta, GA
| | - Yuan Liu
- Departments of Biostatistics and Bioinformatics, Emory University, Atlanta, GA
| | | |
Collapse
|
37
|
Bari S, Jain S, Yadav H, Liu M, Hodge E, Kirtane K, Chung CH, Conejo-Garcia J, Muzaffar J. Gut microbiome/metabolome predicts response to immune checkpoint blockers (ICB) in patients with recurrent metastatic head and neck squamous cell cancer (RM HNSCC). J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.6055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6055 Background: Gut microbiome has emerged as an important predictor of response to ICB therapy in various cancers, most notably in melanoma. Due to functional redundancy of microbiota, there has been lack of consistency in gut microbial signature associated with ICB response. Microbial metabolites in addition to taxonomy may play a superior role in predicting response to ICB. Gut microbiome/metabolome signatures of ICB response is unknown in RM HNSCC patients. Methods: Two cohorts of patients were included (stool and plasma samples were collected)- cohort 1, newly diagnosed RM HNSCC patients starting first line ICB, for whom samples were collected before ICB initiation (baseline) and post-treatment at 3, 6, and 12 months. Cohort 2 with durable response (disease control lasting ≥ 6 months), with single sample collected at study entry. 16s rRNA sequencing was performed on stool samples while plasma metabolites were quantitated using Q Exactive plus Orbitrap mass spectrometer. Response was defined as partial response (PR) or complete response (CR) as per RECIST 1.1 Results: The 16-S sequence was carried on 31 samples (cohort 1- 16 baseline, 7 post treatment; cohort 2- 8 durable responders). Targeted metabolomics was completed on 92 plasma samples [cohort 1-27 baseline and 50 post-treatment, cohort 2- 15]. Responders had a significantly higher Shannon’s diversity index, lower Fermicutes to Bacteroidetes ratio, and were enriched with genus Bacteroides and Lachnospiracea incerate sedis at baseline and post treatment, compared to non-responders (p < 0.05). At species level, baseline and post treatment microbiome of responders was enriched with Eubacterium oxidoreducens and Bacteroides uniformis. Ruminococcus was preferentially enriched in durable responders. Targeted analysis of plasma metabolites (associated with gut microbial metabolism) showed that responders had a significantly lower baseline adenosine, Inosine and xanthine level as compared to non responders. Further, Inosine levels decreased with response, while levels increased in non-responders (p < 0.05), suggestive of consumption by re-activated T cells Further, ICB responders had significantly lower Kynurenine to tryptophan ratio compared to non responders Conclusions: This is the first study evaluating association of gut microbiome and metabolome on response to first line ICB, in RM HNSCC patients. We found higher diversity and specific gut microbial signatures associated with ICB response. Interestingly, we found that inosine and kynurenine/tryptophan pathways, both which play a crucial role in host as well as gut microbial metabolism were differentially expressed in ICB responders. Our results if validated in larger cohort, lays groundwork for gut microbiome and importantly microbial metabolite modulation to improve response to ICB in RM HNSCC.
Collapse
Affiliation(s)
- Shahla Bari
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
| | | | | | - Min Liu
- Moffitt Cancer Center, Tampa, FL
| | | | | | | | | | - Jameel Muzaffar
- Head and Neck and Endocrine Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| |
Collapse
|
38
|
Tarasova V, Tsai J, McIver B, Hallanger-Johnson JE, Veloski C, Agosto Salgado S, Masannat J, Drusbosky L, Chung CH. Characterization of genomic landscape using comprehensive circulating cell-free tumor DNA next generation sequencing in advanced thyroid carcinoma. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.3045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3045 Background: Availability of targeted therapies in thyroid carcinoma (TC) has challenged the conventional treatment algorithms and established urgency for timely identification of targetable genetic abnormalities. Tissue-based next generation sequencing (NGS) is often limited by tumor insufficiency and slow turn-around time. Plasma-based circulating tumor DNA (ctDNA) NGS overcomes these barriers and has been widely adopted across advanced-stage solid tumors. To date, plasma-based NGS characterization of genomic alterations in TC has not been determined. Herein, we profile potential actionable mutations detected via ctDNA in patients with advanced TC subtypes. Methods: A retrospective analysis of Guardant Health, Inc database was performed using the commercially available Guardant360 plasma-NGS test on advanced metastatic TC samples collected between 2016 and 2021. Patients with papillary TC (PTC), follicular TC (FTC), poorly differentiated TC (PDTC), medullary TC (MTC), and anaplastic TC (ATC) were clustered into four groups (G1: ATC, G2: PTC, FTC, and PDTC, G3: MTC, and G4: unspecified TC). The landscape of genetic alterations, frequencies of alterations in clinically relevant genes, and tumor mutation burden (TMB) were analyzed. Results: Of the 1,108 patients included, 47.1% were male. The median age was 65 years old (range 13-98), and 0.18% (n = 5) patients were under 18 years old. Alteration frequencies of selected, clinically relevant genes are demonstrated in the table below. TMB analysis was performed on 315 samples, and the mean TMB was higher in G1 compared to G2, G3, and G4 (p = 0.0029, 0.0826, and 0.0112, respectively). Conclusions: Plasma-based comprehensive NGS by Guardant360 may be utilized in patients with advanced metastatic TC for detecting clinically relevant genetic alterations for the selection of available targeted therapies, immunotherapy, or determination of the clinical trial eligibility. Future validation of the clinical utility by analysis of paired tumor and plasma samples is warranted. [Table: see text]
Collapse
Affiliation(s)
- Valentina Tarasova
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL
| | - Jill Tsai
- Guardant Health, Inc., Redwood City, CA
| | - Bryan McIver
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL
| | | | - Colleen Veloski
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL
| | | | | | | | | |
Collapse
|
39
|
Krzakowski MJ, Lu S, Cousin S, Smit EF, Springfeld C, Goto K, Garrido P, Chung CH, Lin JJ, Bray VJ, Pitcher B, Zeuner H, Patel S, Bordogna W, Gelderblom H. Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive ( NTRK-fp) solid tumors. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.3099] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3099 Background: NTRK gene fusions, coding for chimeric TRK proteins, are oncogenic drivers in many solid tumors. In an integrated analysis of three phase 1/2 trials (ALKA-372-001 [EudraCT 2012-000148-88]; STARTRK-1 [NCT02097810]; STARTRK-2 [NCT02568267]), entrectinib, a potent CNS-active TRK inhibitor, showed durable systemic and intracranial responses in pts with NTRK-fp solid tumors. We report updated data from a larger cohort with longer follow-up (clinical cutoff 2 Aug 2021). Methods: Pts with locally advanced/metastatic NTRK-fp solid tumors and ≥12 months’ follow-up from first tumor assessment were efficacy evaluable. The safety cohort also included pts from TAPISTRY (NCT04589845). Tumor responses were assessed by blinded independent central review (BICR) per RECIST v1.1 at Week 4 and every 8 weeks thereafter. Primary endpoints: objective response rate (ORR) and duration of response (DoR). Progression-free survival (PFS), overall survival (OS), intracranial (IC)-ORR and safety were also assessed. Results: The efficacy-evaluable cohort comprised 150 adults (vs 121 previously) with 17 different solid tumor types. Median age was 58.5 years; 91% of pts had ECOG PS 0–1 and 37% had received ≥2 prior lines of therapy. Median survival follow-up was 30.6 months. ORR was 61.3% (n = 92/150; 95% CI: 53.1–69.2), including 25 complete responses. Responses were observed in all tumor types with n>1 (Table). Median DoR, PFS and OS were 20.0 months (95% CI 13.2–31.1), 13.8 months (95% CI 10.1–20.0), and 37.1 months (95% CI 27.2–not estimable [NE]), respectively. In pts with and without investigator-assessed baseline CNS metastases (n = 31 / n = 119), ORR was 61.3% (95% CI 42.2–78.2) and 61.3% (95% CI 52.0–70.1) respectively. IC-ORR was 69.2% (n = 9/13) in pts with BICR-assessed measurable CNS metastases; median IC-DoR was 17.2 months (7.4–NE). In the safety population (N = 235: all treated pts), most treatment-related adverse events (TRAEs) were grade 1/2 and not serious; the most frequent were dysgeusia (36.6%), diarrhea (29.8%) and weight increase (28.5%). TRAEs led to dose interruption, reduction and discontinuation in 32.8%, 24.3% and 7.2% of pts, respectively. Conclusions: In this updated analysis, entrectinib continued to demonstrate deep and durable responses and was well tolerated in pts with NTRK-fp solid tumors with or without baseline CNS metastases. Clinical trial information: STARTRK-2 [NCT02568267]. [Table: see text]
Collapse
Affiliation(s)
- Maciej Jerzy Krzakowski
- Lung and Thoracic Cancer Department, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
| | - Shun Lu
- Department of Medical Oncology, Shanghai Chest Hospital, Jiao Tong University, Shanghai, China
| | - Sophie Cousin
- Early Phase Clinical Trials Unit and Thoracic Unit, Institut Bergonié, Bordeaux, France
| | - Egbert F. Smit
- Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands
| | - Christoph Springfeld
- Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany
| | - Koichi Goto
- Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
| | - Pilar Garrido
- Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Madrid, Spain
| | | | | | - Victoria J. Bray
- Medical Oncology Department, Liverpool Hospital, Liverpool, NSW, Australia
| | | | | | | | | | | |
Collapse
|
40
|
Kirtane K, Muzaffar J, Kish J, Oswald LB, Gonzalez BD, Welniak T, Rodriguez Y, Chung CH. YIA22-004: The Feasibility of a Digitized Peer-To-Peer Patient Support System for Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiation. J Natl Compr Canc Netw 2022. [DOI: 10.6004/jnccn.2021.7152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
41
|
Chung CH, Li J, Steuer CE, Bhateja P, Johnson M, Masannat J, Poole MI, Song F, Hernandez-Prera JC, Molina H, Wenig BM, Kumar S, Kuperwasser C, Stephens PJ, Farinhas JM, Shin DM, Kish JA, Muzaffar J, Kirtane K, Rocco JW, Schell MJ, Saba NF, Bonomi M. Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma. Clin Cancer Res 2022; 28:2329-2338. [PMID: 35344035 DOI: 10.1158/1078-0432.ccr-21-3849] [Citation(s) in RCA: 25] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2021] [Revised: 01/11/2022] [Accepted: 03/24/2022] [Indexed: 11/16/2022]
Abstract
PURPOSE A phase II multi-institutional clinical trial was conducted to determine overall survival (OS) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with a combination of cetuximab and nivolumab. EXPERIMENTAL DESIGN Patients with R/M HNSCC were treated with cetuximab 500 mg/m2 IV Day (D) -14 as a lead-in followed by cetuximab 500 mg/m2 IV and nivolumab 240 mg IV on D1 and D15 of each 28-D cycle. Expression of p16 and programmed cell death-ligand 1 (PD-L1) in archived tumors were determined. Tumor-tissue-modified human papillomavirus (TTMV) DNA was quantified in plasma. RESULTS Ninety-five patients were enrolled, and 88 patients were evaluable for OS with a median follow-up of 15.9 months. Median OS in the 45 patients who had prior therapy for R/M HNSCC (Cohort A) was 11.4 months, with a 1-year OS 50% (90% CI, 0.43-0.57). Median OS in the 43 patients who had no prior therapy (Cohort B) was 20.2 months, with a 1-year OS 66% (90% CI, 0.59-0.71). In the combined cohorts, the p16-negative immunostaining was associated with higher response rate (RR, p=0.02) but did not impact survival while higher PD-L1 combined positive score was associated with higher RR (p=0.03) and longer OS (log-rank p=0.04). In the p16-positive patients, median (log-rank p=0.05). CONCLUSION The combination of cetuximab and nivolumab is effective in patients with both previously treated and untreated R/M HNSCC and warrants further evaluation.
Collapse
Affiliation(s)
| | - Jiannong Li
- Moffitt Cancer Center, Tampa, Florida, United States
| | - Conor E Steuer
- Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
| | - Priyanka Bhateja
- University Hospital Seidman Cancer Center, Cleveland, Ohio, United States
| | | | | | - Maria I Poole
- Moffitt Cancer Center, Tampa, Florida, United States
| | - Feifei Song
- Moffitt Cancer Center, Tampa, FL, United States
| | | | - Helen Molina
- Moffitt Cancer Center, Tampa, Florida, United States
| | | | | | | | | | | | | | - Julie A Kish
- Moffitt Cancer Center, Tampa, Florida, United States
| | | | - Kedar Kirtane
- Moffitt Cancer Center, Tampa, Florida, United States
| | | | | | | | - Marcelo Bonomi
- Ohio State University Comprehensive Cancer Center, Columbus, OH, United States
| |
Collapse
|
42
|
Ferris RL, Flamand Y, Weinstein GS, Li S, Quon H, Mehra R, Garcia JJ, Chung CH, Gillison ML, Duvvuri U, O'Malley BW, Ozer E, Thomas GR, Koch WM, Gross ND, Bell RB, Saba NF, Lango M, Méndez E, Burtness B. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). J Clin Oncol 2022; 40:138-149. [PMID: 34699271 PMCID: PMC8718241 DOI: 10.1200/jco.21.01752] [Citation(s) in RCA: 152] [Impact Index Per Article: 76.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Revised: 07/30/2021] [Accepted: 09/17/2021] [Indexed: 01/12/2023] Open
Abstract
PURPOSE Definitive or postoperative chemoradiation (CRT) is curative for human papillomavirus-associated (HPV+) oropharynx cancer (OPC) but induces significant toxicity. As a deintensification strategy, we studied primary transoral surgery (TOS) and reduced postoperative radiation therapy (RT) in intermediate-risk HPV+ OPC. METHODS E3311 is a phase II randomized trial of reduced- or standard-dose postoperative RT for resected stage III-IVa (American Joint Committee on Cancer-seventh edition) HPV+ OPC, determined by pathologic parameters. Primary goals were feasibility of prospective multi-institutional study of TOS for HPV+ OPC, and oncologic efficacy (2-year progression-free survival) of TOS and adjuvant therapy in intermediate-risk patients after resection. TOS plus 50 Gy was considered promising if the lower limit of the exact 90% binomial confidence intervals exceeded 85%. Quality of life and swallowing were measured by functional assessment of cancer therapy-head and neck and MD Anderson Dysphagia Index. RESULTS Credentialed surgeons performed TOS for 495 patients. Eligible and treated patients were assigned as follows: arm A (low risk, n = 38) enrolled 11%, intermediate risk arms B (50 Gy, n = 100) or C (60 Gy, n = 108) randomly allocated 58%, and arm D (high risk, n = 113) enrolled 31%. With a median 35.2-month follow-up for 359 evaluable (eligible and treated) patients, 2-year progression-free survival Kaplan-Meier estimate is 96.9% (90% CI, 91.9 to 100) for arm A (observation), 94.9% (90% CI, 91.3 to 98.6]) for arm B (50 Gy), 96.0% (90% CI, 92.8 to 99.3) for arm C (60 Gy), and 90.7% (90% CI, 86.2 to 95.4) for arm D (66 Gy plus weekly cisplatin). Treatment arm distribution and oncologic outcome for ineligible or step 2 untreated patients (n = 136) mirrored the 359 evaluable patients. Exploratory comparison of functional assessment of cancer therapy-head and neck total scores between arms B and C is presented. CONCLUSION Primary TOS and reduced postoperative RT result in outstanding oncologic outcome and favorable functional outcomes in intermediate-risk HPV+ OPC.
Collapse
Affiliation(s)
| | - Yael Flamand
- Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA
| | | | - Shuli Li
- Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA
| | | | | | | | | | | | | | | | | | | | | | - Neil D. Gross
- The University of Texas, MD Anderson Cancer Center, Houston, TX
| | | | - Nabil F. Saba
- Winship Cancer Institute at Emory University, Atlanta, GA
| | | | | | | |
Collapse
|
43
|
Oswald LB, Brownstein NC, Whiting J, Hoogland AI, Saravia S, Kirtane K, Chung CH, Vinci C, Gonzalez BD, Johnstone PAS, Jim HSL. OUP accepted manuscript. Oncologist 2022; 27:e176-e184. [PMID: 35641215 PMCID: PMC8895733 DOI: 10.1093/oncolo/oyab029] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Accepted: 09/29/2021] [Indexed: 11/15/2022] Open
Abstract
Background Cigarette smoking is related to greater cancer incidence, worse cancer-related clinical outcomes, and worse patient quality of life. Few studies have evaluated the role of smoking in patients’ experiences of cancer-related symptom burden. This study examined relationships between smoking and total symptom burden as well as the incidence of severe symptoms among adult cancer patients. Patients and Methods Patients at Moffitt Cancer Center completed self-report surveys as part of routine cancer care. Symptom burden was evaluated as the sum of individual symptom ratings (total symptom burden) and the number of symptoms rated severe (incidence of severe symptoms). Zero-inflated negative binomial modeling was used to evaluate the relationships between smoking status (ever vs never smoker) and symptom burden outcomes controlling for relevant sociodemographic and clinical covariates and accounting for the proportion of participants reporting no symptom burden. Results This study included 12 571 cancer patients. More than half reported a history of cigarette smoking (n = 6771, 55%). Relative to never smokers, participants with a smoking history had 15% worse expected total symptom burden (ratio = 1.15, 95% confidence interval [CI] 1.11-1.20, P < .001) and 13% more expected severe symptoms (ratio = 1.13, 95% CI 1.05-1.21, P = .001) above and beyond the effects of relevant sociodemographic and clinical characteristics. Conclusion Results provide support that smoking is associated with worse cancer symptom burden. More research is needed to evaluate how smoking history (ie, current vs former smoker) and smoking cessation influence cancer symptom burden.
Collapse
Affiliation(s)
- Laura B Oswald
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA
- Corresponding author: Laura B. Oswald, PhD, Department of Health Outcomes and Behavior, Moffitt Cancer Center, 12902 Magnolia Drive, MFC-EDU, Tampa, FL 33612, USA. Tel: 813-745-1338;
| | - Naomi C Brownstein
- Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USA
| | - Junmin Whiting
- Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USA
| | - Aasha I Hoogland
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA
| | - Sabrina Saravia
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA
| | - Kedar Kirtane
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | - Christine H Chung
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | - Christine Vinci
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA
| | - Brian D Gonzalez
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA
| | | | - Heather S L Jim
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA
| |
Collapse
|
44
|
Kirtane K, Geiss C, Arredondo B, Hoogland AI, Chung CH, Muzaffar J, Patel KB, Gonzalez BD, Jim HSL, Oswald LB. "I have cancer during COVID; that's a special category": a qualitative study of head and neck cancer patient and provider experiences during the COVID-19 pandemic. Support Care Cancer 2022; 30:4337-4344. [PMID: 35091844 PMCID: PMC8799415 DOI: 10.1007/s00520-021-06773-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2021] [Accepted: 12/18/2021] [Indexed: 01/09/2023]
Abstract
PURPOSE The COVID-19 pandemic has drastically changed cancer care delivery strategies. Patients with locally advanced head and neck cancer (LA-HNC) may be particularly affected by the COVID-19 pandemic, as they often undergo treatments that require daily clinic visits (e.g., radiation therapy). The goal of this study was to characterize the lived experience of LA-HNC patients and their healthcare providers during the COVID-19 pandemic. METHODS LA-HNC patients who completed a full course of chemotherapy and radiation therapy during the COVID19 pandemic (N = 20) and LA-HNC healthcare providers (N = 13) participated in semi-structured interviews. Interviews were audio-recorded, transcribed verbatim, and analyzed for qualitative themes. RESULTS The COVID-19 pandemic had a significant impact on patients' overall quality of life and health care. Results were organized in four main themes: (1) increased psychological distress; (2) exacerbated social isolation; (3) added stress in clinic for patients and providers; and (4) delays in health care. CONCLUSIONS Findings highlight myriad ways LA-HNC patients and providers have been affected by the COVID-19 pandemic. Results can inform the development of supportive interventions to assist LA-HNC in managing COVID-19-related stress and unmet needs related to social isolation and in-clinic support.
Collapse
Affiliation(s)
- Kedar Kirtane
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL, 33612, USA.
| | - Carley Geiss
- Participant Research, Interventions, and Measurement Core, Moffitt Cancer Center, Tampa, FL, USA
| | - Brandy Arredondo
- Participant Research, Interventions, and Measurement Core, Moffitt Cancer Center, Tampa, FL, USA
| | - Aasha I Hoogland
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA
| | - Christine H Chung
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL, 33612, USA
| | - Jameel Muzaffar
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL, 33612, USA
| | - Krupal B Patel
- Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL, 33612, USA
| | - Brian D Gonzalez
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA
| | - Heather S L Jim
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA
| | - Laura B Oswald
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA
| |
Collapse
|
45
|
Aguilar M, Cavasonza LA, Ambrosi G, Arruda L, Attig N, Barao F, Barrin L, Bartoloni A, Başeğmez-du Pree S, Battiston R, Behlmann M, Beranek B, Berdugo J, Bertucci B, Bindi V, Bollweg K, Borgia B, Boschini MJ, Bourquin M, Bueno EF, Burger J, Burger WJ, Burmeister S, Cai XD, Capell M, Casaus J, Castellini G, Cervelli F, Chang YH, Chen GM, Chen GR, Chen HS, Chen Y, Cheng L, Chou HY, Chouridou S, Choutko V, Chung CH, Clark C, Coignet G, Consolandi C, Contin A, Corti C, Cui Z, Dadzie K, Dass A, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Felice V, Díaz C, Dimiccoli F, von Doetinchem P, Dong F, Donnini F, Duranti M, Egorov A, Eline A, Feng J, Fiandrini E, Fisher P, Formato V, Freeman C, Gámez C, García-López RJ, Gargiulo C, Gast H, Gervasi M, Giovacchini F, Gómez-Coral DM, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Haino S, Han KC, Hashmani RK, He ZH, Heber B, Hsieh TH, Hu JY, Incagli M, Jang WY, Jia Y, Jinchi H, Karagöz G, Khiali B, Kim GN, Kirn T, Konyushikhin M, Kounina O, Kounine A, Koutsenko V, Krasnopevtsev D, Kuhlman A, Kulemzin A, La Vacca G, Laudi E, Laurenti G, Lazzizzera I, Lebedev A, Lee HT, Lee SC, Li JQ, Li M, Li Q, Li S, Li JH, Li ZH, Liang J, Light C, Lin CH, Lippert T, Liu JH, Liu Z, Lu SQ, Lu YS, Luebelsmeyer K, Luo JZ, Luo X, Machate F, Mañá C, Marín J, Marquardt J, Martin T, Martínez G, Masi N, Maurin D, Medvedeva T, Menchaca-Rocha A, Meng Q, Mikhailov VV, Molero M, Mott P, Mussolin L, Negrete J, Nikonov N, Nozzoli F, Oliva A, Orcinha M, Palermo M, Palmonari F, Paniccia M, Pashnin A, Pauluzzi M, Pensotti S, Phan HD, Plyaskin V, Pohl M, Poluianov S, Qin X, Qu ZY, Quadrani L, Rancoita PG, Rapin D, Conde AR, Robyn E, Rosier-Lees S, Rozhkov A, Rozza D, Sagdeev R, Schael S, von Dratzig AS, Schwering G, Seo ES, Shakfa Z, Shan BS, Siedenburg T, Solano C, Song JW, Song XJ, Sonnabend R, Strigari L, Su T, Sun Q, Sun ZT, Tacconi M, Tang XW, Tang ZC, Tian J, Ting SCC, Ting SM, Tomassetti N, Torsti J, Urban T, Usoskin I, Vagelli V, Vainio R, Valencia-Otero M, Valente E, Valtonen E, Vázquez Acosta M, Vecchi M, Velasco M, Vialle JP, Wang CX, Wang L, Wang LQ, Wang NH, Wang QL, Wang S, Wang X, Wang Y, Wang ZM, Wei J, Weng ZL, Wu H, Xiong RQ, Xu W, Yan Q, Yang Y, Yashin II, Yi H, Yu YM, Yu ZQ, Zannoni M, Zhang C, Zhang F, Zhang FZ, Zhang JH, Zhang Z, Zhao F, Zheng C, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zuccon P. Periodicities in the Daily Proton Fluxes from 2011 to 2019 Measured by the Alpha Magnetic Spectrometer on the International Space Station from 1 to 100 GV. Phys Rev Lett 2021; 127:271102. [PMID: 35061443 DOI: 10.1103/physrevlett.127.271102] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/19/2021] [Revised: 09/24/2021] [Accepted: 11/08/2021] [Indexed: 06/14/2023]
Abstract
We present the precision measurement of the daily proton fluxes in cosmic rays from May 20, 2011 to October 29, 2019 (a total of 2824 days or 114 Bartels rotations) in the rigidity interval from 1 to 100 GV based on 5.5×10^{9} protons collected with the Alpha Magnetic Spectrometer aboard the International Space Station. The proton fluxes exhibit variations on multiple timescales. From 2014 to 2018, we observed recurrent flux variations with a period of 27 days. Shorter periods of 9 days and 13.5 days are observed in 2016. The strength of all three periodicities changes with time and rigidity. The rigidity dependence of the 27-day periodicity is different from the rigidity dependences of 9-day and 13.5-day periods. Unexpectedly, the strength of 9-day and 13.5-day periodicities increases with increasing rigidities up to ∼10 GV and ∼20 GV, respectively. Then the strength of the periodicities decreases with increasing rigidity up to 100 GV.
Collapse
Affiliation(s)
- M Aguilar
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - L Ali Cavasonza
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - G Ambrosi
- INFN Sezione di Perugia, 06100 Perugia, Italy
| | - L Arruda
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), 1649-003 Lisboa, Portugal
| | - N Attig
- Jülich Supercomputing Centre and JARA-FAME, Research Centre Jülich, 52425 Jülich, Germany
| | - F Barao
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), 1649-003 Lisboa, Portugal
| | - L Barrin
- European Organization for Nuclear Research (CERN), 1211 Geneva 23, Switzerland
| | | | - S Başeğmez-du Pree
- Kapteyn Astronomical Institute, University of Groningen, P.O. Box 800, 9700 AV Groningen, Netherlands
| | - R Battiston
- INFN TIFPA, 38123 Povo, Trento, Italy
- Università di Trento, 38123 Povo, Trento, Italy
| | - M Behlmann
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - B Beranek
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - J Berdugo
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - B Bertucci
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - V Bindi
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - K Bollweg
- National Aeronautics and Space Administration Johnson Space Center (JSC), Houston, Texas 77058, USA
| | - B Borgia
- INFN Sezione di Roma 1, 00185 Roma, Italy
- Università di Roma La Sapienza, 00185 Roma, Italy
| | - M J Boschini
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
| | - M Bourquin
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | - E F Bueno
- Kapteyn Astronomical Institute, University of Groningen, P.O. Box 800, 9700 AV Groningen, Netherlands
| | - J Burger
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | | | - S Burmeister
- Institut für Experimentelle und Angewandte Physik, Christian-Alberts-Universität zu Kiel, 24118 Kiel, Germany
| | - X D Cai
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - M Capell
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - J Casaus
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | | | | | - Y H Chang
- Institute of Physics, Academia Sinica, Nankang, Taipei, 11529, Taiwan
| | - G M Chen
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing, 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing, 100049, China
| | - G R Chen
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong, 250100, China
| | - H S Chen
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing, 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing, 100049, China
| | - Y Chen
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong, 250100, China
| | - L Cheng
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong, 250100, China
| | - H Y Chou
- Institute of Physics, Academia Sinica, Nankang, Taipei, 11529, Taiwan
| | - S Chouridou
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - V Choutko
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - C H Chung
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - C Clark
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
- National Aeronautics and Space Administration Johnson Space Center (JSC), Houston, Texas 77058, USA
| | - G Coignet
- Université Grenoble Alpes, Université Savoie Mont Blanc, CNRS, LAPP-IN2P3, 74000 Annecy, France
| | - C Consolandi
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - A Contin
- INFN Sezione di Bologna, 40126 Bologna, Italy
- Università di Bologna, 40126 Bologna, Italy
| | - C Corti
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - Z Cui
- Shandong University (SDU), Jinan, Shandong, 250100, China
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong, 250100, China
| | - K Dadzie
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Dass
- INFN TIFPA, 38123 Povo, Trento, Italy
- Università di Trento, 38123 Povo, Trento, Italy
| | - C Delgado
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | | | - M B Demirköz
- Department of Physics, Middle East Technical University (METU), 06800 Ankara, Turkey
| | - L Derome
- Université Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France
| | | | - V Di Felice
- INFN Sezione di Roma Tor Vergata, 00133 Roma, Italy
| | - C Díaz
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | | | - P von Doetinchem
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - F Dong
- Southeast University (SEU), Nanjing, 210096, China
| | - F Donnini
- INFN Sezione di Roma Tor Vergata, 00133 Roma, Italy
| | - M Duranti
- INFN Sezione di Perugia, 06100 Perugia, Italy
| | - A Egorov
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Eline
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - J Feng
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - E Fiandrini
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - P Fisher
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - V Formato
- INFN Sezione di Roma Tor Vergata, 00133 Roma, Italy
| | - C Freeman
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - C Gámez
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - R J García-López
- Instituto de Astrofísica de Canarias (IAC), 38205 La Laguna, and Departamento de Astrofísica, Universidad de La Laguna, 38206 La Laguna, Tenerife, Spain
| | - C Gargiulo
- European Organization for Nuclear Research (CERN), 1211 Geneva 23, Switzerland
| | - H Gast
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - M Gervasi
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - F Giovacchini
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - D M Gómez-Coral
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - J Gong
- Southeast University (SEU), Nanjing, 210096, China
| | - C Goy
- Université Grenoble Alpes, Université Savoie Mont Blanc, CNRS, LAPP-IN2P3, 74000 Annecy, France
| | - V Grabski
- Instituto de Física, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, 01000 Mexico
| | - D Grandi
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - M Graziani
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - S Haino
- Institute of Physics, Academia Sinica, Nankang, Taipei, 11529, Taiwan
| | - K C Han
- National Chung-Shan Institute of Science and Technology (NCSIST), Longtan, Tao Yuan, 32546, Taiwan
| | - R K Hashmani
- Department of Physics, Middle East Technical University (METU), 06800 Ankara, Turkey
| | - Z H He
- Sun Yat-Sen University (SYSU), Guangzhou, 510275, China
| | - B Heber
- Institut für Experimentelle und Angewandte Physik, Christian-Alberts-Universität zu Kiel, 24118 Kiel, Germany
| | - T H Hsieh
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - J Y Hu
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing, 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing, 100049, China
| | - M Incagli
- INFN Sezione di Pisa, 56100 Pisa, Italy
| | - W Y Jang
- CHEP, Kyungpook National University, 41566 Daegu, Korea
| | - Yi Jia
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - H Jinchi
- National Chung-Shan Institute of Science and Technology (NCSIST), Longtan, Tao Yuan, 32546, Taiwan
| | - G Karagöz
- Department of Physics, Middle East Technical University (METU), 06800 Ankara, Turkey
| | - B Khiali
- INFN Sezione di Roma Tor Vergata, 00133 Roma, Italy
| | - G N Kim
- CHEP, Kyungpook National University, 41566 Daegu, Korea
| | - Th Kirn
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - M Konyushikhin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - O Kounina
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Kounine
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - V Koutsenko
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - D Krasnopevtsev
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Kuhlman
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - A Kulemzin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - G La Vacca
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - E Laudi
- European Organization for Nuclear Research (CERN), 1211 Geneva 23, Switzerland
| | - G Laurenti
- INFN Sezione di Bologna, 40126 Bologna, Italy
| | - I Lazzizzera
- INFN TIFPA, 38123 Povo, Trento, Italy
- Università di Trento, 38123 Povo, Trento, Italy
| | - A Lebedev
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - H T Lee
- Academia Sinica Grid Center (ASGC), Nankang, Taipei, 11529, Taiwan
| | - S C Lee
- Institute of Physics, Academia Sinica, Nankang, Taipei, 11529, Taiwan
| | - J Q Li
- Southeast University (SEU), Nanjing, 210096, China
| | - M Li
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - Q Li
- Southeast University (SEU), Nanjing, 210096, China
| | - S Li
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - J H Li
- Shandong University (SDU), Jinan, Shandong, 250100, China
| | - Z H Li
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing, 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing, 100049, China
| | - J Liang
- Shandong University (SDU), Jinan, Shandong, 250100, China
| | - C Light
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - C H Lin
- Institute of Physics, Academia Sinica, Nankang, Taipei, 11529, Taiwan
| | - T Lippert
- Jülich Supercomputing Centre and JARA-FAME, Research Centre Jülich, 52425 Jülich, Germany
| | - J H Liu
- Institute of Electrical Engineering (IEE), Chinese Academy of Sciences, Beijing, 100190, China
| | - Z Liu
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | - S Q Lu
- Institute of Physics, Academia Sinica, Nankang, Taipei, 11529, Taiwan
| | - Y S Lu
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing, 100049, China
| | - K Luebelsmeyer
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - J Z Luo
- Southeast University (SEU), Nanjing, 210096, China
| | - Xi Luo
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong, 250100, China
| | - F Machate
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - C Mañá
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - J Marín
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - J Marquardt
- Institut für Experimentelle und Angewandte Physik, Christian-Alberts-Universität zu Kiel, 24118 Kiel, Germany
| | - T Martin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
- National Aeronautics and Space Administration Johnson Space Center (JSC), Houston, Texas 77058, USA
| | - G Martínez
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - N Masi
- INFN Sezione di Bologna, 40126 Bologna, Italy
- Università di Bologna, 40126 Bologna, Italy
| | - D Maurin
- Université Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France
| | - T Medvedeva
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Menchaca-Rocha
- Instituto de Física, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, 01000 Mexico
| | - Q Meng
- Southeast University (SEU), Nanjing, 210096, China
| | - V V Mikhailov
- NRNU MEPhI (Moscow Engineering Physics Institute), Moscow, 115409 Russia
| | - M Molero
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - P Mott
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
- National Aeronautics and Space Administration Johnson Space Center (JSC), Houston, Texas 77058, USA
| | - L Mussolin
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - J Negrete
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - N Nikonov
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - F Nozzoli
- INFN TIFPA, 38123 Povo, Trento, Italy
| | - A Oliva
- INFN Sezione di Bologna, 40126 Bologna, Italy
| | - M Orcinha
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), 1649-003 Lisboa, Portugal
| | - M Palermo
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - F Palmonari
- INFN Sezione di Bologna, 40126 Bologna, Italy
- Università di Bologna, 40126 Bologna, Italy
| | - M Paniccia
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | - A Pashnin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - M Pauluzzi
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - S Pensotti
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - H D Phan
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - V Plyaskin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - M Pohl
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | - S Poluianov
- Sodankylä Geophysical Observatory and Space Physics and Astronomy Research Unit, University of Oulu, 90014 Oulu, Finland
| | - X Qin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - Z Y Qu
- Institute of Physics, Academia Sinica, Nankang, Taipei, 11529, Taiwan
| | - L Quadrani
- INFN Sezione di Bologna, 40126 Bologna, Italy
- Università di Bologna, 40126 Bologna, Italy
| | - P G Rancoita
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
| | - D Rapin
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | - A Reina Conde
- Instituto de Astrofísica de Canarias (IAC), 38205 La Laguna, and Departamento de Astrofísica, Universidad de La Laguna, 38206 La Laguna, Tenerife, Spain
| | - E Robyn
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | - S Rosier-Lees
- Université Grenoble Alpes, Université Savoie Mont Blanc, CNRS, LAPP-IN2P3, 74000 Annecy, France
| | - A Rozhkov
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - D Rozza
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - R Sagdeev
- East-West Center for Space Science, University of Maryland, College Park, Maryland 20742, USA
| | - S Schael
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | | | - G Schwering
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - E S Seo
- IPST, University of Maryland, College Park, Maryland 20742, USA
| | - Z Shakfa
- Department of Physics, Middle East Technical University (METU), 06800 Ankara, Turkey
| | - B S Shan
- Beihang University (BUAA), Beijing, 100191, China
| | - T Siedenburg
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - C Solano
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - J W Song
- Shandong University (SDU), Jinan, Shandong, 250100, China
| | - X J Song
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong, 250100, China
| | - R Sonnabend
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - L Strigari
- INFN Sezione di Roma 1, 00185 Roma, Italy
| | - T Su
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong, 250100, China
| | - Q Sun
- Shandong University (SDU), Jinan, Shandong, 250100, China
| | - Z T Sun
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing, 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing, 100049, China
| | - M Tacconi
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - X W Tang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing, 100049, China
| | - Z C Tang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing, 100049, China
| | - J Tian
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - Samuel C C Ting
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
- European Organization for Nuclear Research (CERN), 1211 Geneva 23, Switzerland
| | - S M Ting
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - N Tomassetti
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Università di Perugia, 06100 Perugia, Italy
| | - J Torsti
- Space Research Laboratory, Department of Physics and Astronomy, University of Turku, 20014 Turku, Finland
| | - T Urban
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
- National Aeronautics and Space Administration Johnson Space Center (JSC), Houston, Texas 77058, USA
| | - I Usoskin
- Sodankylä Geophysical Observatory and Space Physics and Astronomy Research Unit, University of Oulu, 90014 Oulu, Finland
| | - V Vagelli
- INFN Sezione di Perugia, 06100 Perugia, Italy
- Agenzia Spaziale Italiana (ASI), 00133 Roma, Italy
| | - R Vainio
- Space Research Laboratory, Department of Physics and Astronomy, University of Turku, 20014 Turku, Finland
| | - M Valencia-Otero
- Physics Department and Center for High Energy and High Field Physics, National Central University (NCU), Tao Yuan, 32054, Taiwan
| | - E Valente
- INFN Sezione di Roma 1, 00185 Roma, Italy
- Università di Roma La Sapienza, 00185 Roma, Italy
| | - E Valtonen
- Space Research Laboratory, Department of Physics and Astronomy, University of Turku, 20014 Turku, Finland
| | - M Vázquez Acosta
- Instituto de Astrofísica de Canarias (IAC), 38205 La Laguna, and Departamento de Astrofísica, Universidad de La Laguna, 38206 La Laguna, Tenerife, Spain
| | - M Vecchi
- Kapteyn Astronomical Institute, University of Groningen, P.O. Box 800, 9700 AV Groningen, Netherlands
| | - M Velasco
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain
| | - J P Vialle
- Université Grenoble Alpes, Université Savoie Mont Blanc, CNRS, LAPP-IN2P3, 74000 Annecy, France
| | - C X Wang
- Shandong University (SDU), Jinan, Shandong, 250100, China
| | - L Wang
- Institute of Electrical Engineering (IEE), Chinese Academy of Sciences, Beijing, 100190, China
| | - L Q Wang
- Shandong University (SDU), Jinan, Shandong, 250100, China
| | - N H Wang
- Shandong University (SDU), Jinan, Shandong, 250100, China
| | - Q L Wang
- Institute of Electrical Engineering (IEE), Chinese Academy of Sciences, Beijing, 100190, China
| | - S Wang
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - X Wang
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - Yu Wang
- Shandong University (SDU), Jinan, Shandong, 250100, China
| | - Z M Wang
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong, 250100, China
| | - J Wei
- DPNC, Université de Genève, 1211 Genève 4, Switzerland
| | - Z L Weng
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - H Wu
- Southeast University (SEU), Nanjing, 210096, China
| | - R Q Xiong
- Southeast University (SEU), Nanjing, 210096, China
| | - W Xu
- Shandong University (SDU), Jinan, Shandong, 250100, China
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong, 250100, China
| | - Q Yan
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - Y Yang
- National Cheng Kung University, Tainan, 70101, Taiwan
| | - I I Yashin
- NRNU MEPhI (Moscow Engineering Physics Institute), Moscow, 115409 Russia
| | - H Yi
- Southeast University (SEU), Nanjing, 210096, China
| | - Y M Yu
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - Z Q Yu
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing, 100049, China
| | - M Zannoni
- INFN Sezione di Milano-Bicocca, 20126 Milano, Italy
- Università di Milano-Bicocca, 20126 Milano, Italy
| | - C Zhang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing, 100049, China
| | - F Zhang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing, 100049, China
| | - F Z Zhang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing, 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing, 100049, China
| | - J H Zhang
- Southeast University (SEU), Nanjing, 210096, China
| | - Z Zhang
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - F Zhao
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing, 100049, China
- University of Chinese Academy of Sciences (UCAS), Beijing, 100049, China
| | - C Zheng
- Shandong Institute of Advanced Technology (SDIAT), Jinan, Shandong, 250100, China
| | - Z M Zheng
- Beihang University (BUAA), Beijing, 100191, China
| | - H L Zhuang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing, 100049, China
| | - V Zhukov
- I. Physics Institute and JARA-FAME, RWTH Aachen University, 52056 Aachen, Germany
| | - A Zichichi
- INFN Sezione di Bologna, 40126 Bologna, Italy
- Università di Bologna, 40126 Bologna, Italy
| | - P Zuccon
- INFN TIFPA, 38123 Povo, Trento, Italy
- Università di Trento, 38123 Povo, Trento, Italy
| |
Collapse
|
46
|
Xie M, Lee K, Lockhart JH, Cukras SD, Carvajal R, Beg AA, Flores ER, Teng M, Chung CH, Tan AC. TIMEx: tumor-immune microenvironment deconvolution web-portal for bulk transcriptomics using pan-cancer scRNA-seq signatures. Bioinformatics 2021; 37:3681-3683. [PMID: 33901274 PMCID: PMC11025676 DOI: 10.1093/bioinformatics/btab244] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Revised: 03/18/2021] [Accepted: 04/13/2021] [Indexed: 11/14/2022] Open
Abstract
SUMMARY The heterogeneous cell types of the tumor-immune microenvironment (TIME) play key roles in determining cancer progression, metastasis and response to treatment. We report the development of TIMEx, a novel TIME deconvolution method emphasizing on estimating infiltrating immune cells for bulk transcriptomics using pan-cancer single-cell RNA-seq signatures. We also implemented a comprehensive, user-friendly web-portal for users to evaluate TIMEx and other deconvolution methods with bulk transcriptomic profiles. AVAILABILITY AND IMPLEMENTATION TIMEx web-portal is freely accessible at http://timex.moffitt.org. SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.
Collapse
Affiliation(s)
- Mengyu Xie
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
| | - Kyubum Lee
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
| | - John H Lockhart
- Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
| | - Scott D Cukras
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
| | - Rodrigo Carvajal
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
| | - Amer A Beg
- Department of Immunology H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
| | - Elsa R Flores
- Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
| | - Mingxiang Teng
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
| | - Christine H Chung
- Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
| | - Aik Choon Tan
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
| |
Collapse
|
47
|
Aguilar M, Cavasonza LA, Alpat B, Ambrosi G, Arruda L, Attig N, Barao F, Barrin L, Bartoloni A, Başeğmez-du Pree S, Battiston R, Behlmann M, Beranek B, Berdugo J, Bertucci B, Bindi V, Bollweg K, Borgia B, Boschini MJ, Bourquin M, Bueno EF, Burger J, Burger WJ, Burmeister S, Cai XD, Capell M, Casaus J, Castellini G, Cervelli F, Chang YH, Chen GM, Chen GR, Chen HS, Chen Y, Cheng L, Chou HY, Chouridou S, Choutko V, Chung CH, Clark C, Coignet G, Consolandi C, Contin A, Corti C, Cui Z, Dadzie K, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Felice V, Díaz C, Dimiccoli F, von Doetinchem P, Dong F, Donnini F, Duranti M, Egorov A, Eline A, Feng J, Fiandrini E, Fisher P, Formato V, Freeman C, Gámez C, García-López RJ, Gargiulo C, Gast H, Gervasi M, Giovacchini F, Gómez-Coral DM, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Haino S, Han KC, Hashmani RK, He ZH, Heber B, Hsieh TH, Hu JY, Incagli M, Jang WY, Jia Y, Jinchi H, Khiali B, Kim GN, Kirn T, Konyushikhin M, Kounina O, Kounine A, Koutsenko V, Krasnopevtsev D, Kuhlman A, Kulemzin A, La Vacca G, Laudi E, Laurenti G, Lazzizzera I, Lebedev A, Lee HT, Lee SC, Li JQ, Li M, Li Q, Li S, Li JH, Li ZH, Liang J, Light C, Lin CH, Lippert T, Liu JH, Liu Z, Lu SQ, Lu YS, Luebelsmeyer K, Luo JZ, Luo X, Machate F, Mañá C, Marín J, Marquardt J, Martin T, Martínez G, Masi N, Maurin D, Medvedeva T, Menchaca-Rocha A, Meng Q, Mikhailov VV, Molero M, Mott P, Mussolin L, Negrete J, Nikonov N, Nozzoli F, Oliva A, Orcinha M, Palermo M, Palmonari F, Paniccia M, Pashnin A, Pauluzzi M, Pensotti S, Phan HD, Plyaskin V, Pohl M, Poluianov S, Qin X, Qu ZY, Quadrani L, Rancoita PG, Rapin D, Conde AR, Robyn E, Rosier-Lees S, Rozhkov A, Rozza D, Sagdeev R, Schael S, von Dratzig AS, Schwering G, Seo ES, Shakfa Z, Shan BS, Siedenburg T, Solano C, Song JW, Song XJ, Sonnabend R, Strigari L, Su T, Sun Q, Sun ZT, Tacconi M, Tang XW, Tang ZC, Tian J, Ting SCC, Ting SM, Tomassetti N, Torsti J, Tüysüz C, Urban T, Usoskin I, Vagelli V, Vainio R, Valencia-Otero M, Valente E, Valtonen E, Vázquez Acosta M, Vecchi M, Velasco M, Vialle JP, Wang CX, Wang L, Wang LQ, Wang NH, Wang QL, Wang S, Wang X, Wang Y, Wang ZM, Wei J, Weng ZL, Wu H, Xiong RQ, Xu W, Yan Q, Yang Y, Yashin II, Yi H, Yu YM, Yu ZQ, Zannoni M, Zhang C, Zhang F, Zhang FZ, Zhang JH, Zhang Z, Zhao F, Zheng C, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zuccon P. Erratum: Properties of a New Group of Cosmic Nuclei: Results from the Alpha Magnetic Spectrometer on Sodium, Aluminum, and Nitrogen [Phys. Rev. Lett. 127, 021101 (2021)]. Phys Rev Lett 2021; 127:159901. [PMID: 34678040 DOI: 10.1103/physrevlett.127.159901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/23/2021] [Indexed: 06/13/2023]
Abstract
This corrects the article DOI: 10.1103/PhysRevLett.127.021101.
Collapse
|
48
|
Lee K, Lockhart JH, Xie M, Chaudhary R, Slebos RJC, Flores ER, Chung CH, Tan AC. Deep Learning of Histopathology Images at the Single Cell Level. Front Artif Intell 2021; 4:754641. [PMID: 34568816 PMCID: PMC8461055 DOI: 10.3389/frai.2021.754641] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2021] [Accepted: 08/27/2021] [Indexed: 12/12/2022] Open
Abstract
The tumor immune microenvironment (TIME) encompasses many heterogeneous cell types that engage in extensive crosstalk among the cancer, immune, and stromal components. The spatial organization of these different cell types in TIME could be used as biomarkers for predicting drug responses, prognosis and metastasis. Recently, deep learning approaches have been widely used for digital histopathology images for cancer diagnoses and prognoses. Furthermore, some recent approaches have attempted to integrate spatial and molecular omics data to better characterize the TIME. In this review we focus on machine learning-based digital histopathology image analysis methods for characterizing tumor ecosystem. In this review, we will consider three different scales of histopathological analyses that machine learning can operate within: whole slide image (WSI)-level, region of interest (ROI)-level, and cell-level. We will systematically review the various machine learning methods in these three scales with a focus on cell-level analysis. We will provide a perspective of workflow on generating cell-level training data sets using immunohistochemistry markers to "weakly-label" the cell types. We will describe some common steps in the workflow of preparing the data, as well as some limitations of this approach. Finally, we will discuss future opportunities of integrating molecular omics data with digital histopathology images for characterizing tumor ecosystem.
Collapse
Affiliation(s)
- Kyubum Lee
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States
| | - John H. Lockhart
- Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States
| | - Mengyu Xie
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States
| | - Ritu Chaudhary
- Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States
| | - Robbert J. C. Slebos
- Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States
| | - Elsa R. Flores
- Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States
- Cancer Biology and Evolution Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States
| | - Christine H. Chung
- Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States
- Molecular Medicine Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States
| | - Aik Choon Tan
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States
- Molecular Medicine Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States
| |
Collapse
|
49
|
de la Iglesia JV, Slebos RJC, Martin-Gomez L, Wang X, Teer JK, Tan AC, Gerke TA, Aden-Buie G, van Veen T, Masannat J, Chaudhary R, Song F, Fournier M, Siegel EM, Schabath MB, Wadsworth JT, Caudell J, Harrison L, Wenig BM, Conejo-Garcia J, Hernandez-Prera JC, Chung CH. Correction: Effects of Tobacco Smoking On the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 2021; 27:4941. [PMID: 34470812 DOI: 10.1158/1078-0432.ccr-21-2432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
50
|
Mansfield AS, Hong DS, Hann CL, Farago AF, Beltran H, Waqar SN, Hendifar AE, Anthony LB, Taylor MH, Bryce AH, Tagawa ST, Lewis K, Niu J, Chung CH, Cleary JM, Rossi M, Ludwig C, Valenzuela R, Luo Y, Aggarwal R. A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. NPJ Precis Oncol 2021; 5:74. [PMID: 34354225 PMCID: PMC8342450 DOI: 10.1038/s41698-021-00214-y] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Accepted: 07/14/2021] [Indexed: 11/10/2022] Open
Abstract
Delta-like protein 3 (DLL3) is highly expressed in solid tumors, including neuroendocrine carcinomas/neuroendocrine tumors (NEC/NET). Rovalpituzumab tesirine (Rova-T) is a DLL3-targeting antibody-drug conjugate. Patients with NECs and other advanced DLL3-expressing tumors were enrolled in this phase I/II study (NCT02709889). The primary endpoint was safety. Two hundred patients were enrolled: 101 with NEC/NET (large-cell NEC, gastroenteropancreatic NEC, neuroendocrine prostate cancer, and other NEC/NET) and 99 with other solid tumors (melanoma, medullary thyroid cancer [MTC], glioblastoma, and other). The recommended phase II dose (RP2D) was 0.3 mg/kg every 6 weeks (q6w) for two cycles. At the RP2D, grade 3/4 adverse events included anemia (17%), thrombocytopenia (15%), and elevated aspartate aminotransferase (8%). Responses were confirmed in 15/145 patients (10%) treated at 0.3 mg/kg, including 9/69 patients (13%) with NEC/NET. Rova-T at 0.3 mg/kg q6w had manageable toxicity, with antitumor activity observed in patients with NEC/NET, melanoma, MTC, and glioblastoma.
Collapse
Affiliation(s)
| | - David S Hong
- The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Christine L Hann
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
| | | | | | - Saiama N Waqar
- Washington University School of Medicine, St. Louis, MO, USA
| | | | - Lowell B Anthony
- University of Kentucky Chandler Medical Center, Lexington, KY, USA
| | - Matthew H Taylor
- Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA
| | | | | | - Karl Lewis
- University of Colorado Denver, Aurora, CO, USA
| | - Jiaxin Niu
- Banner MD Anderson Cancer Center, Gilbert, AZ, USA
| | | | | | | | | | | | - Yan Luo
- AbbVie, Inc, North Chicago, IL, USA
| | - Rahul Aggarwal
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
| |
Collapse
|